Synthesis of Heterocyclic Compounds of Therapeutic Interest by Dholariya, Bipin H.
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Dholariya, Bipin H., 2011, “Synthesis of Heterocyclic Compounds of 
Therapeutic Interest”,  thesis PhD, Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/id/eprint/533 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given.  
 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author 
 
Synthesis of Heterocyclic 
Compounds of Therapeutic Interest  
 
 
A Thesis Submitted in the Fulfillment of the 
Requirements of the Award of the Degree 
 
 
Doctor of Philosophy 
 
 
From 
 
Saurashtra University 
  
 
By 
 
Bipin H. Dholariya 
 
Under the Guidance of 
Prof. V. H. Shah 
 
Department of Chemistry 
(DST-FIST Funded & UGC-SAP Sponsored) 
Saurashtra University 
Rajkot, Gujarat 
India 
 
 
March 2011 
 
Statement under O.Ph.D.7 of Saurashtra University 
 
 
The work included in the thesis is done by me under the supervision of  
Dr. V. H. Shah and the contribution made thereof is my own work.  
 
 
 
Date: 31/03/2011 
Place: Rajkot             (Bipin H. Dholariya) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Department of Chemistry 
                        (FIST-DST Funded & UGC-SAP Sponsored) 
               Saurashtra University, Rajkot - 360 005. Gujarat (INDIA) 
 
Fax : +91 281-2576802        
Phone : +91 281-2589443       Dr. V. H. Shah 
e-mail : drvireshshah@gmail.com      M. Sc., Ph. D., F.I.C.S. 
  shah_v_h@yahoo.com      Professor     
      
No.:          Date: 
 
 
Resi. : “Vighnahar parasnath”, 26-A/1, Saurashtra University Karmchari Society, University 
Road, Rajkot- 360 005.  Gujarat (India) Tel.: 0281- 2581817 
 
 
Certificate 
 
This is to certify that the present work submitted for the Ph. D. degree of Saurashtra University, 
Rajkot, Gujarat (India) by Mr. Bipin H. Dholariya has been the result of work carried out under my 
supervision and is a significant contribution in the field of synthetic organic chemistry. 
 
 
 
Date: 31/03/2011       Dr. Viresh H. Shah 
Place: Rajkot        Professor, 
Department of Chemistry, 
Saurashtra University, 
Rajkot-360005 
Gujarat (India). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is not because things are difficult that we do not dare, 
It is because we do not dare that they are difficult. 
-Seneca 
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General remarks 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR spectrometer 
using TMS as an internal reference. 
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FT-IR-8400 spectrometer. 
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Merck, Thomas-baker and SD fine chemical. 
 
7. Melting Points were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave synthesizer. 
 
9. All the structures are drawn according to ACS Document 1996 style. 
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 Chapter 1 
 
 General Introduction   
 
 
 
 
 
1.1 Heterocycles in drug discovery 
Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of 
research and development and a simultaneous stagnating number of new chemical 
entities (NCEs).  
The cause of this innovation deficit is definitively not the biology. Decoding 
of the human genome has led to a wealth of drug targets. With more than 30,000 
human genes, the assumption is that at least 1,000 are significantly involved in the 
emergence and course of disease. Furthermore, because each of these genes is linked 
to the function of between five and ten proteins, the conclusion is that there might be 
5,000–10,000 targets for new drugs [1]. Despite the successful introduction of protein 
therapeutics and the promise of gene therapy, major pharmaceutical companies are 
still focused on the discovery and development of low-molecular weight compounds. 
Hence, the challenge is to select the most drugable targets and to find the 
corresponding drug-like molecules, substances that not only interact with the target, 
but also have specific pharmacokinetic and toxicological properties, that allow them 
to be developed as a drug.  
 Medicinal chemistry as a scientific discipline has introduced several new 
techniques over the last few years in order to speed up the drug discovery process, 
such as combinatorial chemistry, microwave-assisted organic synthesis (MAOS) and 
high-throughput purification [2]. Despite this steady increase in R & D, the number of 
NCEs reaching the market has actually decreased dramatically. 
 It seems clear that selecting appropriate molecules to synthesize is one of the 
most troublesome questions. It has been estimated that the number of possible 
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molecules with a molecular weight of less than 500 Da is 10200, of which only 1060 
may possess drug-like properties. The proportion of these drug-like molecules 
synthesized to date has been estimated as one part in 1057, or roughly the ratio of the 
mass of one proton to the mass of the sun! The issue is therefore the selection of new 
molecules from this vast universe, which have the potential to be biologically active 
[3]. 
In order to start a new drug discovery project and to find biologically active 
compounds, different options are available. Hits can be obtained via a virtual 
screening approach or can be copied from scientific or patent literature. Very often, 
drug discovery projects start with a high-throughput screening campaign of 
commercially available compound libraries against the target of interest. It became 
clear in recent years that combinatorial libraries are not diverse enough. As the main 
interest of the laboratory of medicinal chemistry lays in the synthesis and biological 
evaluation of aromatic heterocycles, we performed a literature survey of 
commercially available combinatorial libraries. This search revealed that the number 
of available heterocycles is mainly limited to well-known nitrogen containing 
compounds, such as quinazolines (1), indoles (2) and benzimidazole (3). 
 
N
N N
H NH
N
(1) Quinazoline (2) Indole (3) Benzimidazole
N
H
N
O
(4) 1,4-Benzodiazepine-2-one
O O
(5) Coumarine
N
N
(6) Quinoxaline
O
(7) Benzofuran
S
(8) Benzothiophene
Examples of privileged structures  
 
 These structural classes are considered to be privileged structures. The concept 
of “privileged structures” was first proposed by Evans et al. to describe selected 
structural types that bind to multiple, unrelated classes of protein receptors and 
enzymes as high affinity ligands [4]. These privileged structures are typically rigid, 
polycyclic heteroatomic systems capable of orienting the various substituents in a 
well-defined three-dimensional space. Well-known examples of privileged 
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substructures include benzodiazepines (4), coumarins (5), quinoxalines (6), 
benzofurans (7) and benzothiophenes (8) [5]. In order to improve the hit rate in HTS 
campaigns, privileged structures provide an ideal source of lead compounds. A single 
library based upon privileged substructures can lead to active compounds in variety of 
biological assays. Several research groups have utilized these structures in such a 
manner. For example, Nicolau and co-workers constructed a library based on the 
benzopyran (9) privileged scaffold [6], whereas Schultz and co-workers made use of 
the purine (10) scaffold [7]. 
 
O
(9) Benzopyran
N
N NH
N
(10) Purine
Thr benzopyran and purine privileged scaffold
 
 
1.2 Nomenclature of the fused ring system 
As the following chapters deal with the synthesis of bicyclic and tricyclic fused ring 
systems, its nomenclature is herewith shortly reviewed. The nomenclature follows the 
following rules: 
(1) The individual components are named without any application of fused ring 
system. 
(2) The parent component is represented in the fusion name by citing it last in the 
name. The parent component is the one with highest priority according to the 
following criteria: 
(a) A heterocyclic component containing the heteroatom occurring earliest in 
the order: N, F, Cl, Br, I, O, S, Se, Te, P, As, Sb, Bi, Si, Ge, Sn, Pb, B, Hg. 
(b) A component containing the larger ring 
(c) A component containing the greater number of heteroatoms. 
(d) A component containing the greater variety of heteroatoms. 
(3) The attached component is then added as a prefix to the parent component. In 
the name of the prefix, the terminal 'e' is changed to 'o'. 
(4) The bonds of the parent component are indicated by a, b, c…starting with the 
bond normally occupying the 1,2 positions. The atoms of the attached 
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component are numbered as usual, following the order of numbers in the 
original heterocycle. 
(5) The numbering of the final condensed heterocycle is carried out 
independently, starting at an atom adjacent to a bridged-head atom, whereby 
heteroatoms receive the smallest possible number. 
 
1.3 Objectives 
Our interest in the synthesis and biological evaluation of heterocyclic bicycles and the 
fact that some of these compounds 3-cyano-2-pyridones (11), pyrano[2,3-c]pyrazoles 
(12) and 1,2,4-triazolo[1,5-a]pyrimidines (13) are not frequently used in commercial 
compound libraries, prompted us to elaborate this type of chemistry and to synthesize 
three different heterocyclic scaffolds. 
 
N
N N
N
(13) 1,2,4-triazolo[1,5-a]pyrimidine
N
H
O
N
N
HO
CN
(11) 3-cyano-2-pyridones (12) pyrano[2,3-c]pyrazoles
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 Chapter 2 
  
 Synthesis and biological evaluation of  
 cyanopyridones 
 
 
  
2.1 Introduction 
The pyridine skeleton is of great importance to chemists as well as to biologists as it is 
found in a large variety of naturally occurring compounds and also in clinically useful 
molecules having diverse biological activities. The pyridine ring systems have 
emerged as integral backbones of over 7000 existing drugs [1, 2]. The pyridine ring is 
also an integral part of anticancer and anti-inflammatory agents [3]. 
In association with those, Pyridone and their derivatives play an essential role 
in several biological processes and have considerable chemical and pharmacological 
importance [4-6]. 2-Pyridones represent a unique class of pharmacophore, which are 
observed in various therapeutic agents [7] and antibiotics [8]. These heterocycles 
attracted attention because of their applications as bioactive compounds for example 
as a promising class of HIV-1 non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) [9],
 
as antibacterial [10],
 
antifungal [11], sedative [12]
 
and cardiotonic 
agents [13].
 
Moreover, such derivatives have recently become important due to their 
structural similarity to nucleosides [14].
 
Also, 2-pyridones were used as ligands for 
the late 3d-metals [15].
 
 
They are also versatile precursors for the construction of complex natural 
products [16], pyridines [17] and larger pyridone systems such as those found in the 
nitroguanidine insecticide Imidacloprid [18] and subtype selective GABAA receptor 
agonists [19]. Consequently, methodologies for the preparation of pyridones have 
attracted much attention from both industry and academia. 
3-Cyano-2-Pyridones are much interest in the anticancer activity of these 
compounds owing to different types of biological targets they might interfere with for 
this effect to occur e.g. PDE3, PIM1 Kinase, and Survivin protein. 
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The 3-cyanopyridin-2-one nucleus is the structural basis of the alkaloid 
ricinine (2), the first known alkaloid containing a cyano-group. 
 
 
N
H
O
N
 Milrinone
N
N O
N
Ricinine
O
(2)(1)
 
 
Milrinone (1) is a 3-cyano-2-oxopyridine derivative that has been introduced 
to the clinic for the treatment of congestive heart failure. Its mechanism of action 
involves PDE3 inhibition, leading to high levels of cAMP and consequent inotropic 
effect. Recent studies showed that PDE3, PDE4 and PDE5 are over expressed in 
cancerous cells compared with normal cells. In addition, cross inhibition of PDE3 
together with other PDEs may lead to inhibition of tumor cell growth and 
angiogenesis [20-24]. The inhibition of PDE3 was able to inhibit the growth and 
proliferation of the squamous cell carcinoma cell line HeLa, and in HSG cells and 
further studies revealed that the pyridone derivative, cilostamide- a selective PDE3 
inhibitor- has synergism action to the anti-apoptotic action of PDE4 inhibitors in 
leukemia cells [23-25]. 
Cheney et al. reported 4,6-diaryl-2-oxo-1,2-dihydropyridine-3-carbonitriles 
(3), as inhibitors of the oncogenic serine/threonine kinase PIM-1, which plays a role 
in cancer cell survival, differentiation and proliferation. PIM-1 kinase has been shown 
to be over expressed in a variety of cancer cell lines [26]. 
Wendt et al. showed that several compounds with the same general formula as 
above but with higher lipophilic properties (4) can inhibit survivin which is a member 
of the inhibitor of apoptosis family (IAP) [27]. The level of expression of surviving in 
tumor cells is often associated with poor prognosis and shorter patient survival rates. 
Survivin is highly expressed in most human tumors and fetal tissue but undetectable 
in most terminally differentiated adult tissues. This fact therefore makes survivin an 
ideal target for cancer therapy [28, 29]. 
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N
H
CN
O
OH
Br
N
H
CN
O
Cl
Cl
(4) Survivin inhibition(3) PIM-1 kinase inhibition
 
 
          The thienopyridone agonist (5) is showed modest AMPK activity. AMPK 
(adenosine monophosphate-activated protein kinase), a heterotrimeric serine/ 
threonine kinase, is well established as a key sensor and regulator of intracellular and 
whole-body energy metabolism [30]. Activation of AMPK alters carbohydrate and 
lipid metabolism to increase fatty acid oxidation and glucose uptake and decrease 
fatty acid and cholesterol synthesis. Through its central role in the regulation of 
glucose and lipid metabolism, AMPK is emerging as an attractive molecular target for 
the treatment of diabetes, metabolic syndrome, and obesity [31, 32]. 
 
N
H
CN
O
OH
S
(5) Activity: AMPK Activator [33]
N
H
CN
O
(6) Activity: Cardiotonic [34]
OHO
O
 
 
 
 
 
 
 
 
 
 
 
Chapter 2                                                                                                Cyanopyridones 
     
   9
2. 2 Reported synthetic strategies 
2.2.1 One-pot multi-component synthesis of 3-cyano-2-pyridinones 
Beheshtia et al. developing new selective and environmental friendly methodologies 
for the preparation of fine chemicals, they performed the synthesis of 4-alkyl(aryl)-6-
aryl-3-cyano-2(1H)-pyridinones and their 2-imino isosteres [35, 36] through one-pot 
multi-component reaction of 3,4-dimethoxyacetophenone, malonitrile or ethyl 
cyanoacetate, an aldehyde and ammonium acetate in the presence of K2CO3 (Scheme 
2.1). 
This reaction was carried out in various solvents such as water, DMF, 
chloroform, ethanol, CH2Cl2 and toluene. The best results in terms of yield and time 
were obtained in ethanol. By carrying out reactions with different amounts of 
ammonium acetate, it has been found that 8 mmol of the ammonium acetate furnished 
the maximum yield for 1 mmol of the reactants. When ethyl cyanoacetate was used 
instead of malononitrile, the corresponding 2-pyridone was obtained in good yield. 
 
COCH3
OMe
OMe
+ RCHO
X
CN
CH3COONH4+ +
K2CO3
reflux NH
Z
CN
R
OMe
MeO
X = CN, COOEt
Z = NH, O
Scheme 2.1  
 
Also, they have used Et3N instead of K2CO3 in these reactions, but K2CO3 
affords better yields. In addition, the time required for completion of the reaction was 
found to be less with K2CO3. 
The one-pot reaction of 2-cyanoacetohydrazide (Scheme 2.2) with aldehyde 
and an activated nitrile in ethanol containing a catalytic amount of piperidine yielded 
pyridine-2-one derivative [37-39]. 
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O NH
NC
NH2
+
NH
R
NC
O
NH2
X
N
R
NC
O
NH2
NH2
X
Scheme 2.2
R CHO +
X
CN
EtOH
piperidine CN
R = H, Me, aryl
X = CN, COPh, CO2Ph
 
 
2.2.2 From α,β-unsaturated reagents 
Condensation of ethyl cyanoacetate with α,β-unsaturated ketones in presence of 
excess ammonium acetate afforded 3-cyanopyridin-2-ones [40-43] (Scheme 2.3). 
Also, a green chemistry approach describing reaction of α,β-unsaturated ketones with 
ethyl cyanoacetate using samarium iodide as catalyst has been reported recently [44]. 
 
+R1
O
NH4OAc
N
H
R
R1 O
CN
R
COOEt
CN
R, R1 = aryl or heteroaryl
Scheme 2.3
 
 
Barat reported first that condensation of cyanoacetamide with α,β-unsaturated 
ketones also affords 3-cyanopyridin-2-ones. Number of reports following this 
approach have been reported till date [45-47] (Scheme 2.4). 
 
+R1
O
NH4OAc
N
H
R
R1 O
CN
R
R, R1 = aryl or heteroaryl
Scheme  2.4
C
CN
O
H2N
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Chase et al. have synthesized 6-amino-5-phenyl-3-cyanopyridin-2-one by the 
reaction of 3-isobutoxy-2-phenylacrylonitrile with cyanoacetamide [48] (Scheme 2.5).  
 
CN
Ph
O +
N
H
H2N O
CNPh
C
CN
O
H2N
Scheme 2.5
 
 
Reaction of ethyl-(2,3,4-trimethoxybenzoyl)-pyruvate with cyanoacetamide in 
ethanol in presence of  piperidine gave 4-carbehtoxy-6-(2,3,4-trimethoxybenzyl)-3-
cyanopyridin-2-one [49]  (Scheme 2.6). 
 
OOCH3
OEt
O
+
OCH3
H3CO
H3CO
H3CO
H3CO
HN
O
CN
COOEt
Scheme 2.6
C
CN
O
H2N
 
 
Alnajjar et al. [50] reported the conversions of 2-cyano-5-(dimethylamino)-5-
phenylpenta-2,4-dienamides into nicotinic acid derivatives by boiling in EtOH/HCl. 
But, When 2-cyano-5-(dimethylamino)-5-phenylpenta-2,4-dienamides are heated 
under reflux in AcOH, nicotinic nitrile derivatives are obtained (Scheme 2.7). 
 
NMe2
CN
CONH2
EtOH HCl
AcOH
N
H
O
COOH
N
H
O
CN
Scheme 2.7
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The condensation of an enone or enal with cyanoacetamide derivatives and t- 
BuOK furnishes either 3-cyano-2-pyridones or 3-unsubstituted-2-pyridones (Scheme 
2.8), depending on whether the reaction is carried out in the presence or in the 
absence of O2. In the first case, in situ oxidation of Michael-type intermediates takes 
place; in the second case, a "decyanidative aromatization" of such intermediates 
occurs [51, 52]. 
 
R1 O
R2
R3
+
CONH2
CN DMSO
excess O2
no O2
H
N OR1
R2
R3
CN
H
N OR1
R2
R3Scheme 2.8
t-BuOK
 
 
The synthesis of 2,6-piperidindione derivatives (Scheme 2.9) was achieved by 
the Michael addition of dialkylmalonates to benzylidene cyanoacetamide derivative. 
Here benzylidene cyanoacetamide derivative were obtained by reaction of cyano-
acetamide with certain aromatic aldehydes according to the reported procedure [53]. 
 
R1 NH2
CN
O
R2O OR2
OO
+
N
H
CN
OO
R1
R2O
O
Scheme 2.9
R1 = 3,4,5-(OCH3)3C6H2, 3,4-(OCH3)2C6H3
R2 = CH3, C2H5
 
 
Enaminonitrile reacted with an equimolar amount of a-cinnamonitriles to 
provide pyridine and pyridinone derivatives [54], respectively. Formation of pyridine 
and pyridinone derivatives is assumed to proceed via an acyclic intermediate form 
followed by intramolecular cyclization and spontaneous autooxidation under the 
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reaction conditions in the case of pyridine derivatives and elimination of ethanol in 
the case of pyridone derivatives (Scheme 2.10). 
Here, the enaminonitrile can be readily prepared by reaction of acetonitrile 
with 4-cyanopyridine in the presence of potassium-t-butoxide [55]. 
 
N
CN
H2N
+
Ar
X
NC
N
CN
H2N
Ar
NC
X
Ar = Aryl,
X = CN, COOEt X = CNX= COOEt
N
NH2N
NC
Ar
CN
N
N
H
O
NC
Ar
CN
Scheme 2.10
 
 
Mathews et al. [56] attempted the reaction of 2-aroyl-3,3-bis(alkylsulfanyl) 
acrylaldehydes with cyanoacetamide in the presence of ammonium acetate/acetic acid 
at 80 °C, it afforded only the Knoevenagel condensation adduct, 4-aroyl-2-cyano-5,5-
bis-(methylsulfanyl)-2,4-pentadien-amides and no 2-pyridone was formed. As the 
condensation product has the scope for cyclization to produce 2-pyridones by the 
elimination of an alkylsulfanyl group, they tried the thermal cyclization of the 
condensation products by heating in xylene at 130 °C (Scheme 2.11).  
 
R
O
CHO
SMe
SMe
CNCH2CONH2
NH4Ac / AcOH
R
O
SMe
SMe
CN
CONH2
Xylene
130 °C
R
O
NH
SMe
CN
O
R = H, CH3, OCH3, Br, Cl
Scheme 2.11
 
 
Chapter 2                                                                                                Cyanopyridones 
     
   14
Condensation of ketone with dimethylformamide dimethylacetal afforded 
vinylogous amide, which in turn reacted with cyanoacetamide under basic conditions 
to generate the 5,6-diaryl-3-cyano-2-pyridones (Scheme 2.12) [57]. 
 
O
Cl
Cl Cl
(CH3)2N(OCH3)2
DMF, 90 °C O
Cl
Cl Cl
NMe2
2-cyanoacetamide
NaOCH3, DMF, 90 °C
Cl
Cl Cl
N
H
O
CN
Scheme 2.12
 
The reaction of (E)-1-(β-D-glucopyranosyl)-4-(aryl)but-3-en-2-ones and 
cyanoacetamide was carried out (Scheme 2.13) with t-BuOK in DMSO under N2 
atmosphere at ambient temperature to give the respective 3-cyano-4-phenyl-6-[(β-D-
glucopyranosyl)methyl]pyridones [58]. The reaction mixture was brought under the 
influence of an O2 atmosphere to carry out oxidative aromatization. 
 Here, the starting butenonyl C-glycosides were prepared from commercially 
available D-glucose following earlier reported protocols [59-62]. 
 
O
HO
HO
OH
OH
Ar
O
Cyanoacetamide
base
solvent, N2, O2
O
HO
HO
OH
OH
HN
O
Ar
CN
Scheme 2.13
 
 
2-alkoxy-3-cyanopyridines is achieved by the reaction of chalcones with 
malononitrile in corresponding sodium alkoxide [63-66] (Scheme 2.14). 
 
+R1
O
R2ONa
N
R
R1 OR2
CN
R
N
N
R, R1 = aryl or heteroaryl
Scheme 2.14
R2OH
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Another frequently used approach for the synthesis of 2-alkoxy-3-cyano-
pyridines is the O-alkylation of 3-cyanopyridin-2-ones by the reaction with 
appropriate alkyl/aryl halide [67, 68] (Scheme 2.15). 
 
N
H
O
CN
R + R1Br
N
H
OR1
CN
R
R = substituent/substituents on 4, 5 and/or 6 position of pyridine
R1 = alkyl or aryl
Scheme 2.15
 
 
2.2.3 From 1,3-dicarbonyl reagents 
Literature survey revealed many reports on synthesis of 3-cyanopyridin-2-one and 3-
cyanopyridin-2-thione by reaction of 1,3-dicarbonyl compounds with cyanoacetamide 
[69-72] and cyanothioacetamide [73-75] respectively (Scheme  2.16). 
 
+ C
CN
X
H2NO
R1
O
N
H
X
CN
R1
R1 = H [67, 68], R1 = COOCH3 [69], R1 = heteroaryl [70],          X = O [67-70], S [71-73]
R1 = benzoyl [71], R1 = CH3, OC2H5 [72], R1 = OC2H5 [73]
Scheme 2.16
 
 
The pyridone derivatives were also obtained from a cyclo-condensation 
reaction in one step (Scheme 2.17) [28]. Reaction of commercially available diketone 
with cyanoacetamide, in the presence of DBU in toluene at 90 °C for 16 h, readily 
afforded the title compounds. 
 
R1 R2 NH2
NC
O O O+ HN
R1 R2
O
CNDBU, toluene
90 °C, 16 h.
R1, R2 = CF3, thiophene, aryl
Scheme 2.17
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5-Substituted-4-methyl-3-cyano-6-hydroxy-2-pyridones were synthesized 
from cyanoacetamide and the corresponding alkyl ethyl acetoacetate in methanol in 
the presence of potassium hydroxide at 60 ºC. Cyclization of cyanoacetamide with an 
alkyl ethyl acetoacetate belongs to a 3-2 type of condensation where the pyridine 
nucleus is formed (Scheme 2.18) [76]. 
 
H3C
CH
EtO
R
O
O
+
CN
H2C
H2N
O
N
H
O
CN
CH3
R
HO
Scheme 2.18
KOH
 
 
2.2.4 Miscellaneous 
Literature survey also revealed a few ring transformation reactions of 4-amino-1H-
1,5-benzodiazepine-3-carbonitrile [77] and substituted uracil [78] yielding 3-cyano-
pyridones.  
Nohara et al. have reported that heating 2-cyano-3-(6-ethyl-4-oxo-4H-1-
benzopyran-3-yl) acrylamide in pyridine yields 3-cyano-5-(5-ethyl-2-hydroxy-
benzoyl)-2(1H)-pyridones [79] (Scheme 2.19). 
 
O
CN
NH2
OO
C5H5N
OH O
NH
O
CN
Scheme 2.19
 
 
Treatment of the ketones with dimethylformamide-dimethylacetal (DMF-
DMA) gave the corresponding 3-dimethylaminopropen-2-ones, and generally without 
purification, these were condensed with 2-cyanoacetamide under basic condition give 
the 3-cyano-2-pyridones, reported by Collins et al. [12] (Scheme 2.20). 
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O NH2
NC
+
N
H
O
NC
R2
Scheme 2.20
R1O
DMF-DMAR2
NaOMe
R1
R1 = Ph, 4-NMe2-Ph
R2 = Ph, 4-MeO-Ph
 
 
The 2-(2-cyano-acetylamino)-4-aryl-thiophene-3-carboxylic acid ethyl esters 
were treated with sodium hydride in tetrahydrofuran at temperatures ranging from 25 
to 80 °C to provide the thienopyridone compounds [35] (Scheme 2.21). 
 
S
Ar
COOEt
N
H
O
CN S
Ar
N
H
O
OH
CN
Ar = Aryl
NaH, THF
reflux
Scheme 2.21
 
 
2.2.5 Synthesis of N-substituted-cyanopyridones 
Melikyan et al. have reported synthesis of novel N-substituted-3-cyanopyridin-2-ones 
from ylidenecyanoacetic acid ethyl esters in two steps [80] (Scheme 2.22). 
 
Scheme 2.22
R1
CN
COOEt
N
O
O+ R1
CN
COOEt
N(Me)2
N O
CN
R1
R2
R1, R2 = alkyl
R2NH2
 
 
On heating 2-cyanoacetohydrazide and arylidene of ethyl cyanoacetate in 
ethanol containing triethyl amine under reflux afforded diaminopyridine derivative 
rather than aminopyridine derivative [81, 82] (Scheme 2.23). 
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O NH
NC
NH2
Ar
CN
COOEt
+ EtOH
Et3N
N
Ar
NC
O
NH2
NH2
COOEt
N
Ar
NC
O
NH2
OH
CN
N
Ar
NC
O
NH2
NH2
COOEt
N
Ar
NC
O
NH2
OH
CN
-H2
-H2
Ar = aryl, furyl
Scheme 2.23
 
Martin and coworkers reinvestigated the cyclocondensation of 2-cyanoaceto-
hydrazide with (4-methoxybenzylidene)malononitrile (Scheme 2.24). They have 
found that prolonged heating lead only to the formation of 1,6-diamino-4-(4-methoxy-
phenyl) -3,5-dicyano-2-pyridone [83]. 
 
O NH
NH2
NC
+
N
NH2
O
NC CN
NH2
Scheme 2.24
OCH3 OCH3
NC
CN
EtOH / Et3N
24h, 
 
 
Substituted N-benzoylaminopyridone was prepared by cyclocondensation of 
N-benzoylcyano-acetohydrazide with ethyl acetoacetate in presence of sodium 
methoxide [84] (Scheme 2.25). 
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O NH
NHCOPh
NC
+
N
NHCOPh
O
NC
OH
Scheme 2.25
Me
OEtO
O NaOCH3
Me
 
 
The reaction of N-cyanoacetylhydrazone of epiandrosterone with 
malononitrile in ethanol in the presence of a catalytic amount of piperidine afforded 
pyridine-2-one derivative [85] (Scheme 2.26). 
 
Me Me
Me
HO
H
H H
N
HN
CN
O
Me Me
Me
HO
H
H H
N
N
CNNC
EtOH / piperidine
Scheme 2.26
NH2
NH2
NC
O
 
 
Shams et al. [86] reported the reaction of the benzylidene derivative with 
methylene carbonitrile reagents (XCH2CN; X = CN, X = CO2Et) afforded the 
respective pyridone derivatives (Scheme 2.4). The reaction took place via β-attack on 
the benzylidene moiety followed by 1,6-intramolecular dipolar cyclization with 
concomitant aromatization. Further confirmation of the reaction products was 
achieved through an alternative synthetic route involving treatment of the starting 
compound cyano acetamide with benzylidene carbonitrile reagents (PhCH=C(CN)X; 
X = CN; X = COOEt) to afford the same pyridone derivatives with better yields (80%, 
86%) than in their formation by the reaction of benzylidene derivative and either 
malononitrile (75% yield) or ethyl cyanoacetate (73% yield) (Scheme 2.27). 
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S
CN
NHCOCH2CN
S
CN
N
H
O
CHPh
CN
+
+
XCH2CN
X = CN, COOEt
S
CN
N
H
O
CPh
CN
X
NC
- attack
Ph CH
CN
X
S
CN
N
O
CN
Ph
X
H2N
Scheme 2.27
 
Reactions of N-substituted cyanoacetamides with diethyl-2-(ethoxymethylene) 
malonate (DEEMM) [87] in EtOH in the presence of EtONa at room temperature 
resulted in the isolation of diaryl derivatives as major products (Method A) instead of 
the expected ethyl carboxylates (Scheme 2.28). 
 
N
H
O
CN
N N
H
O
NH2N
CN
O
R
+
EtOOC
COOEt
OEt
EtONa
EtOH, rt
Method A
+
EtOOC
NHO
CN
O
R R
R = H, 4-Me, 2-OMe, 2-Et, 3-Me, 4-F
Scheme 2.28
 
Thus, to examine a possible alternative synthetic route to such molecules, and 
also to model one of the possible reaction stages of their formation from 
cyanoacetamides and DEEMM (Scheme 2.28), ethoxymethylene derivatives were 
used (Scheme 2.29). Thus, their reaction with cyanoacetamides under the same 
conditions resulted in formation of the desired derivatives (Method B) [88]. 
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N
H
O
CN
N N
H
O
NH2N
CN
OR HC(OEt)3
R
R = H, 4-Me, 2-OMe, 2-Et, 3-Me, 4-F
Scheme 2.29
Ac2O NH
O
CN
R
OEt
EtONa
EtOH, rt
Method B
R
 
El-Rady et al. [89] reported the synthesis of 5-cyano-3-phenylmethylene-
pyridines by the condensation of 2-cyano-3-phenyl-N-p-tolylacrylamide with 
cyanoacetamide or cyanothioacet-amide or cyanoacetic acid hydrazide in ethanolic 
solution at reflux in the presence of drops of piperidine (Scheme 2.30). The isomers 
3,5-dicyano-2,3-dihydropyridines which have the same m/e are ruled out based 
mainly on the spectral analysis. 
 
Ar
HN O
CN
Ph
CN
NHRX
EtOH / pip.
reflux, 2h. Ar
HN
CN
Ph
CN
NHR
X
NPh
HN
Ar CN
X
R
NH
X = O, S
R = H, NH2
N
HN
Ar CN
X
R
Ph
NC
Ar = aryl
Scheme 2.30
 
 
2.2.6 Enzymatic synthesis of 3-cyano-2-pyridones 
Lipases, including Candida rugosa, formerly C. cylindracea, were used to synthesize 
the substituted 3-cyano-2-pyridones [90-93]. Unlike conventional syntheses that 
require heating in the presence of various catalysts and usually polar organic solvents, 
enzymatic synthesis was achieved under mild reaction conditions. Under such 
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conditions, various 4,6-disubstituted-3-cyano-2-pyridones were obtained, including 
aryl-substituted-3-cyano-2-pyridones (Scheme 2.31). 
 
+H3C
O
Lipase
N
H
CH3
H3C O
CN
CH3
C
CN
O
H2NO
+ 2H2O
Scheme 2.31
 
 
Prlainovic et al. [94] studies the kinetics of the enzyme-catalyzed synthesis of 
4,6-disubstituted-3-cyano-2-pyridones showed that the behavior of the lipase used as 
the catalyst in the synthesis of 4,6-dimethyl-3-cyano-2-pyridone is more complicated 
than that of chemical catalysts [92]. 
 
2.2.7 Cyanopyridones via Ultrasound and Microwave irradiation 
Al-Zaydi [95] reported the synthesis of cyanopyridones via heating cyano-acetamide 
derivative with ethyl acetoacetate in absence of solvent under reflux conventionally or 
ultrasound irradiation or in a microwave oven. 
They have prepared Several cyanoacetamides via treatment of ethylcyano-
acetate with primary amines either at room temperature for a longer time or via 
irradiation with microwave for 1 min. at 100 W or with ultrasound for 2 min. at 40 ºC. 
Then cyanoacetamides was reacted with an ethyl acetoacetate also either via a longer 
time using reflux of neat reagents and by a short time microwave or by ultrasound to 
afford cyanopyridones (Scheme 2.32). 
 
OEt
NC
O +
CH2 CH2
H
NH2N O
NC
CH3
O
OEtO
N
CH2Ph
O O
CN
CH3
Scheme 2.32
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Also, Gorobets et al. [96] develop a rapid microwave assisted protocol for the 
solution phase synthesis of highly substituted 2-pyridone derivatives (Scheme 2.33). 
They introduce general microwave-assisted [97] three component one-pot synthesis of 
highly substituted 2-pyridones, utilizing CH-acidic substrates, dimethylformamide 
dimethylacetal (DMF-DMA) and diverse methylene active nitriles [98]. 
The substituted 2-pyridone derivatives were obtained when a mixture of 
enamine, malononitrile and catalytic amounts of piperidine in i-PrOH was irradiated 
at 100 °C for 5 min. 
 
O
OMe
Me
N
Me
Me +
CN
CN
i-PrOH, piperidine
MW, 100 °C, 5 min.
DMF, HCl
O
Me
Me
N
H
O
CN
Scheme 2.33  
 
2.2.8 Synthesis of 3-cyano-2-pyridones by using vinamidinium salts 
5-Aryl-3-cyano-2-pyridones have been prepared by the cyclization of cyanoacetamide 
condensated with 2-aryl-3-dimethylamino-2-propenals. As shown in Scheme 2.34, the 
2-arylvinamidinium salts were condensed with cyanoacetamide in refluxing methanol 
that contained sodium methoxide to give the desired 5-aryl-3-cyano-2-pyridones [99]. 
The vinamidinium salts were prepared by the standard Vilsmeier-Haack reaction from 
the appropriate aryl acetic acid. 
 
N
N
ClO4
R
+
H2N
O
CN
NaOCH3, CH3OH
reflux, HCl, H2O R NH
CN
O
Scheme 2.34
 
 
2.2.9 Synthesis of azo-cyanopyridones 
Azo pyridines were synthesized by the diazotization-coupling reaction, as shown in 
Scheme 2.35. In this procedure acetylacetone was coupled with diazotised substituted 
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aniline to give an intermediate (3-(substituted-phenylazo)-2,4-pentanedione), which 
was then cyclized with cyanoacetamide to yield an azo-pyridones [100]. 
 
H3C
H3C
O
OH
+
N2
X X
N N
O
H3C
O
H3C
X
N N
NH3C
H
O
CN
CH3
Scheme 2.35
X = H, 4-CN, 4-Cl, 4-NO2, etc.
CN
H2N
O
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2.3 Current work 
The chemistry of pyridine and its derivatives has been studied for over a century due 
to their diverse biological activities. 3-cyano-2-pyridone derivatives draw a special 
attention for their wide spectrum biological activities along with their importance and 
utility as intermediates in preparing variety of heterocyclic compounds.  
Keeping in mind, various biomedical applications and with a view to further 
assess the pharmacological profile of this class of compounds, four novel series of 3-
cyano-2-pyridones (BHD-101 to BHD-140) have been synthesized. 
The synthesis of 3-cyano-2-pyridones was achieved by the reaction of an 
appropriate aromatic aldehydes, 2-cyano-N-(substituted)acetamides and malononitrile 
by using methanol as a solvent and piperidine as a catalyst. 2-cyano-N-(substituted) 
acetamides were prepared by the reaction of substituted anilines with ethyl 
cyanoacetate [101]. The products were characterized by FT-IR, mass, 1H NMR 
spectroscopy and elemental analyses. The newly synthesized compounds were 
subjected to various biological activities viz., antimicrobial, antimycobacterial, 
anticancer and antiviral. 
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2.4 Reaction scheme 
NC
+
CN
CN
CHO
R2 R2
N
CN
NH2
NC
BHD-101 to 140
a
Reagents and conditions: (a) Piperidine, MeOH, reflux, 10-12 h.
R1
O
NHO
R1
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
BHD-101 pyridin-2-yl H C18H11N5O 313 240-242 71 0.52 0.70 
BHD-102 pyridin-2-yl 4-F C18H10FN5O 331 189-191 66 0.50 0.69 
BHD-103 pyridin-2-yl 4-Cl C18H10ClN5O 347 245-247 75 0.48 0.65 
BHD-104 pyridin-2-yl 4-NO2 C18H10N6O3 358 270-272 74 0.45 0.68 
BHD-105 pyridin-2-yl 4-CH3 C19H13N5O 327 261-263 78 0.53 0.72 
BHD-106 pyridin-2-yl 4-OCH3 C19H13N5O2 343 204-206 72 0.44 0.64 
BHD-107 pyridin-2-yl 3,4-OCH3 C20H15N5O3 373 244-246 65 0.55 0.73 
BHD-108 pyridin-2-yl 3-NO2 C18H10N6O3 358 231-233 61 0.50 0.67 
BHD-109 pyridin-2-yl 3-Cl C18H10ClN5O 347 269-271 70 0.41 0.60 
BHD-110 pyridin-2-yl 2-Cl C18H10ClN5O 347 199-201 72 0.46 0.66 
BHD-111 3-Cl-4-F-C6H3 H C19H10ClFN4O 364 219-221 70 0.52 0.69 
BHD-112 3-Cl-4-F-C6H3 4-F C19H9ClF2N4O 382 227-229 79 0.56 0.74 
BHD-113 3-Cl-4-F-C6H3 4-Cl C19H9Cl2FN4O 399 190-192 75 0.50 0.66
BHD-114 3-Cl-4-F-C6H3 4-NO2 C19H9ClFN5O3 409 247-249 68 0.52 0.69 
BHD-115 3-Cl-4-F-C6H3 4-CH3 C20H12ClFN4O 378 239-241 76 0.61 0.77 
BHD-116 3-Cl-4-F-C6H3 4-OCH3 C20H12ClFN4O2 394 215-217 77 0.54 0.68
BHD-117 3-Cl-4-F-C6H3 3,4-OCH3 C21H14ClFN4O3 424 233-235 69 0.50 0.70 
BHD-118 3-Cl-4-F-C6H3 3-NO2 C19H9ClFN5O3 409 190-192 66 0.64 0.78 
BHD-119 3-Cl-4-F-C6H3 3-Cl C19H9Cl2FN4O 399 262-264 70 0.48 0.64
BHD-120 3-Cl-4-F-C6H3 2-Cl C19H9Cl2FN4O 399 260-262 75 0.51 0.69 
BHD-121 4-CH3-C6H4 H C20H14N4O 326 256-258 75 0.45 0.59 
BHD-122 4-CH3-C6H4 4-F C20H13FN4O 344 230-232 74 0.55 0.68
BHD-123 4-CH3-C6H4 4-Cl C20H13ClN4O 360 215-217 80 0.52 0.70 
BHD-124 4-CH3-C6H4 4-NO2 C20H13N5O3 371 270-272 70 0.50 0.66 
BHD-125 4-CH3-C6H4 4-CH3 C21H16N4O 340 203-205 79 0.58 0.73
BHD-126 4-CH3-C6H4 4-OCH3 C21H16N4O2 356 186-188 82 0.43 0.59 
BHD-127 4-CH3-C6H4 3,4-OCH3 C22H18N4O3 386 264-266 75 0.53 0.69 
BHD-128 4-CH3-C6H4 3-NO2 C20H13N5O3 371 218-220 72 0.52 0.67 
BHD-129 4-CH3-C6H4 3-Cl C20H13ClN4O 360 258-260 85 0.50 0.63 
BHD-130 4-CH3-C6H4 2-Cl C20H13ClN4O 360 220-222 71 0.48 0.58 
BHD-131 3-CF3-C6H4 H C20H11F3N4O 380 228-230 68 0.51 0.65 
BHD-132 3-CF3-C6H4 4-F C20H10F4N4O 398 239-241 71 0.45 0.61 
BHD-133 3-CF3-C6H4 4-Cl C20H10ClF3N4O 414 201-203 74 0.47 0.60 
BHD-134 3-CF3-C6H4 4-NO2 C20H10F3N5O3 425 266-268 65 0.57 0.74 
BHD-135 3-CF3-C6H4 4-CH3 C21H13F3N4O 394 257-259 69 0.49 0.62 
BHD-136 3-CF3-C6H4 4-OCH3 C21H13F3N4O2 410 230-232 74 0.52 0.65 
BHD-137 3-CF3-C6H4 3,4-OCH3 C22H15F3N4O3 440 250-252 70 0.48 0.65 
BHD-138 3-CF3-C6H4 3-NO2 C20H10F3N5O3 425 270-272 75 0.43 0.59 
BHD-139 3-CF3-C6H4 3-Cl C20H10ClF3N4O 414 221-223 68 0.50 0.64
BHD-140 3-CF3-C6H4 2-Cl C20H10ClF3N4O 414 217-219 72 0.54 0.68 
TLC Solvent system Rf1: Hexane: Ethyl acetate - 6:4; TLC Solvent system Rf2: Chloroform: Methanol - 9:1 
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2.4.1 Plausible Reaction Mechanism 
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2.5 Experimental 
 
2.5.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
with the structures assigned. 
 
2.5.2 Synthesis of 2-cyano-N-(substituted)acetamides 
 
Synthesis of 2-cyano-N-(substituted)acetamides was achieved using previously 
published methods [101]. 
 
2.5.3 General procedure for the synthesis of 6-amino-1,2-dihydro-4-(aryl)-2-oxo-1-
(pyridin-2-yl)pyridine-3,5-dicarbonitriles (BHD 101-110) 
 
A mixture of 2-cyano-N-(pyridin-2-yl)acetamide (0.01 mol), appropriate aromatic 
aldehydes (0.01 mol), malononitrile (0.01 mol) and catalytical amount of piperidine in 
methanol (20 ml) was heated under reflux condition for 10-12 h. The reaction mixture 
was kept at room temperature for 2-4 h. The solid product obtained was isolated and 
recrystallized from ethanol. 
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2.5.3.1 6-amino-1,2-dihydro-2-oxo-4-phenyl-1-(pyridin-2-yl)pyridine-3,5-dicarbo- 
nitrile (BHD-101) Yield: 71%; mp 240-242 ºC; IR (cm-1): 
3466 and 3331 (N-H stretching of primary amine), 3064 (C-H 
stretching of aromatic ring), 2220 and 2206 (C≡N stretching of 
nitrile group), 1656 (C=O stretching of pyridone ring), 1606 
(N-H deformation of NH2 group), 1629 (C=N stretching of 
pyridine ring), 1546 and 1518 (C=C stretching of aromatic ring), 
999 (C-H in plane bending for aromatic ring); 802 (C-H out of 
plane bending for 1,4-disubstituted aromatic ring); 1H NMR 
(DMSO-d6) δ ppm: 7.47-7.49 (d, 1H, Ha, J = 7.8 Hz), 7.55 (s, 6H, Hb-ee’), 7.58 (s, 2H, 
Hf), 8.02-8.06 (t, 1H, Hg, J = 7.7 Hz), 8.71-8.72 (d, 1H, Hh); MS: m/z 313; Anal. 
Calcd. for C18H11N5O: C, 69.00; H, 3.54; N, 22.35. Found: C, 68.80; H, 3.50; N, 
22.27%. 
 
2.5.3.2 6-amino-4-(4-fluorophenyl)-1,2-dihydro-2-oxo-1-(pyridin-2-yl)pyridine-3,5- 
dicarbonitrile (BHD-102) Yield: 66%; mp 189-191 ºC; MS: 
m/z 331; Anal. Calcd. for C18H10FN5O: C, 65.26; H, 3.04; N, 
21.14. Found: C, 65.11; H, 3.00; N, 21.09%. 
 
 
 
 
 
2.5.3.3 6-amino-4-(4-chlorophenyl)-1,2-dihydro-2-oxo-1-(pyridin-2-yl)pyridine-3,5- 
dicarbonitrile (BHD-103) Yield: 75%; mp 245-247 ºC; IR 
(cm-1): 3485 and 3321 (N-H stretching of primary amine), 
3072 (C-H stretching of aromatic ring), 2216 (C≡N stretching 
of nitrile group), 1672 (C=O stretching of pyridone ring), 1643 
(C=N stretching of pyridine ring), 1595 (N-H deformation of NH2 
group), 1531 and 1498 (C=C stretching of aromatic ring), 1352 
(C-N stretching for carbon bonded to amino group), 1014 (C-H in 
plane bending for aromatic ring), 839 (C-H out of plane 
bending for 1,4-disubstituted aromatic ring), 771 (C-Cl stretching); 1H NMR (DMSO-
N
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d6) δ ppm: 7.39-7.42 (d, 1H, Ha, J = 7.1 Hz), 7.46-7.59 (m, 5H, Hb-dd’), 7.65 (s, 2H, 
He), 8.03-8.07 (t, 1H, Hf, J = 7.7 Hz), 8.73-8.74 (d, 1H, Hg); MS: m/z 347; Anal. 
Calcd. for C18H10ClN5O: C, 62.17; H, 2.90; N, 20.14. Found: C, 61.98; H, 2.84; N, 
20.11%. 
 
2.5.3.4 6-amino-1,2-dihydro-4-(4-nitrophenyl)-2-oxo-1-(pyridin-2-yl)pyridine-3,5- 
dicarbonitrile (BHD-104) Yield: 74%; mp 270-272 ºC; IR 
(cm-1): 3296 and 3269 (N-H stretching of primary amine), 
3082 (C-H stretching of aromatic ring), 2218 (C≡N stretching 
of nitrile group), 1664 (C=O stretching of pyridone ring), 1647 
(C=N stretching of pyridine ring), 1602 (N-H deformation of NH2 
group), 1552 (NO2 asymmetrical stretching), 1533 and 1516 
(C=C stretching of aromatic ring), 1346 (C-N stretching for 
carbon bonded to amino group), 1290 (NO2 symmetrical 
stretching), 852 (C-H out of plane bending for 1,4-disubstituted aromatic ring); 1H 
NMR (DMSO-d6) δ ppm: 7.47-7.49 (d, 1H, Ha, J = 8.0 Hz), 7.56-7.59 (t, 3H, Hbc), 
7.77-7.79 (d, 2H, Hdd’, J = 8.6 Hz), 8.03-8.07 (t, 1H, He, J = 7.3 Hz), 8.39-8.41 (d, 2H, 
Hff’, J = 8.6 Hz); 8.73-8.74 (d, 1H, Hg); MS: m/z 358; Anal. Calcd. for C18H10N6O3: C, 
60.34; H, 2.81; N, 23.45. Found: C, 60.19; H, 2.75; N, 23.42%. 
 
2.5.3.5 6-amino-1,2-dihydro-2-oxo-1-(pyridin-2-yl)-4-p-tolylpyridine-3,5-dicarbonitrile 
(BHD-105) Yield: 78%; mp 261-263 ºC; MS: m/z 327; Anal. 
Calcd. for C19H13N5O: C, 69.71; H, 4.00; N, 21.39. Found: C, 
69.57; H, 3.99; N, 21.31%. 
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2.5.3.6 6-amino-1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-1-(pyridin-2-yl)pyridine- 
3,5-dicarbonitrile (BHD-106) Yield: 72%; mp 204-206 ºC; 
MS: m/z 343; Anal. Calcd. for C19H13N5O2: C, 66.47; H, 3.82; 
N, 20.40. Found: C, 66.31; H, 3.80; N, 20.32%. 
 
 
 
 
 
2.5.3.7 6-amino-1,2-dihydro-4-(3,4-dimethoxyphenyl)-2-oxo-1-(pyridin-2-yl)pyridine-  
3,5-dicarbonitrile (BHD-107) Yield: 65%; mp 244-246 ºC; 
MS: m/z 373; Anal. Calcd. for C20H15N5O3: C, 64.34; H, 4.05; 
N, 18.76. Found: C, 64.20; H, 4.01; N, 18.69%. 
 
 
 
 
 
2.5.3.8 6-amino-1,2-dihydro-4-(3-nitrophenyl)-2-oxo-1-(pyridin-2-yl)pyridine-3,5- 
dicarbonitrile (BHD-108) Yield: 61%; mp 231-233 ºC; MS: 
m/z 358; Anal. Calcd. for C18H10N6O3: C, 60.34; H, 2.81; N, 
23.45. Found: C, 60.16; H, 2.77; N, 23.40%. 
 
 
 
 
2.5.3.9 6-amino-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-1-(pyridin-2-yl)pyridine-3,5- 
dicarbonitrile (BHD-109) Yield: 70%; mp 269-271 ºC; MS: 
m/z 347; Anal. Calcd. for C18H10ClN5O: C, 62.17; H, 2.90; N, 
20.14. Found: C, 62.01; H, 2.86; N, 20.08%. 
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2.5.3.10 6-amino-4-(2-chlorophenyl)-1,2-dihydro-2-oxo-1-(pyridin-2-yl)pyridine- 
3,5-dicarbonitrile (BHD-110) Yield: 72%; mp 199-201 ºC; 
MS: m/z 347; Anal. Calcd. for C18H10ClN5O: C, 62.17; H, 2.90; 
N, 20.14. Found: C, 62.00; H, 2.87; N, 20.10%. 
 
 
 
 
2.5.4 General procedure for the synthesis of 6-amino-1-(3-chloro-4-fluorophenyl)-
1,2-dihydro-4-(aryl)-2-oxopyridine-3,5-dicarbonitrile (BHD 111-120) 
 
A mixture of N-(3-chloro-4-fluorophenyl)-2-cyano-acetamide (0.01 mol), appropriate 
aromatic aldehydes (0.01 mol), malononitrile (0.01 mol) and catalytical amount of 
piperidine in methanol (20 ml) was heated under reflux condition for 10-12 h. The 
reaction mixture was kept at room temperature for 2-4 h. The solid product obtained 
was isolated and recrystallized from ethanol. 
 
2.5.4.1 6-amino-1-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-4-phenylpyridine- 
3,5-dicarbonitrile (BHD-111) Yield: 70%; mp 219-221 ºC; IR 
(cm-1): 3444 and 3304 (N-H stretching of primary amine), 
3109 (C-H stretching of aromatic ring), 2224 (C≡N stretching 
of nitrile group), 1660 (C=O stretching of pyridone ring), 1629 
(N-H deformation of NH2 group), 1527 and 1494 (C=C 
stretching of aromatic ring), 1300 (C-N stretching for carbon 
bonded to amino group), 1078 (C-F stretching), 1058 (C-H in 
plane bending for aromatic ring), 833 (C-H out of plane 
bending for 1,4-disubstituted aromatic ring), 773 (C-Cl stretching); 1H NMR (DMSO-
d6) δ ppm: 7.27-7.29 (d, 1H, Ha), 7.41-7.45 (t, 1H, Hb), 7.48-7.56 (m, 6H, Hcc’-f), 7.77 
(s, 1H, Hg); MS: m/z 364; Anal. Calcd. for C19H10ClFN4O: C, 62.56; H, 2.76; N, 
15.36. Found: C, 62.40; H, 2.73; N, 15.29%. 
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2.5.4.2 6-amino-1-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1,2-dihydro-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-112) Yield: 79%; mp 227-
229 ºC; MS: m/z 382; Anal. Calcd. for C19H9ClF2N4O: C, 
59.62; H, 2.37; N, 14.64. Found: C, 59.49; H, 2.31; N, 14.54%. 
 
 
 
 
 
 
2.5.4.3 6-amino-1-(3-chloro-4-fluorophenyl)-4-(4-chlorophenyl)-1,2-dihydro-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-113) Yield: 75%; mp 190-
192 ºC; MS: m/z 399; Anal. Calcd. for C19H9Cl2FN4O: C, 
57.16; H, 2.27; N, 14.03. Found: C, 57.01; H, 2.21; N, 13.97%. 
 
 
 
 
 
 
2.5.4.4 6-amino-1-(3-chloro-4-fluorophenyl)-1,2-dihydro-4-(4-nitrophenyl)-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-114) Yield: 68%; mp 247-
249 ºC; MS: m/z 409; Anal. Calcd. for C19H9ClFN5O3: C, 
55.69; H, 2.21; N, 17.09. Found: C, 55.53; H, 2.20; N, 16.98%. 
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2.5.4.5 6-amino-1-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-4-p-tolylpyridine- 
3,5-dicarbonitrile (BHD-115) Yield: 76%; mp 239-241 ºC; 
IR (cm-1): 3423 and 3315 (N-H stretching of primary amine), 
3041 (C-H stretching of aromatic ring), 2949 (C-H 
symmetrical stretching of CH3 group), 2864 (C-H 
asymmetrical stretching of CH3 group), 2224 and 2206 (C≡N 
stretching of nitrile group), 1662 (C=O stretching of pyridone 
ring), 1645 (N-H deformation of NH2 group), 1533 and 1465 
(C=C stretching of aromatic ring), 1300 (C-N stretching for 
carbon bonded to amino group), 1093 (C-F stretching), 1064 (C-
H in plane bending for aromatic ring), 817 (C-H out of plane bending for 1,4-
disubstituted aromatic ring), 773 (C-Cl stretching); 1H NMR (DMSO-d6) δ ppm: 2.43 
(s, 3H, Ha), 7.23-7.27 (m, 1H, Hb), 7.33-7.35 (d, 2H, Hcc’), 7.39-7.47 (m, 4H, Hdd’-f), 
7.53 (s, 2H, Hg); MS: m/z 378; Anal. Calcd. for C20H12ClFN4O: C, 63.42; H, 3.19; N, 
14.79. Found: C, 63.27; H, 3.15; N, 14.70%. 
 
2.5.4.6 6-amino-1-(3-chloro-4-fluorophenyl)-1,2-dihydro-4-(4-methoxyphenyl)-2- 
oxopyridine-3,5-dicarbonitrile (BHD-116) Yield: 77%; mp 
215-217 ºC; MS: m/z 394; Anal. Calcd. for C20H12ClFN4O2: C, 
60.85; H, 3.06; N, 14.19. Found: C, 60.69; H, 3.02; N, 14.14%. 
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2.5.4.7 6-amino-1-(3-chloro-4-fluorophenyl)-1,2-dihydro-4-(3,4-dimethoxyphenyl)- 
2-oxopyridine-3,5-dicarbonitrile (BHD-117) Yield: 69%; mp 
233-235 ºC; MS: m/z 424; Anal. Calcd. for C21H14ClFN4O3: C, 
59.37; H, 3.32; N, 13.19. Found: C, 59.21; H, 3.27; N, 13.10%. 
 
 
 
 
 
 
2.5.4.8 6-amino-1-(3-chloro-4-fluorophenyl)-1,2-dihydro-4-(3-nitrophenyl)-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-118) Yield: 66%; mp 190-
192 ºC; MS: m/z 409; Anal. Calcd. for C19H9ClFN5O3: C, 
55.69; H, 2.21; N, 17.09. Found: C, 55.50; H, 2.17; N, 17.03%. 
 
 
 
 
 
2.5.4.9 6-amino-1-(3-chloro-4-fluorophenyl)-4-(3-chlorophenyl)-1,2-dihydro-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-119) Yield: 70%; mp 262-
264 ºC; IR (cm-1): 3419 and 3331 (N-H stretching of primary 
amine), 3068 (C-H stretching of aromatic ring), 2218 (C≡N 
stretching of nitrile group), 1691 (C=O stretching of pyridone 
ring), 1631 (N-H deformation of NH2 group), 1531 and 1465 
(C=C stretching of aromatic ring), 1300 (C-N stretching for 
carbon bonded to amino group), 1074 (C-F stretching), 802 (C-H 
out of plane bending for 1,3-disubstituted aromatic ring); 1H 
NMR (DMSO-d6) δ ppm: 7.26-7.30 (m, 1H, Ha), 7.42-7.55 (m, 6H, Hb-g), 7.80 (s, 2H, 
Hh); MS: m/z 399; Anal. Calcd. for C19H9Cl2FN4O: C, 57.16; H, 2.27; N, 14.03. 
Found: C, 57.01; H, 2.21; N, 13.97%. 
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2.5.4.10 6-amino-1-(3-chloro-4-fluorophenyl)-4-(2-chlorophenyl)-1,2-dihydro-2- 
oxo-pyridine-3,5-dicarbonitrile (BHD-120) Yield: 75%; mp 
260-262 ºC; MS: m/z 399; Anal. Calcd. for C19H9Cl2FN4O: C, 
57.16; H, 2.27; N, 14.03. Found: C, 56.98; H, 2.20; N, 13.99%. 
 
 
 
 
 
2.5.5 General procedure for the synthesis of 6-amino-1,2-dihydro-4-(aryl)-2-oxo-1-
p-tolylpyridine-3,5- dicarbonitrile (BHD 121-130) 
 
A mixture of 2-cyano-N-p-tolylacetamide (0.01 mol), appropriate aromatic aldehydes 
(0.01 mol), malononitrile (0.01 mol) and catalytical amount of piperidine in methanol 
(20 ml) was heated under reflux condition for 10-12 h. The reaction mixture was kept 
at room temperature for 2-4 h. The solid product obtained was isolated and 
recrystallized from ethanol. 
 
2.5.5.1 6-amino-1,2-dihydro-2-oxo-4-phenyl-1-p-tolylpyridine-3,5-dicarbonitrile 
(BHD-121) Yield: 75%; mp 256-258 ºC; IR (cm-1): 3429 and 
3275 (N-H stretching of primary amine), 3064 (C-H stretching 
of aromatic ring), 2229 and 2214 (C≡N stretching of nitrile 
group), 1647 (C=O stretching of pyridone ring), 1597 (N-H 
deformation of NH2 group), 1560 and 1514 (C=C stretching of 
aromatic ring), 825 (C-H out of plane bending for 1,4-
disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 2.46 
(s, 3H, Ha), 7.18-7.20 (d, 2H, Hbb’, J = 8.1 Hz), 7.42-7.44 (d, 
2H, Hcc’, J = 7.9 Hz), 7.54-7.55 (d, 5H, Hd-ff’), 7.71 (s, 2H, Hg); MS: m/z 326; Anal. 
Calcd. for C20H14N4O: C, 73.61; H, 4.32; N, 17.17. Found: C, 73.47; H, 4.25; N, 
17.10%. 
 
 
 
N
CN
NH2
NC
O
Cl
F
Cl
N
CN
NH2
NC
O
CH3a
b b'
c c'
d
e e'
f f'
g
 
 
Chapter 2                                                                                                Cyanopyridones 
     
   37
2.5.5.2 6-amino-4-(4-fluorophenyl)-1,2-dihydro-2-oxo-1-p-tolylpyridine-3,5-dicarbo- 
nitrile (BHD-122) Yield: 74%; mp 230-232 ºC; MS: m/z 344; 
Anal. Calcd. for C20H13FN4O: C, 69.76; H, 3.81; N, 16.27. 
Found: C, 69.63; H, 3.80; N, 16.24%. 
 
 
 
 
 
 
2.5.5.3 6-amino-4-(4-chlorophenyl)-1,2-dihydro-2-oxo-1-p-tolylpyridine-3,5-dicarbo- 
nitrile (BHD-123) Yield: 80%; mp 215-217 ºC; MS: m/z 360; 
Anal. Calcd. for C20H13ClN4O: C, 66.58; H, 3.63; N, 15.53. 
Found: C, 66.41; H, 3.60; N, 15.42%. 
 
 
 
 
 
 
2.5.5.4 6-amino-1,2-dihydro-4-(4-nitrophenyl)-2-oxo-1-p-tolylpyridine-3,5-dicarbo- 
nitrile (BHD-124) Yield: 70%; mp 270-272 ºC; IR (cm-1): 
3429 and 3267 (N-H stretching of primary amine), 3064 (C-H 
stretching of aromatic ring), 2229 and 2214 (C≡N stretching 
of nitrile group), 1649 (C=O stretching of pyridone ring), 
1599 (N-H deformation of NH2 group), 1558 and 1516 (C=C 
stretching of aromatic ring), 1290 (C-N stretching for carbon 
bonded to amino group), 1070 (C-H in plane bending for 
aromatic ring), 823 (C-H out of plane bending for 1,4-
disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 
2.47 (s, 3H, Ha), 7.18-7.20 (d, 2H, Hbb’, J = 8.2 Hz), 7.43-7.45 (d, 2H, Hcc’, J = 8.1 
Hz), 7.75 (s, 2H, Hd), 7.78-7.81 (d, 2H, Hee’), 7.39-7.42 (d, 2H, Hff’); MS: m/z 371; 
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Anal. Calcd. for C20H13N5O3: C, 64.69; H, 3.53; N, 18.86. Found: C, 64.54; H, 3.49; 
N, 18.79%. 
 
2.5.5.5 6-amino-1,2-dihydro-2-oxo-1,4-dip-tolylpyridine-3,5-dicarbonitrile (BHD- 
125) Yield: 79%; mp 203-205 ºC; MS: m/z 340; Anal. Calcd. 
for C21H16N4O: C, 74.10; H, 4.74; N, 16.46. Found: C, 73.97; 
H, 4.69; N, 16.40%. 
 
 
 
 
 
 
2.5.5.6 6-amino-1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-1-p-tolylpyridine-3,5-di- 
carbonitrile (BHD-126) Yield: 82%; mp 186-188 ºC; MS: m/z 
356; Anal. Calcd. for C21H16N4O2: C, 70.77; H, 4.53; N, 15.72. 
Found: C, 70.60; H, 4.47; N, 15.61 %. 
 
 
 
 
 
 
2.5.5.7 6-amino-1,2-dihydro-4-(3,4-dimethoxyphenyl)-2-oxo-1-p-tolylpyridine-3,5- 
dicarbonitrile (BHD-127) Yield: 75%; mp 264-266 ºC; IR 
(cm-1): 3435 and 3365 (N-H stretching of primary amine), 
3068 (C-H stretching of aromatic ring), 2997 (C-H 
symmetrical stretching of CH3 group), 2839 (C-H 
asymmetrical stretching of CH3 group), 2212 (C≡N stretching 
of nitrile group), 1660 (C=O stretching of pyridone ring), 
1600 (N-H deformation of NH2 group), 1560 and 1518 (C=C 
stretching of aromatic ring), 1325 (C-N stretching for carbon 
bonded to amino group), 1265 (C-O-C asymmetrical stretching 
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of OCH3 group), 1145 (C-O-C symmetrical stretching OCH3 group), 1022 (C-H in 
plane bending for aromatic ring), 877 (C-H out of plane bending for 1,4-disubstituted 
aromatic ring); 1H NMR (DMSO-d6) δ ppm: 2.46 (s, 3H, Ha), 3.93 (s, 6H, Hb), 7.01-
7.21 (m, 5H, Hc-ff’), 7.42-7.44 (d, 2H, Hgg’, J = 7.9 Hz), 7.71 (s, 2H, Hh); MS: m/z 386; 
Anal. Calcd. for C22H18N4O3: C, 68.38; H, 4.70; N, 14.50. Found: C, 68.21; H, 4.67; 
N, 14.43 %. 
 
2.5.5.8 6-amino-1,2-dihydro-4-(3-nitrophenyl)-2-oxo-1-p-tolylpyridine-3,5-dicarbo- 
nitrile (BHD-128) Yield: 72%; mp 218-220 ºC; MS: m/z 371; 
Anal. Calcd. for C20H13N5O3: C, 64.69; H, 3.53; N, 18.86. 
Found: C, 64.51; H, 3.47; N, 18.81%. 
 
 
 
 
 
2.5.5.9 6-amino-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-1-p-tolylpyridine-3,5-dicarbo- 
nitrile (BHD-129) Yield: 85%; mp 258-260 ºC; MS: m/z 360; 
Anal. Calcd. for C20H13ClN4O: C, 66.58; H, 3.63; N, 15.53. 
Found: C, 66.45; H, 3.58; N, 15.43%. 
 
 
 
 
 
2.5.5.10 6-amino-4-(2-chlorophenyl)-1,2-dihydro-2-oxo-1-p-tolylpyridine-3,5-di- 
carbonitrile (BHD-130) Yield: 71%; mp 220-222 ºC; MS: m/z 
360; Anal. Calcd. for C20H13ClN4O: C, 66.58; H, 3.63; N, 
15.53. Found: C, 66.40; H, 3.60; N, 15.46%. 
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2.5.6 General procedure for the synthesis of 6-amino-1-(3-(trifluoromethyl)phenyl)-
1,2-dihydro-4-(aryl)-2-oxopyridine-3,5-dicarbonitrile (BHD 131-140) 
 
A mixture of 2-cyano-N-(3-(trifluoromethyl)phenyl)acetamide (0.01 mol), appropriate 
aromatic aldehydes (0.01 mol), malononitrile (0.01 mol) and catalytical amount of 
piperidine in methanol (20 ml) was heated under reflux condition for 10-12 h. The 
reaction mixture was kept at room temperature for 2-4 h. The solid product obtained 
was isolated and recrystallized from ethanol. 
 
2.5.6.1 6-amino-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-2-oxo-4-phenylpyridine- 
3,5-dicarbonitrile (BHD-131) Yield: 68%; mp 228-230 ºC; IR 
(cm-1): 3456 and 3311 (N-H stretching of primary amine), 
3066 (C-H stretching of aromatic ring), 2218 (C≡N stretching 
of nitrile group), 1674 (C=O stretching of pyridone ring), 1631 
(N-H deformation of NH2 group), 1525 and 1464 (C=C 
stretching of aromatic ring), 1329 (C-N stretching for carbon 
bonded to amino group), 1001 (C-H in plane bending for 
aromatic ring), 781 (C-H out of plane bending for 1,3-
disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 7.53-7.57 (t, 7H, Ha-e), 7.64 
(s, 2H, Hf), 7.77-7.86 (m, 2H, Hgh); MS: m/z 380; Anal. Calcd. for C20H11F3N4O: C, 
63.16; H, 2.92; N, 14.73. Found: C, 63.02; H, 2.90; N, 14.65%. 
 
2.5.6.2 6-amino-1-(3-(trifluoromethyl)phenyl)-4-(4-fluorophenyl)-1,2-dihydro-2- 
oxopyridine-3,5-dicarbonitrile (BHD-132) Yield: 71%; mp 
239-241 ºC; IR (cm-1): 3462 and 3311 (N-H stretching of 
primary amine), 3076 (C-H stretching of aromatic ring), 2225 
and 2212 (C≡N stretching of nitrile group), 1687 (C=O 
stretching of pyridone ring), 1629 (C=N stretching of pyridine 
ring), 1600 (N-H deformation of NH2 group), 1550 and 1465 
(C=C stretching of aromatic ring), 1330 (C-N stretching for 
carbon bonded to amino group), 1070 (C-F stretching), 842 (C-H 
out of plane bending for 1,4-disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 
7.25-7.27 (d, 2H, Haa’), 7.54-7.62 (m, 6H, Hbb’-e), 7.78-7.86 (m, 2H, Hfg); MS: m/z 398; 
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Anal. Calcd. for C20H10F4N4O: C, 60.31; H, 2.53; N, 14.07. Found: C, 60.25; H, 2.51; 
N, 13.97%. 
 
2.5.6.3 6-amino-4-(4-chlorophenyl)-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-2- 
oxopyridine-3,5-dicarbonitrile (BHD-133) Yield: 74%; mp 
201-203 ºC; MS: m/z 414; Anal. Calcd. for C20H10ClF3N4O: C, 
57.92; H, 2.43; N, 13.51. Found: C, 57.80; H, 2.40; N, 13.47%. 
 
 
 
 
 
 
2.5.6.4 6-amino-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-4-(4-nitrophenyl)-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-134) Yield: 65%; mp 266-
268 ºC; MS: m/z 425; Anal. Calcd. for C20H10F3N5O3: C, 
56.48; H, 2.37; N, 16.47. Found: C, 56.40; H, 2.33; N, 16.41%. 
 
 
 
 
 
 
2.5.6.5 6-amino-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-2-oxo-4-p-tolylpyridine- 
3,5-dicarbonitrile (BHD-135) Yield: 69%; mp 257-259 ºC; 
MS: m/z 394; Anal. Calcd. for C21H13F3N4O: C, 63.96; H, 3.32; 
N, 14.21. Found: C, 63.82; H, 3.28; N, 14.14%. 
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2.5.6.6 6-amino-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-4-(4-methoxyphenyl)-2- 
oxopyridine-3,5-dicarbonitrile (BHD-136) Yield: 74%; mp 
230-232 ºC; IR (cm-1): 3460 and 3292 (N-H stretching of 
primary amine), 3078 (C-H stretching of aromatic ring), 2224 
and 2212 (C≡N stretching of nitrile group), 1689 (C=O 
stretching of pyridone ring), 1629 (C=N stretching of pyridine 
ring), 1593 (N-H deformation of NH2 group), 1516 and 1460 
(C=C stretching of aromatic ring), 1330 (C-N stretching for 
carbon bonded to amino group), 1232 (C-O-C asymmetrical 
stretching of OCH3 group), 1070 (C-O-C symmetrical 
stretching OCH3 group), 1020 (C-F stretching), 837 (C-H out of plane bending for 
1,4-disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 3.88 (s, 3H, Ha), 7.05-
7.07 (d, 2H, Hbb’), 7.51-7.57 (m, 4H, Hcc’-e), 7.64 (s, 2H, Hf), 7.76-7.85 (m, 2H, Hgh); 
MS: m/z 410; Anal. Calcd. for C21H13F3N4O2: C, 61.47; H, 3.19; N, 13.65. Found: C, 
61.39; H, 3.17; N, 13.59%. 
 
2.5.6.7 6-amino-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-4-(3,4-dimethoxyphenyl)-  
2-oxopyridine-3,5-dicarbonitrile (BHD-137) Yield: 70%; mp 
250-252 ºC; MS: m/z 440; Anal. Calcd. for C22H15F3N4O3: C, 
60.00; H, 3.43; N, 12.72. Found: C, 59.87; H, 3.40; N, 12.65%. 
 
 
 
 
 
 
2.5.6.8 6-amino-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-4-(3-nitrophenyl)-2-oxo- 
pyridine-3,5-dicarbonitrile (BHD-138) Yield: 75%; mp 270-
272 ºC; MS: m/z 425; Anal. Calcd. for C20H10F3N5O3: C, 
56.48; H, 2.37; N, 16.47. Found: C, 56.36; H, 2.35; N, 16.39%. 
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2.5.6.9 6-amino-4-(3-chlorophenyl)-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-2- 
oxopyridine-3,5-dicarbonitrile (BHD-139) Yield: 68%; mp 
221-223 ºC; MS: m/z 414; Anal. Calcd. for C20H10ClF3N4O: C, 
57.92; H, 2.43; N, 13.51. Found: C, 57.77; H, 2.37; N, 13.45%. 
 
 
 
 
 
2.5.6.10 6-amino-4-(2-chlorophenyl)-1-(3-(trifluoromethyl)phenyl)-1,2-dihydro-2- 
oxopyridine-3,5-dicarbonitrile (BHD-140) Yield: 72%; mp 
217-219 ºC; MS: m/z 414; Anal. Calcd. for C20H10ClF3N4O: C, 
57.92; H, 2.43; N, 13.51. Found: C, 57.75; H, 2.39; N, 13.41%. 
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2.6 Spectral discussion 
2.6.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
2.6.1.1 Plausible mass fragmentation pattern for BHD-101 
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2.6.1.2 Plausible mass fragmentation pattern for BHD-119 
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2.6.1.3 Plausible mass fragmentation pattern for BHD-121 
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2.6.1.4 Plausible mass fragmentation pattern for BHD-132 
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2.6.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For 3-cyano-2-pyridones (BHD-101 to 140), 
confirmatory bands for primary amine (-NH2), carbonyl (C=O) and nitrile (C≡N) 
stretching band was observed at 3250-3500 cm-1, 1650-1700 cm-1 and 2200-2230 cm-1 
respectively. Another characteristic band for N-H deformation and C-N stretching 
were observed at 1595-1650 cm-1 and 1290-1360 cm-1 respectively, which suggested 
the formation of pyridone ring. 
 
2.6.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
1H NMR spectra confirmed the structures of 3-cyano-2-pyridones (BHD-101 
to 140) on the basis of following signals: singlet for primary amino group proton was 
observed at 7.50-7.90 δ ppm. The aromatic ring protons and J value were found to be 
in accordance with substitution pattern on phenyl ring.  
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Mass spectrum of BHD-101 
 
IR spectrum of BHD-101 
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1H NMR spectrum of BHD-101 
 
Expanded 1H NMR spectrum of BHD-101 
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Mass spectrum of BHD-103 
 
IR spectrum of BHD-103 
40060080010001200140016001800200024002800320036004000
1/cm
-15
0
15
30
45
60
75
90
105
%T
35
53
.0
0
34
85
.4
9
33
21
.5
3
33
08
.0
3
32
48
.2
3
32
07
.7
3
30
97
.7
8
30
72
.7
1
22
16
.2
8
16
72
.3
4
16
43
.4
1
16
10
.6
1
15
95
.1
8
15
77
.8
2
15
31
.5
3
14
98
.7
4
14
69
.8
1
14
48
.5
9
13
96
.5
1
13
52
.1
4
12
74
.9
9
12
24
.8
4
11
51
.5
4
10
93
.6
7
10
14
.5
9
83
9.
06
82
1.
70
77
1.
55
66
3.
53
61
9.
17
52
0.
80
45
9.
07
103  
 
Chapter 2                                                                                                Cyanopyridones 
     
   52
1H NMR spectrum of BHD-103 
 
Expanded 1H NMR spectrum of BHD-103 
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Mass spectrum of BHD-104 
 
IR spectrum of BHD-104 
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1H NMR spectrum of BHD-104 
 
Expanded 1H NMR spectrum of BHD-104 
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Mass spectrum of BHD-111 
 
IR spectrum of BHD-111 
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1H NMR spectrum of BHD-111 
 
Expanded 1H NMR spectrum of BHD-111 
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 Mass spectrum of BHD-115 
 
IR spectrum of BHD-115 
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1H NMR spectrum of BHD-115 
 
Expanded 1H NMR spectrum of BHD-115 
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Mass spectrum of BHD-119 
 
IR spectrum of BHD-119 
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1H NMR spectrum of BHD-119 
 
Expanded 1H NMR spectrum of BHD-119 
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Mass spectrum of BHD-121 
 
IR spectrum of BHD-121 
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1H NMR spectrum of BHD-121 
 
Expanded 1H NMR spectrum of BHD-121 
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Mass spectrum of BHD-124 
 
IR spectrum of BHD-124 
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1H NMR spectrum of BHD-124 
 
Expanded 1H NMR spectrum of BHD-124 
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Mass spectrum of BHD-127 
 
IR spectrum of BHD-127 
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1H NMR spectrum of BHD-127 
 
Expanded 1H NMR spectrum of BHD-127 
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Mass spectrum of BHD-131 
 
IR spectrum of BHD-131 
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1H NMR spectrum of BHD-131 
 
Expanded 1H NMR spectrum of BHD-131 
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Mass spectrum of BHD-132 
 
IR spectrum of BHD-132 
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1H NMR spectrum of BHD-132 
 
Expanded 1H NMR spectrum of BHD-132 
 
 
Chapter 2                                                                                                Cyanopyridones 
     
   71
Mass spectrum of BHD-136 
 
IR spectrum of BHD-136 
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1H NMR spectrum of BHD-136 
 
Expanded 1H NMR spectrum of BHD-136 
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2.7 Biological evaluation 
2.7.1 Antimicrobial evaluation 
All the synthesized compounds (BHD-101 to BHD-140) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [102, 103] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and greseofulvin as 
standard drugs. The standard strains were procured from the Microbial Type Culture 
Collection (MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, 
India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [102]. Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 200 μg mL-1, 100 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.25 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied.  
The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds BHD-101 to 140 
 
Code Minimal inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
BHD-101 200 500 250 200 1000 500 500 
BHD-102 200 500 200 200 500 >1000 >1000 
BHD-103 100 250 62.5 100 >1000 500 >1000 
BHD-104 250 250 100 250 1000 500 1000 
BHD-105 250 62.5 50 100 500 250 500 
BHD-106 500 200 62.5 200 250 1000 1000 
BHD-107 200 500 250 250 500 1000 1000 
BHD-108 500 500 200 200 1000 500 >1000 
BHD-109 100 100 250 250 >1000 500 1000 
BHD-110 150 100 62.5 100 500 250 500 
BHD-111 200 500 250 250 >1000 >1000 >1000 
BHD-112 500 250 200 100 500 1000 1000 
BHD-113 250 500 250 500 >1000 1000 1000 
BHD-114 250 250 100 250 500 1000 500 
BHD-115 200 200 100 100 500 >1000 1000 
BHD-116 250 500 500 200 >1000 500 >1000 
BHD-117 200 100 250 62.5 500 500 >1000 
BHD-118 500 500 200 250 500 1000 500 
BHD-119 200 200 100 250 500 1000 >1000 
BHD-120 200 250 100 250 >1000 >1000 1000 
BHD-121 500 500 500 200 >1000 >1000 >1000 
BHD-122 500 500 250 250 >1000 500 >1000 
BHD-123 100 250 250 200 500 >1000 500 
BHD-124 250 250 100 100 >1000 >1000 >1000 
BHD-125 200 200 500 500 >1000 1000 >1000 
BHD-126 500 500 250 500 >1000 >1000 >1000 
BHD-127 200 200 100 200 1000 1000 250 
BHD-128 250 500 200 250 500 1000 >1000 
BHD-129 500 500 100 250 1000 1000 250 
BHD-130 200 200 200 250 1000 1000 >1000 
BHD-131 500 500 250 200 >1000 >1000 >1000 
BHD-132 100 50 250 200 500 100 250 
BHD-133 250 250 500 500 500 250 500 
BHD-134 100 500 250 200 >100 >1000 >1000 
BHD-135 500 500 250 500 250 >1000 >1000 
BHD-136 250 200 150 100 500 500 250 
BHD-137 200 500 250 500 250 500 >1000 
BHD-138 200 100 62.5 250 1000 1000 500 
BHD-139 500 250 500 500 >1000 >1000 >1000 
BHD-140 250 250 500 250 1000 500 >1000 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Greseofulvin - - - - 500 100 100 
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2.7.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds BHD-101 to BHD-140 is currently under investigation and results are 
awaited. 
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 Chapter 3 
  
 Multicomponent one-pot synthesis and    
 biological evaluation of pyrano[2,3-c] 
 pyrazoles 
 
 
  
3.1 Introduction - MCRs 
Despite recent advances in molecular biology and the progress in combinatorial 
synthetic methodology, the rate of introduction of new medicines has decreased 
markedly over the past two decades [1]. Structural diversity in a focused collection of 
potential therapeutics is believed to increase the positive hit rate. Most medicines in 
use are still small synthetic organic molecules that often contain a heterocyclic ring. 
However, the range of easily accessible and suitably functionalized heterocyclic 
building blocks for the synthesis of structurally diverse libraries is rather limited. 
Therefore, the development of new, rapid and clean synthetic routes towards focused 
libraries of such compounds is of great importance to both medicinal and synthetic 
chemists [2]. Undoubtedly, the most efficient strategies involve multicomponent 
reactions (MCRs), which have emerged as a powerful tool for the rapid introduction 
of molecular diversity. Consequently, the design and development of (new) MCRs for 
the generation of heterocycles receives growing interest [3-6]. 
Multicomponent reactions (MCRs) are special types of synthetically useful 
organic reactions in which three or more different starting materials react to a final 
product in the one-pot procedure [3]. Such reactions are atom-efficient processes by 
incorporating the essential parts of the starting materials into the final product. MCRs 
are powerful tools in the modern drug discovery process and allow the fast, automated, 
and high-throughput generation of organic compounds [7]. In the past years the 
pharmaceutical industry has focused more and more on diversity-oriented and biased 
combinatorial libraries [8, 9]. Furthermore, the discovery of novel MCRs can be 
considered as an interesting topic for academic research that also satisfies a practical 
interest of applied science [10-12].  
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3.2 Multicomponent Reactions - A Special Class of Tandem Reactions 
In traditional organic synthesis individual bonds are formed in a stepwise procedure. 
This often involves isolation and purification of intermediates and alteration of 
reaction conditions for the next synthetic step. In the ideal case, however, a target 
molecule is prepared from readily available starting materials in one simple, safe, 
environmentally friendly and resource-efficient operation that proceeds quickly and in 
quantitative yield (Figure 1) [3]. 
In the past decade, many research groups have aimed for the realization of this 
concept of Ideal Synthesis by the development of multi-step, single operation 
processes for the construction of complex molecules in which several bonds are 
formed in a chain of events and without the necessity of isolating the intermediates. 
Reactions that meet these criteria, commonly referred to as tandem reactions [13], 
allow the economically and environmentally favorable synthesis of a wide range of 
organic molecules. 
 
Ideal Synthesis
Simple
Quantitative 
yield
Total 
conversion
Safe
Readily available 
starting materialEnvironmentally
friendly
Resource
efficient
One-pot
 
 
Figure 1. General aspects of the Ideal Synthesis 
 
As suggested by Denmark [14], a distinction can be made between three 
categories of tandem reactions:  
i) cascade or domino reactions 
ii)  consecutive reactions 
iii)  sequential reactions  
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In a tandem cascade reaction, every reaction step causes the structural change 
required for the next reaction step. The overall reaction proceeds without modification 
of reaction conditions or the addition of extra reagents. The intermediates in cascade 
reactions cannot be isolated. An example of a cascade reaction is depicted in Scheme 
3.1 [15]. 
 
NH
OAc
AcO
C8H12
+ X
O
O
[4+2]
NH
OAc
AcO
C8H12
X
O
O
N
OAc
AcO
C8H12
X
O
O
intramolecular
acylation
X= O or N-Ph
Scheme 3.1
 
Tandem consecutive reactions differ from cascade reactions in that the 
intermediate is an isolable entity. The intermediate contains the required functionality 
to undergo the second reaction step, but additional promotion in the form of energy 
(light or heat) is needed to overcome the activation barriers. In the consecutive 
reaction shown in Scheme 3.2, intermediate can be isolated, but the application of 
additional heating in the same reaction vessel promotes the second Diels-Alder 
cyclisation [16]. 
 
OR
O
Ph
OR
OPh
heat
[4+2]
OR
O
Ph
Scheme 3.2
 
In tandem sequential reactions, the functionalities created in the first reaction 
step must enable the intermediate to engage in the following reaction step. However, 
these types of reactions require the addition of an extra component for the tandem 
process to proceed (Scheme 3.3) [17]. The intermediate may be isolable, but this is 
not necessary. 
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CO2Me
H
[4+2]
MeO2C TMSO
[4+2]
CO2Me
H
O
Scheme 3.3
 
 
A special class of tandem sequential reactions constitutes the multicomponent 
reaction (MCRs). MCRs are defined as one-pot reactions in which three or more 
components react to form a single product, incorporating essentially all atoms of the 
starting materials [11]. A MCR in which a small molecule, like water, is expelled is 
also referred to as a multicomponent condensation. MCRs are well appreciated 
because of their superior atom economy, simple procedures, the highly convergent 
character and the high and ever increasing number of accessible backbones. Different 
classification schemes of MCRs are possible, for example classifications according to 
variability, mechanisms or components involved. Although the three-component 
synthesis depicted in Scheme 3.4 gives access to 1,3-oxathiolan-2-one in good yield 
under mild conditions and in one operation [18], this is an example of a MCR of low 
variability, because only the substituents on the epoxide can be varied, while the other 
components are fixed. This MCR is therefore of low exploratory power (EN) [4]. 
 
O
+ S + CO
NaH (cat.)
THF
O
S
O
Scheme 3.4
 
 
 On the other hand, MCRs of high variability, like the tandem Petasis-Ugi 
reaction depicted in Scheme 3.5 [19], are of high exploratory power, because both 
high complexity and broad diversity are generated in this procedure. Given the 
numbers of commercially available starting materials, this MCR can virtually provide 
a library that spans a chemical space of 1000 × 500 × 1000 × 1000 × 1000 = 5 × 1014 
small molecules [20]. 
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H CO2H
O
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N
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R3
R1 O
Ugi
R4 -NH2
R5 -CHO
R6 -CN
R2
N
N
R3
R1 O
R4
R5
O
H
N
R6
Scheme 3.5
 
Based on reaction mechanisms, MCRs are divided into three subclasses, as 
shown in Table 1 [3a]. 
 
In type I MCRs, the starting materials, intermediates and products are in 
equilibrium with each other. The yield of the final product depends on the 
thermodynamics and the product is often isolated as a mixture with intermediates and 
starting materials. A well-known type I MCR is the Strecker reaction (Scheme 3.6). 
 
R1
NH2
+
R2
O
+ HCN
R2
NC N
H
R1
Scheme 3.6
 
 
Type II MCRs are sequences of reversible reactions that are terminated by an 
irreversible reaction step, which drives the reaction to completion. This last step often 
involves a highly exothermic reaction like an aromatization, a ring closure or the 
oxidation of the CII of isocyanides to CIV. 
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Although they are not uncommon in biochemical pathways in living cells, type 
III MCRs, in which all reaction steps are irreversible, are very rare in preparative 
chemistry. Most successful MCRs are of type II, like the Biginelli reaction (Scheme 
3.7). The irreversibility of the last reaction step does not exclude the formation of side 
products. However, very often possible side reactions are reversible as well and 
therefore, the irreversibly formed product P dominates. It should be noted that the 
classification of MCRs according to mechanism is not strict, but that transitions 
between the different types are fluid. 
 
O
O
R2
R1
O +
NH2
H2N O
R3
O
O
O
R2
R1
N
H
NH
R3
O
Scheme 3.7  
 
Finally, MCRs can be classified according to the functional groups involved in 
the reaction. Examples are imine based MCRs, isocyanide based MCRs (IMCRs) and 
carbine based MCRs. Many known MCRs belong to the first type because the first 
step involves the condensation of an amine and an aldehyde or ketone to form an 
imine. One of the most famous MCRs, the Ugi four-component reaction, belongs to 
both imine and isocyanide based MCRs (Scheme 3.8). 
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NH2
+
R2
O
+
R3
HO O
+ R4
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R1
O
R3
Scheme 3.8
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3.3 History of Multicomponent Chemistry  
The concept of MCRs is not unknown in nature, it is important especially in evolution. 
It seems that adenine, one of the major constituents of DNA and RNA, was 
prebiotically  formed by the condensation of five molecules of HCN, a plentiful 
component of prebiotic atmosphere, in a reaction catalyzed by NH3 (Scheme 3.9) [21-
25]. The other nucleic bases have been generated in similar reactions involving HCN 
and H2O.   
5 HCN
N
N NH
N
NH2
Scheme 3.9  
 
 The first modern contribution to the development of multicomponent 
chemistry was made in 1850 by Strecker. The crucial step in the well-known Strecker 
synthesis of α-amino acids is the formation of α-amino nitriles from aldehydes, HCN 
and NH3 in one-pot [26]. Subsequent hydrolysis of these synthetically valuable 
intermediates results in the amino acids (Scheme 3.10). 
 
NH3+
R1
O
+HCN
R1
H2N CN
Scheme 3.10
R1
H2N COOH
 
 
 Further progress of multicomponent chemistry can be attributed to the work of 
Hantzsch in 1882. He synthesized symmetrically substituted dihydropyridines from 
NH3, aldehydes and two equivalents of β-ketoesters (Scheme 3.11) [27]. 
 
O
O
R2
Et
O + NH3
R1
O
O
O
R2
Et
N
H
R1
Scheme 3.11
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O
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O
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 Another contribution made by Hantzsch to MCRs was the synthesis of 
pyrroles by reacting primary amines 16, β-ketoesters and α-halogenated β-ketoesters 
(Scheme 3.12).[27] 
 
O
O
R2
Et
O
Scheme 3.12
R3
NH2
O
O
R2
Et
N
H
R3
R1
O
Br
COOEt
R2 N
R3
R1
COOEt
EtOOC
 
 
 The Biginelli reaction first described in 1893 represents multicomponent 
synthesis of substituted dihydropyrimidines by acid-catalyzed cyclocondensation of β-
ketoesters, aromatic aldehydes and urea (Scheme 3.13) [28-31].  
 
O
O
R2
R1
O +
NH2
H2N O
Ar
O
O
O
R2
R1
N
H
NH
Ar
O
Scheme 3.13
 
 
 The first important application of MCRs in natural product synthesis was the 
Robinson synthesis of the alkaloid tropinone from succinic dialdehyde, methylamine 
and calcium salt of acetonedicarboxylic acid, carried out in 1917 (Scheme 3.14) [33]. 
 
H
H
O
O
+ MeNH2 +
O
O
O
O
O
Ca +2
N
O
Me
Scheme 3.14
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 The first MCR involving isocyanides was discovered in 1921 by Passerini [21], 
Carboxylic acids, carbonyl compounds and isocyanides afforded α-acyloxy 
carboxamides in a one-pot procedure (Scheme 3.15) [23, 33]. 
 
R1 OH
O
R1 R3
O
+ + CN
R4
O
R1
NH
O
R2
R3
O
R4
Scheme 3.15  
 
 In 1934, Bucherer and Bergs described a four-component reaction for 
synthesis of hydantoins. One-pot reaction of hydrogen cyanide, aldehydes, NH3 and 
CO2 afforded hydantoins [34], which can be easily transformed into α-amino acids by 
simple hydrolysis (Scheme 3.16) [35, 36]. 
 
R1
O
+ +
Scheme 3.16
HCN (NH4)2CO3
HN
NH
O
O
R1
 
 
 The next important example is the Asinger reaction reported in 1958. α-
Halogenated carbonyl compounds and sodium hydrogen sulfide generated in situ 
thiols which reacted with carbonyl compounds and ammonia to afford thiazolines 
(Scheme 3.17) [37]. 
 
R1
O
+
Scheme 3.17
S
N
R3
R4
R2
SH
R4
R3
O
R1
R2NH3
 
 
 One of the most utilized multicomponent reactions was discovered in 1959 by 
Ugi et al.[23] Synthesis of α-acylamino amides was achieved by reacting aldehydes, 
primary amines, carboxylic acids and isocyanides (Scheme 3.8). [23-25, 33] 
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 In 1961 Gewald and co-workers described the synthesis of polysubstituted 
thiophenes with electron withdrawing substituents such as cyano, carboethoxy and 
carboxamido in the 3-positions and alkyl, aryl, cycloalkyl and hetaryl groups in the 4- 
and 5-positions. Three major modifications of this method are described in literature 
which gives access to various 2-aminothiophenes (Scheme 3.18) [38]. The most 
elegant and simplest version consists of a one-pot procedure which includes the 
condensation of aldehydes, ketones or 1,3-dicarbonyl compounds with activated 
nitriles and sulfur in the presence of amine at room temperature. Ethanol, methanol, 
dimethylformamide, dioxane, excess ketone such as methyl ethyl ketone or 
cyclohexanone are preferred solvents and the most often employed amines are 
diethylamine, morpholine or triethylamine. 
 
R1
O
+
Scheme 3.18
S
R2
R1
base
R2
X
CN
+ S8
NH2
X
 
 
 The year 1993 began a new era of the formation and investigation of the 
products and the libraries of the Ugi reaction (U-4CR) and higher MCRs of the 
isocyanides. Already in 1961, Ugi and Steinbrückner [24] described the libraries of U-
4CR products, and this was mentioned again in 1971. For many decades nobody had 
been interested in libraries. In 1982, Furka [39] formed peptide libraries by the solid-
phase method of Merrifield [40], and since then this was increasingly applied. 
Libraries of other compounds were subsequently also formed by multistep solid-phase 
procedures [41]. 
 In 1995, Armstrong et al. [42] and in the Hofmann LaRoche AG Weber et al. 
[43] published the first industrial libraries of U-4CR products; the latter group had 
then found two Thrombine inhibitors, whereas the search for such products by the 
then conventional methods was not successful for a decade. A still-increasing number 
of industrial companies began to produce and to investigate the libraries of the U-4CR 
products and related compounds. Nowadays, the search for new pharmaceutical and 
plantprotecting compounds is accomplished by forming libraries of up to 20,000 and 
more different compounds in one day by a single person. 
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3.4 Reported synthetic strategies 
3.4.1 Three-component synthesis of Dihydropyrano[2,3-c]pyrazoles 
Laufer et al. [44] have synthesized 1,4-dihydropyrano[2,3-c]pyrazoles (Scheme 3.19) 
with various substituents at the 1-, 3-, and 4-position. Given the large number of 
commercially available aldehydes and the easy access to hydrazines and β-keto esters, 
this method should be applicable to synthesis of libraries with high diversity.  
The corresponding β-keto esters were synthesized either according to Yuasa 
and Tsuruta [45] or by deprotonation of esters and subsequent reaction with ethyl 
acetate. This second procedure (deprotonation of esters), described in a patent 
application for the synthesis of ethyl 3-oxo-3-(pyridin-4-yl)propanoate [46], is more 
advantageous because the reaction can be performed using ethyl acetate as both the 
solvent and reagent without further purification. The reaction was performed at room 
temperature overnight, and nearly all products precipitated as discrete crystals. 
 
R1
H
N
NH2
+
R2 O
O O
EtOH, 
3 h,
reflux N N
R2
O
R1
N N
R2
O
R1
+ NC CN + R3
CHO
EtOH, 
base,
16 h,
rt
O
N
N
R2 R3
CN
NH2
R1
Scheme 3.19
R1= H, CH3, C6H5, 4-OCH3-C6H4, -CH2-C6H5
R2= CH3, C3H7, C6H5, 4-F-C6H4, -CH2-C6H5, pyridine
R3= C6H5, 4-F-C6H4, 4-OCH3-C6H4, 4-Cl-C6H4, 4-OH-C6H4, 2-Cl-5-NO2-C6H4, pyridine
 
 
3.4.2 Four-component pyrano[2,3-c]pyrazoles synthesis  
Shestopalov et al. [47] demonstrated that a four-component reaction of aromatic 
aldehydes, malononitrile, β-ketoesters, and hydrazine hydrate successfully yields 6-
aminopyrano[2,3-c]pyrazol-5-carbonitriles without the need of prior pyrazolin-5-ones 
isolation [48]. The multicomponent synthesis of pyranopyrazoles was carried out by 
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simultaneously refluxing all four starting materials in ethanol for 15 min. in the 
presence of Et3N (Scheme 3.20). 
They showed that aromatic aldehydes with electronwithdrawing, electron-
donating, withdrawing and donating groups, as well as napthaldehydes and hetero-
aromatic aldehydes can be successfully reacted with β-ketoesters, malonodinitrile, and 
hydrazine hydrate  to yield final pyrano[2,3-c]pyrazoles  with high regio-selectivity. 
 
R1
CHO
+ CN
CN
R2
O
O
OEt
+
H2N
NH2
*H2O
EtOH, Et3N, reflux, 15 min.
O
HN
N
R2 R1
CN
NH2
Scheme 3.20
 
 
3.4.3 1,4-dihydropyrano[2,3-c]pyrazoles synthesis in aqueous media 
Shi et al. [49] report one-pot synthesis of 1,4-dihydropyrano[2,3-c]pyrazole 
derivatives by three-component reaction in aqueous media. When aromatic aldehydes, 
malononitrile, 3-methyl-1-phenyl-2-pyrazolin-5-one, and triethylbenzylammonium 
chloride (TEBA) were stirred at 90 °C for 6-10 h in water, the products were obtained 
in good yields (Scheme 3.21). 
  
N N
H3C
O
Ph O
N
N
H3C Ar
CN
NH2
Ph
Ar CHO +
CN
CN
+
H2O, TEBA
90 °C
Scheme 3.21
 
 
The three-component reaction of aromatic aldehydes, malononitrile, and 3-
methyl-1-phenyl-2-pyrazolin-5-one to 6-amino-5-cyano-4-aryl-1,4-dihydropyrano[2,3 
-c]pyrazoles has been efficiently performed in aqueous media. The easy purification 
of products by simple crystallization, and the use of water as solvent combined with 
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the exploitation of the multicomponent strategy open to this process suggest good 
prospects for its industrial applicability. 
 
3.4.4 Base-catalyzed rout of Dihydropyrazolo[3,4-b]pyrans 
3.4.4.1 By using Ammonium acetate 
Li et al. [50] reported the preparation of 2H,4H-dihydropyrazolo[3,4-b]pyrans from 
the reaction of  4-Arylidene-3-methyl-1-phenyl-5-pyrazolones and β-ketoester using 
ammonium acetate as a catalyst (Scheme 3.22). 
Ammonium acetate has been used widely as a base or a catalyst in Biginelli 
reactions [51, 52], Hantsch reactions [53] and other reactions [54, 55]. With this aim 
in view, they applied the ammonium acetate to this reaction. Treatment of 3-methyl-1-
phenyl-4-phenylidene-5-pyrazolone with 1 equiv. of ammonium acetate followed by 
β-ketoester in ethanol at room temperature for 2 h gave the corresponding 1,4,5,6-
tetrahydropyrazolo[3,4-b]pyrans. 
 
F3C OEt
O O
+
N
N
O
Ph
R
O N
N
EtO2C
R CH3
HO
F3C
Ph
NH4OAc
C2H5OH, rt
R = C6H5, p-CH3C6H4, p-CH3OC6H4, p-NO2C6H4, p-BrC6H4, 
       o-CH3C6H4, o-FC6H4, m-ClC6H4, o-OHC6H4
Scheme 3.22
 
 
3.4.4.2 By using TEA 
Mixing equimolecular amounts of ethyl acetoacetate with hydrazine hydrate, 
benzaldehyde and malononitrile has produced corresponding pyranopyrazoles 
(Scheme 3.23). This same product could be obtained in almost the same yield by 
reacting 3-amino-2-pyrazoline-5-one and arylidenemalononitriles in ethanol in the 
presence of chitosan or, as originally reported, in the presence of piperidine. Despite 
the recently claimed isolation of Michael adduct, this could not be repeated even 
when the reaction was conducted at room temperature for a short period. Only either 
unchanged starting materials or cyclic products were isolated. It is of value to report 
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that after an induction period the reaction is exothermic and temperature control is 
somewhat difficult.  
 
H2N NH2
+
R1 O
O O
EtOH 
Et3N
N N
H
R1
O
O
HN
N
R1
CN
NH2
Scheme 3.23
CN
CN
R2
OR3
reflux
15 min
+ R3
R2
CN
CN
R3R2
 
 
The reaction of compound 4-(p-Methylphenylaminomethylidine)-1-phenyl-
3,5-pyrazolidinedione with active nitriles and cyclic ketones, namely malononitrile, 
cyanoacetamide, cyanothioacetamide, cyanoacetic hydrazide, 1-phenyl-3,5-
pyrazolidinedione, 3-methyl-1-phenyl-5-pyrazolone, cyclopentanone, cyclohexanone 
and cycloheptanone in the presence of a catalytic amount of triethylamine gave 
pyrano[2,3-c]pyrazole derivatives (Scheme 3.24) [56]. The reaction pathway of such 
compound was assumed to follow a preliminary formation of carbanion of the active 
methylene reagent, which was added to the double bond followed by a nucleophilic 
attack of the NH group at the CN, CO, and CS groups with the elimination of a water 
molecule in the case of cyanoacetamide and a H2S molecule in the case of 
cyanothioacetamide [57].  
Here, 4-(p-Methylphenylaminomethylidine)-1-phenyl-3,5-pyrazolidinedione 
was prepared from the reaction of 1-phenylpyrazolidine-3,5-dione with ethyl 
orthoformate and p-toluidine in boiling dimethylformamide. 
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3.4.5 Synthesis of spiro-dihydropyrazolo[3,4-b]pyrans 
Evans et al. [58] describe a three-component condensation in which substituted 
piperidin-4-ones have been used in place of aromatic aldehydes to synthesize a new 
spiro heterocyclic system. They report that the base-catalyzed reaction of substituted 
piperidin-4-ones, pyrazol-5-ones, and malononitrile  proceeds in ethanol at 20 °C with 
the formation of substituted 6-amino-5-cyanospiro-4-(piperidine-4’)-2H,4H-
dihydropyrazolopyrans (Scheme 3.25). 
 
Scheme 3.25
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R1 = CH3, CH3CO, COOEt
R2 = CH3, CH3OCH2, CH3CH2CH2
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Three-component condensation of 4-piperidinones, 5-pyrazolones, and 
malononitrile proceeds chemically and electrochemically and is a convenient one-step 
means of synthesis of substituted 6-amino-5-cyanospiro-4-(piperidine-4’)-2H,4H-
dihydropyrazolo[3,4-b]pyrans. The electrochemical reactions proceed under milder 
conditions and with yields 12-15% greater than those of the reactions catalyzed by 
chemical bases. 
 
3.4.6 Dihydropyrazolopyrans from 1H-indole-2,3-dione 
Aly H. Atta [59] reported the synthesis of a new series of compounds containing both 
the two moieties is likely to result in the formation of some interesting bioactive 
compounds. The one-pot reaction of 1H-indole-2,3-dione, 3-methyl-1-phenyl-2-
pyrazolin-5-one, and active methylenes, namely malononitrile, ethyl cyanoacetate, 
pyrazolone, and acetyl acetone afforded the products. These products can be obtained 
via reaction of 3-[3-methyl-5-oxo-1-phenyl-1,5-dihydro-pyrazol-(4Z)-ylidene]-1,3-
dihydro-indol-2-one with the corresponding active methylenes (Scheme 3.26). 
 
N
H
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Scheme 3.26
 
 
3.4.7 Pyrazolopyrans from pyrazole-aldehydes 
Thumar and Patel [60] reported a series of 4-pyrazolyl-4H-pyrazolopyran derivatives 
by one-pot three-component cyclocondensation reaction of 1-phenyl-3-(het)aryl-
pyrazole-4-carbaldehyde, malononitrile and substituted pyrazolin-5-ones in the 
presence of piperidine as catalyst. The mixture refluxing under ethanol or acetonitrile 
gives pyran derivatives (Scheme 3.27). 
The reaction occurs via an in situ initial formation of the heterylidenenitrile, 
containing the electron-poor C=C double bond, from the Knoevenagel condensation 
between pyrazole-4-carbaldehyde and malononitrile by loss of water molecules. 
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Finally, Michael addition into the initially formed unsaturated nitrile, i.e. nucleophilic 
attack of hydroxyl moiety to the cyano moiety affords cyclized pyran derivatives. 
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Scheme 3.27
 
3.4.8 Pyranopyrazoles by using heteropolyacid as a catalyst 
Heravi et al. [61] reported facile method for the synthesis of 1,4-dihydropyrano[2,3-c] 
pyrazole derivatives via three-component one-pot condensation of 3-methyl-1-phenyl-
1H-pyrazol-5(4H)-one, aldehydes and malononitrile in the presence of a catalytic 
amount of preyssler type heteropolyacid as a green and reusable catalyst in water or 
ethanol under refluxing conditions (Scheme 3.28). 
There has been considerable interest in the use of heteropolyacids as 
environmentally benign catalysts due to their unique properties such as high thermal 
stability, low cost, ease of preparation and recyclability. Numerous chemical reactions 
can occur in the presence of heteropolyacids [62]. Preyssler type heteropolyacid, 
H14[NaP5W30O110], is remarkable owing to its exclusive physicochemical properties. 
These include strong Bronsted acidity, reversible transformations, solubility in polar 
and non-polar solvents, high hydrolytic and thermal stability, which are all essential in 
catalytic processes. Preyssler polyanion, as a large anion, can provide many ‘‘sites’’ 
on the oval-shaped molecule that are likely to render the catalyst effective [63]. This 
heteropolyanion with [64] acidic protons, is an efficient ‘‘supper acid’’ solid catalyst 
which can be used both in the homogeneous and heterogeneous phases [65]. 
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3.4.9 Synthesis of aminochromenes 
A four component Knoevenagel-Michael addition-cyclization sequence has been 
studied for the synthesis of dihydropyranopyrazole derivatives from hydrazine 
hydrate, a malonitrile, a β-ketoester, and an aldehyde or a ketone. The reaction was 
described under catalyst- and solvent-free conditions [66] and using piperidine in 
ultrapure aqueous media [67], both at room temperature. But this methodology was 
intensively developed by Shestopalov and co-workers since they used a wide range of 
aldehydes, ketones, and β-ketoesters to form a series of these fused heterocyclic 
skeletons, even if substituted hydrazines were unreactive in this protocol [47]. 
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More recently, an adaptation of this four-component transformation in water 
was proposed as a green combinatorial synthesis of novel aminochromene derivatives 
bearing an hydroxymethyl pyrazole functional group in the four-position, instead of a 
fused skeleton. In this unexpected transformation, 2-hydroxybenzaldhyde plays a 
crucial role by reacting selectively with malonitrile to form the chromene intermediate 
(Scheme 3.29) [68]. 
 
3.4.10 Solvent-free multicomponent synthesis of pyranopyrazoles 
The conventional synthesis of 2-amino-3-cyano-4H-pyrans use organic solvent, but 
these solvents make the workup procedure complicated and lead to poor yields of 
products [69]. In recent years, 2-amino-3-cyano-4H-pyrans have also been 
synthesized under microwave [70], with ultrasound irradiation [71], or in aqueous 
media [49, 72, 73]. Some two-component [74] and three-component [72] condensa-
tions have been introduced for the synthesis of 2-amino-3-cyano-4H-pyrans. Each of 
these methods has its own merit, with at least one of the limitations of low yields, 
long reaction time, effluent pollution, harsh reaction conditions, and tedious workup 
procedues. All of these reasons spur us to study the possibility of synthesis of 2-
amino-3-cycano-4-aryl-7,7-dimethyl-5,6,7,8-tetrahydrobenzo[b]pyrans and 6-amino-
5-cyano-4-aryl-1,4-dihydro-pyrano[2,3-c]pyrazoles under solvent-free conditions.  
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Li et al. [75] report a highly efficient procedure for the synthesis of 2-amino-
3-cycano-4-aryl-7,7-dimethyl-5,6,7,8-tetrahydrobenzo[b]pyrans and 6-amino-5-cyano 
-4-aryl-1,4-dihydropyrano[2,3-c]pyrazoles via a one-pot grinding method under 
solvent-free conditions using an inexpensive and commercially available D,L-proline 
as catalyst (Schemes 3.30 and 3.31). 
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In a typical general experimental procedure, aromatic aldehydes, malononitrile, 
dimedone [1,3-cyclohexanedione or 3-methyl-1-phenyl-2-pyrazolin-5-one], and a 
catalytic amount of D,L-proline are added to a mortar. The mixture is ground by 
mortar and pestle at room temperature for a period. The solid product is obtained from 
an intermediate melt and then is laid up at room temperature for 30 min. The mixture 
is transferred to ice water and then is filtered off. The crude products are purified by 
recrystallization by ethanol to afford the products in good yields. 
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A simple, green and efficient protocol is developed with per-6-amino-b-
cyclodextrin (per-6-ABCD) which acts simultaneously as a supramolecular host and 
as an efficient solid base catalyst for the solvent-free syntheses of various 
dihydropyrano[2,3-c]pyrazole derivatives involving a four-component reaction 
(Scheme 3.32). 
 Per-6-amino-b-cyclodextrin (per-6-ABCD) is used extensively as a 
supramolecular chiral host and as a base catalyst for Cu-catalyzed N-arylation [76] 
and for Michael addition of nitromethane to chalcones [77]. Kanagaraj and 
Pitchumani [78] have utilized per-6-ABCD as an excellent supramolecular host for 
the synthesis of pyranopyrazole derivatives, in an efficient and ecofriendly four-
 
Chapter 3                                                                                     Pyrano[2,3-c]pyrazoles 
     
   103
component reaction protocol under solventfree conditions at room temperature. It is 
also interesting to note that the catalyst can be recovered and reused several times. 
 
3.4.11 Syntheses of Polyfunctionalized Phenols Linked to Heterocycles 
Boghdadie et al. [79] reported that, a solution of 4-(hydroxyl-3-methoxybenzylidine) 
malononitrile and 3-ethyl-1-phenyl-2-pyrazolin-5-one, in ethanol (50 ml) and two 
drops of piperidine was heated under reflux for 2 hours, cooled and poured onto water. 
The products were recrystallized from ethanol to give the corresponding compound 6-
amino-3-ethyl-4-(4-hydroxy-3-methoxyphenyl)-1-phenyl-4H-pyrano[3,2-d]pyrazole-
5-carbonitrile (scheme 3.33). 
 
HO
H3CO
C
H
O +
CN
CN
EtOH / piperidine
reflux, 1/2 h HO
H3CO
C
H
C
CN
CN
HO
H3CO
C
H
C
CN
CN
EtOH / piperidine
reflux, 1/2 h
N
N
O
H3C
HO
H3CO
O
N
N
NC NH2
H3C
Scheme 3.33
 
 
3.4.12 Benzopyran Derivatives 
3.4.12.1 4H-benzo[b]pyrans using TBAB as a catalyst 
Fard et al. [80] reported a highly efficient procedure for the preparation of 4H-
benzo[b]pyrans and pyrano[2,3-d]pyrimidinones via a domino Knoevenagelcyclo-
condensation reaction using TBAB as a catalyst in water. 
In a typical experimental procedure, a mixture of aromatic aldehyde, 
malononitrile, dimedone or barbituric acid in water under reflux condition, was stirred 
in the presence of a catalytic amount of TBAB (10 mol%) to afford the 4H-
benzo[b]pyrans and pyrano[2,3- d]pyrimidinones (Scheme 3.34). 
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CN
CN
Ar CHO + HN
N
H
O
HN
N
H
O
Ar
CN
NH2
O Ar
CN
NH2
O
O
O
O
O O
O
TBAB (10% mol)TBAB (10% mol)
H2O, refluxH2O, reflux
Scheme 3.34
 
3.4.12.2 2-Imino-2H-chromene-3-carbonitrile using NaBH4 as a catalyst 
Rai et al. [81] have reported a synthesis (Scheme 3.35) in ethanol using triethylamine 
to first get 2-Imino-2H-chromene-3-carbonitrile which they reduced using sodium 
borohydride in methanol to give the essential 2-Amion-3-Cyanochromane derivative. 
The reaction mixture here has been conventionally refluxed for 3 h. 
 
CHO
OH
+
CN
CN
EtOH, Et3N
O
CN
NH
NaBH4
Methanol
O
CN
NH2
Scheme 3.35
 
3.4.12.3 2-Amino-3-cyanochromene using MgO as a catalyst 
Kumar et al. [82] have reported an environmentally benign synthetic process using 
Magnesium oxide as the catalyst and by process of grinding (Scheme 3.36). This is 
the classical reaction where in a benzaldehyde or ketone has first been reacted with a 
malanonitrile which has got an active hydrogen site, yielding the benzylidene 
malanonitrile which when reacted to a 1,3-Diketo compound herein a meldurms acid 
afforded the 2-Amino-3-cyanochromene derivative the only difference than the 
classical methodology is that the reaction has been carried at room temperature and it 
is grinded which means there are absolutely no solvent which makes it a green 
process and which is also faster and gives a higher yield. 
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CHO
+
CN
CN
MgO; R.T.
Grinding
CN
CN
O O
MgO, R.T. Grinding
O
O
CN
NH2
Scheme 3.36
 
3.4.12.4 Benzopyrans using chitosan as a catalyst 
Similarly, Al-Matar et al. [83] have synthesized many compounds of this class using 
chitosan as the catalyst (Scheme 3.37). 
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CN
H
H
NC
NH2
Ph
CN
H
Scheme 3.37
 
3.4.12.5 Benzopyrans using piperidine as a catalyst 
More so ever Al-Matar et al. [83] have also studied the formation of the exact product 
i.e. 2-Amino-3-cyano-7-hydroxy-4H-chromene instead of 5-hydroxy derivative when 
resorcinol is reacted with malanonitrile using piperidine and ethanol. They have come 
out with this result using the Nuclear Overhauser Effect calculation from the proton 
NMR spectrum. The reaction scheme is shown in Scheme 3.38. 
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CN
CN
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O NH2
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Scheme 3.38
 
 
 They have also prepared many such compounds using the same methodology 
but different starting materials as shown in Scheme 3.39. 
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H3C Ph
CN
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Scheme 3.39  
 
 Naliyapara et al. [84] have extended this work using 4-Hydroxy coumarin as a 
starting product (Scheme 3.40). 
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O O
OH
+
CN
CNPh
O O
O
NH2
CN
Ph
Scheme 3.40
 
  
 They have synthesized the spiro-compounds using the cyclic ketones to 
produce the desired results but failed to obtain the chromenes when the aryl ketones 
were used in the reaction. The reaction schemes followed are shown in Scheme 3.41. 
 
O
OH
O
+ R
O
+ NC CN
R
CN
CN
+
O
OH
O
O O
O
NH2
CN
R
Scheme 3.41
 
 
3.4.12.6 Benzopyrans using potassium carbonate as a catalyst 
Kidwai et al. [85] has prepared the same class of the compounds using water as a 
solvent and potassium carbonate as the required base catalyst (Scheme 3.42).  
 
CHO +
CN
CN
+
HO OH
O
CN
NH2HO
Scheme 3.42
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 Such compounds were prepared using different starting materials as diverse 
kinds of aldehydes viz. Phenyl, Quinolyl, Indolyl and alkyl were reacted with 
malanonitrile in presence of saturated potassium carbonate solution and then 
microwave irradiation was induced upon the reaction mixture which afforded the 2-
Amino-3-cyano-4-substituted phenyl-7-hydroxy-4H-chromene dervatives.  
 
3.4.12.7 Ionic liquids as catalyst for the synthesisi of benzopyrans  
The synthesis of 4H-benzo[b]pyran derivatives has also been proposed by means of a 
basic ionic liquid-catalyzed three-component approach involving malononitrile, 
aromatic aldehydes and dimedone. The conventional method, requiring the use of 
refluxing DMF or acetic acid, lead to low yields and renders the isolation step 
troublesome. Other procedures have been described but all of them suffer at least 
from one limitation. Alternatively, it has been found that a small amount of N,N-
dimethylaminoethylbenzyl-dimethylammonium chloride catalyzed a rapid and high 
yielding solvent-free transformation at 60 °C with a wide variation of the aldehyde 
partner (Scheme 3.43) [86]. 
 
Ar
O H
+
CN
CN
60 °C, 30-80 min.
80 °C, 30-130 min.
O
O
OH
Me
Me
O
Me
Me
Ar
CN
NH2
NH2
CN
Ar
O
73-94 %
46-95 %
Scheme 3.43
IL (5 mol%)
IL: [PhCH2Me2N+CH2CH2NMe2]Cl-
 
 
 While, Peng and Song conducted this MCR in a mixture of catalytically active 
ionic liquid and water [87], and Lingaiah and co-workers reported the use of a 
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heterogeneous strong basic Mg/La mixed oxide catalyst in methanol [88]. Compared 
to the utilization of more classical solvents and organic bases, these strategies 
combine advantages in efficiency such as shorter reaction times and higher yields, 
with ecological advantages in terms of recovery and reusability of the catalyst. 
 
Ar H
O + CN
CN
MeMe
OO TMAH (10 mol%)
H2O, rt O
CN
NH2
ArO
Me
Me
79-92%
Scheme 3.44  
 
 This approach has been extended to cyclic 1,3-dicarbonyls for the synthesis of 
tetrahydrobenzopyrane derivatives, also known as tetrahydrochromenes, which have 
attracted much attention due to their wide range of biological properties. Thus, a 
mixture of an aromatic aldehyde, dimedone, and malonitrile in aqueous media 
catalyzed either by (S)-proline [89] or tetramethylammonium hydroxide (TMAH) [90] 
gave the bicyclic heterocycle in excellent yields (Scheme 3.44). 
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3.5 Aim of current work 
Pyran and fused pyran derivatives have attached a great deal of interest due to their 
association with various kinds of biological properties. They have been reported for 
their antimicrobial [91-94], antiviral [95, 96], anticonvulsant [97], cytotoxic [98] and 
antigenotoxic [99] activities. The incorporation of another heterocyclic moiety in 
pyrans either in the form of a substituent or as a fused component changes its 
properties and converts it into an altogether new and important heterocyclic derivative.  
 Pyrazole have attracted particular interest over the last few decades due to use 
of such ring system as the core nucleus in various drugs. They are well-known for 
their activities such as antidiabitic [110], antipyretic [101], anti-inflammatory [102], 
anti-hypertansive [103], antitumour [104], peptide deformylase inhibitor [105], and 
antidepressant agents [106]. Considering the importance of pyran and pyrazole 
derivatives, it was thought worthwile to synthesize new compounds incorporating 
both these moieties.   
 It is pertinent to mention that a large number of pyrazole fused and pyrazole 
substituted pyran derivatives are reported as biologically important compounds and 
their chemistry have received considerable attention of chemists in recent days [107-
111]. Thus, pyranopyrazoles exhibit useful biological properties such as antimicrobial 
[112], insecticidal [113], and anti-inflammatory [114]. Furthermore Dihydropyrano 
[2,3-c]pyrazoles showed molluscicidal activity [115, 116] and was identified as a 
screening hit for Chk1 kinase inhibitor [117]. 
Over the last years, the chemistry of dihydropyrano[2,3-c]pyrazoles has 
received great interest. The first approach to synthesize these substances was 
undertaken by Otto [118], in which he initiated the reaction sequence by the base-
catalyzed cyclization of 4-aryliden-5-pyrazolone. In a further report, this same group 
showed that weak bases can also be used for a Michael-type cyclization [119]. 
Extending the work of Otto, Klokol and colleagues performed the direct conversion of 
3-methyl-3-pyrazolin-5-one with malononitrile in the presence of a weak base [120]. 
Recent methods for the synthesis of 1,4-dihydropyrano[2,3-c]pyrazoles include 
synthesis in aqueous media [49, 72b], under microwave irradiation [70d], and under 
solvent-free conditions [75, 121].  
Thus, in view of the diverse therapeutic activity of pyrano[2,3-c]pyrazoles, we 
report one-pot synthesis of pyrano[2,3-c]pyrazole derivatives (BHD-201 to 230) by 
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three-component reaction, a scaffold from which a diverse range of other biologically 
important New Chemical Entities (NCE’s) could be generated. A series of novel 1,4-
dihydropyrano[2,3-c]pyrazole derivatives (BHD-201 to 230) has been synthesized by 
one-pot three-component cyclocondensation reaction of aromatic aldehydes, 
malononitrile and substituted pyrazolin-5-ones in the presence of piperidine as 
catalyst. The mixture refluxing under methanol gives 1,4-dihydropyrano[2,3-
c]pyrazole derivatives. The products were characterized by FT-IR, mass, 1H NMR 
spectroscopy and elemental analyses. The newly synthesized compounds were 
subjected to various biological activities viz., antimicrobial, antimycobacterial, anti-
cancer and antiviral. 
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3.6 Reaction Scheme 
+
CN
CN
CHO
R2
O
CN
NH2
BHD-201 to 230
a
Reagents and conditions: (a) Piperidine, MeOH
                                               When R1= H; reflux, 10-12 h. 
                                               When R2= C6H5; stirring at rt, 6-8 h.
R2
N
N O
N
N
R1
R1
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
BHD-201 H H C16H16N4O 280 201-203 70 0.55 0.70 
BHD-202 H 4-F C16H15FN4O 298 169-171 78 0.51 0.65 
BHD-203 H 4-Cl C16H15ClN4O 314 188-190 81 0.61 0.78 
BHD-204 H 4-Br C16H15BrN4O 358 147-149 72 0.57 0.72 
BHD-205 H 4-NO2 C16H15N5O3 325 221-223 69 0.48 0.67 
BHD-206 H 4-CH3 C17H18N4O 294 173-175 86 0.60 0.74 
BHD-207 H 4-OH C16H16N4O2 296 207-209 76 0.52 0.68 
BHD-208 H 4-OCH3 C17H18N4O2 310 179-181 70 0.62 0.79 
BHD-209 H 3,4-OCH3 C18H20N4O3 340 142-144 68 0.50 0.68 
BHD-210 H 3-Cl C16H15ClN4O 314 183-185 77 0.56 0.76 
BHD-211 H 3-Br C16H15BrN4O 358 206-208 73 0.49 0.69 
BHD-212 H 3-NO2 C16H15N5O3 325 227-229 82 0.47 0.68 
BHD-213 H 3-OH C16H16N4O2 296 234-236 62 0.52 0.73 
BHD-214 H 2-Cl C16H15ClN4O 314 168-170 70 0.50 0.70 
BHD-215 H 2-NO2 C16H15N5O3 325 213-215 66 0.58 0.74 
BHD-216 C6H5 H C22H20N4O 356 157-159 75 0.61 0.81 
BHD-217 C6H5 4-F C22H19FN4O 374 162-164 79 0.56 0.67 
BHD-218 C6H5 4-Cl C22H19ClN4O 390 142-144 83 0.49 0.65 
BHD-219 C6H5 4-Br C22H19BrN4O 434 200-202 67 0.53 0.72 
BHD-220 C6H5 4-NO2 C22H19N5O3 401 187-189 79 0.59 0.78 
BHD-221 C6H5 4-CH3 C23H22N4O 370 135-137 85 0.60 0.79 
BHD-222 C6H5 4-OH C22H20N4O2 372 217-219 71 0.61 0.82 
BHD-223 C6H5 4-OCH3 C23H22N4O2 386 196-198 77 0.51 0.69 
BHD-224 C6H5 3,4-OCH3 C24H24N4O3 416 208-210 73 0.64 0.80 
BHD-225 C6H5 3-Cl C22H19ClN4O 390 233-235 69 0.52 0.66 
BHD-226 C6H5 3-Br C22H19BrN4O 434 156-158 70 0.56 0.70 
BHD-227 C6H5 3-NO2 C22H19N5O3 401 239-241 80 0.50 0.68 
BHD-228 C6H5 3-OH C22H20N4O2 372 214-216 75 0.55 0.71 
BHD-229 C6H5 2-Cl C22H19ClN4O 390 174-176 68 0.49 0.63 
BHD-230 C6H5 2-NO2 C22H19N5O3 401 219-221 63 0.59 0.73 
 
TLC Solvent system  Rf1: Hexane: Ethyl acetate - 6:4;  
TLC Solvent system  Rf2: Chloroform: Methanol - 9:1 
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3.6.1 Plausible Reaction Mechanism 
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The mechanism reaction occurs via an in situ initial formation of the arylidene 
malonoitrile, containing the electron-poor C=C double bond, from the Knoevenagel 
condensation between aromatic aldehydes and malononitrile by loss of water 
molecules. Finally, Michael addition of pyrazolone to the initially formed unsaturated 
nitrile, i.e. nucleophilic attack of hydroxyl moiety to the cyano moiety affords 
cyclized pyran derivatives. 
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3.7 Experimental 
 
3.7.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
with the structures assigned. 
 
3.7.2 Synthesis of 3-isopropyl-1H-pyrazol-5(4H)-one/3-isopropyl-1-phenyl-1H-
pyrazol-5(4H)-one 
 
Synthesis of 3-isopropyl-1H-pyrazol-5(4H)-one/3-isopropyl-1-phenyl-1H-pyrazol-5 
(4H)-one was prepared by known literature method [122]. 
 
3.7.3 General procedure for the 6-amino-1,4-dihydro-3-isopropyl-4-(aryl)pyrano 
[2,3-c]pyrazole-5-carbonitrile (BHD 201-215) 
 
A mixture of the malononitrile (0.01 mol), 3-isopropyl-1H-pyrazol-5(4H)-one (0.01 
mol) and an appropriate aromatic aldehyde (0.01 mol) in 8-10 mL of MeOH with 
catalytic amount of piperidine were refluxed for 10-12 h. After completion of the 
reaction, the reaction mixture was filtered to give the solid products BHD-201 to 215, 
which were recrystallized from ethanol.  
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3.7.3.1 6-amino-1,4-dihydro-3-isopropyl-4-phenylpyrano[2,3-c]pyrazole-5-carbonitrile   
(BHD-201) Yield: 70%; mp 201-203 ºC; MS: m/z 280; 
Anal. Calcd. for C16H16N4O: C, 68.55; H, 5.75; N, 19.99. 
Found: C, 68.55; H, 5.75; N, 19.99%. 
 
 
 
3.7.3.2 6-amino-4-(4-fluorophenyl)-1,4-dihydro-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-202) Yield: 78%; mp 169-171 ºC; 
MS: m/z 298; Anal. Calcd. for C16H15FN4O: C, 64.42; H, 
5.07; N, 18.78. Found: C, 64.42; H, 5.07; N, 18.78%. 
 
 
 
 
3.7.3.3 6-amino-4-(4-chlorophenyl)-1,4-dihydro-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-203) Yield: 81%; mp 188-190 ºC; 
IR (cm-1): 3485 (N-H stretching of free primary amine), 
3290 (N-H stretching of pyrazolo ring), 3109 (C-H 
stretching of aromatic ring), 2198 (C≡N stretching of the 
nitrile group), 1641 (C=N stretching of pyrazolo ring), 
1595 (N-H deformation pyrazolo ring), 1182 (N-N 
deformation of pyrazolo ring),  1028 (C-H in plane bending of aromatic ring), 813 (C-
H out of plane bending for 1,4-disubstituted aromatic ring), 748 (C-Cl stretching); 1H 
NMR (DMSO-d6) δ ppm: 0.85-0.87 (d, 3H, Ha, J = 6.8 Hz), 1.01-1.03 (d, 3H, Hb, J = 
6.9 Hz), 2.50-2.56 (m, 1H, Hc), 4.58 (s, 1H, Hd), 6.47 (s, 2H, He), 7.14-7.16 (d, 2H, 
Hff’), 7.27-7.30 (d, 2H, Hgg’), 12.00 (s, 1H, Hh); MS: m/z 314; Anal. Calcd. for 
C16H15ClN4O: C, 61.05; H, 4.80; N, 17.80. Found: C, 61.05; H, 4.80; N, 17.80%. 
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3.7.3.4 6-amino-4-(4-bromophenyl)-1,4-dihydro-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-204) Yield: 72%; mp 147-149 ºC; 
MS: m/z 358; Anal. Calcd. for C16H15BrN4O: C, 53.50; H, 
4.21; N, 15.60. Found: C, 53.50; H, 4.21; N, 15.60%. 
 
 
 
 
3.7.3.5 6-amino-1,4-dihydro-3-isopropyl-4-(4-nitrophenyl)pyrano[2,3-c]pyrazole-5- 
carbonitrile (BHD-205) Yield: 69%; mp 221-223 ºC; MS: 
m/z 325; Anal. Calcd. for C16H15N5O3: C, 59.07; H, 4.65; 
N, 21.53. Found: C, 59.07; H, 4.65; N, 21.53%. 
 
 
 
 
3.7.3.6 6-amino-1,4-dihydro-3-isopropyl-4-p-tolylpyrano[2,3-c]pyrazole-5-carbonitrile  
(BHD-206) Yield: 86%; mp 173-175 ºC; IR (cm-1): 3479 
(N-H stretching of free primary amine), 3271 (N-H 
stretching of pyrazolo ring), 3111 (C-H stretching of 
aromatic ring), 3047 (C-H symmetrical stretching of CH3 
group), 2966 (C-H asymmetrical stretching of CH3 group), 
2193 (C≡N stretching of the nitrile group), 1639 (C=N 
stretching of pyrazolo ring), 1602 (N-H deformation pyrazolo ring), 1367 (C-N 
stretching of pyrazolo ring), 1188 (N-N deformation of pyrazolo ring),  1026 (C-H in 
plane bending of aromatic ring), 813 (C-H out of plane bending for 1,4-disubstituted 
aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.86-0.88 (d, 3H, Ha, J = 6.8 Hz), 1.01-
1.03 (d, 3H, Hb, J = 6.9 Hz), 2.30 (s, 3H, Hc), 2.51-2.58 (m, 1H, Hd), 4.54 (m, 1H, He), 
5.91 (s, 2H, Hf), 7.00-7.10 (m, 4H, Hg-h’), 11.80 (s, 1H, Hi); MS: m/z 294; Anal. Calcd. 
for C17H18N4O: C, 69.37; H, 6.16; N, 19.03. Found: C, 69.37; H, 6.16; N, 19.03%. 
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3.7.3.7 6-amino-1,4-dihydro-4-(4-hydroxyphenyl)-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-207) Yield: 76%; mp 207-209 ºC; 
MS: m/z 296; Anal. Calcd. for C16H16N4O2: C, 64.85; H, 
5.44; N, 18.91. Found: C, 64.85; H, 5.44; N, 18.91%. 
 
 
 
 
3.7.3.8 6-amino-1,4-dihydro-3-isopropyl-4-(4-methoxyphenyl)pyrano[2,3-c]pyrazole  
-5-carbonitrile (BHD-208) Yield: 70%; mp 179-181 ºC; 
IR (cm-1): 3398 (N-H stretching of free primary amine), 
3321 (N-H stretching of pyrazolo ring), 3101 (C-H 
stretching of aromatic ring), 3020 (C-H symmetrical 
stretching of CH3 group), 2966 (C-H asymmetrical 
stretching of CH3 group), 2193 (C≡N stretching of the 
nitrile group), 1654 (C=N stretching of pyrazolo ring), 1606 (N-H deformation 
pyrazolo ring), 1253 (C-O-C asymmetrical stretching of ether linkage), 1172 (N-N 
deformation of pyrazolo ring), 1107 (C-O-C symmetrical stretching of ether linkage), 
1026 (C-H in plane bending of aromatic ring), 819 (C-H out of plane bending for 1,4-
disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.84-0.86 (d, 3H, Ha, J = 
6.8 Hz), 1.00-1.02 (d, 3H, Hb, J = 6.9 Hz), 2.51-2.58 (m, 1H, Hc), 3.75 (s, 3H, Hd), 
4.52 (s, 1H, He), 6.36 (s, 2H, Hf), 6.80-6.83 (d, 2H, Hgg’), 7.06-7.08 (d, 2H, Hhh’), 
11.96 (s, 1H, Hi); MS: m/z 310; Anal. Calcd. for C17H18N4O2: C, 65.79; H, 5.85; N, 
18.05. Found: C, 65.79; H, 5.85; N, 18.05%. 
 
3.7.3.9 6-amino-1,4-dihydro-3-isopropyl-4-(3,4-dimethoxyphenyl)pyrano[2,3-c]pyr  
azole-5-carbonitrile (BHD-209) Yield: 68%; mp 142-144 
ºC; MS: m/z 340; Anal. Calcd. for C18H20N4O3: C, 63.52; 
H, 5.92; N, 16.46. Found: C, 63.52; H, 5.92; N, 16.46%. 
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3.7.3.10 6-amino-4-(3-chlorophenyl)-1,4-dihydro-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-210) Yield: 77%; mp 183-185 ºC; 
MS: m/z 314; Anal. Calcd. for C16H15ClN4O: C, 61.05; H, 
4.80; N, 17.80. Found: C, 61.05; H, 4.80; N, 17.80%. 
 
 
 
3.7.3.11 6-amino-4-(3-bromophenyl)-1,4-dihydro-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-211) Yield: 73%; mp 206-208 ºC; 
MS: m/z 358; Anal. Calcd. for C16H15BrN4O: C, 53.50; H, 
4.21; N, 15.60. Found: C, 53.50; H, 4.21; N, 15.60%. 
 
 
 
3.7.3.12 6-amino-1,4-dihydro-3-isopropyl-4-(3-nitrophenyl)pyrano[2,3-c]pyrazole-5- 
carbonitrile (BHD-212) Yield: 82%; mp 227-229 ºC; MS: 
m/z 325; Anal. Calcd. for C16H15N5O3: C, 59.07; H, 4.65; 
N, 21.53. Found: C, 59.07; H, 4.65; N, 21.53%. 
 
 
 
3.7.3.13 6-amino-1,4-dihydro-4-(3-hydroxyphenyl)-3-isopropylpyrano[2,3-c]pyrazo 
 le-5-carbonitrile (BHD-213) Yield: 62%; mp 234-236 
ºC; MS: m/z 296; Anal. Calcd. for C16H16N4O2: C, 64.85; 
H, 5.44; N, 18.91. Found: C, 64.85; H, 5.44; N, 18.91%. 
 
 
 
3.7.3.14 6-amino-4-(2-chlorophenyl)-1,4-dihydro-3-isopropylpyrano[2,3-c]pyrazole- 
5-carbonitrile (BHD-214) Yield: 70%; mp 168-170 ºC; 
MS: m/z 314; Anal. Calcd. for C16H15ClN4O: C, 61.05; H, 
4.80; N, 17.80. Found: C, 61.05; H, 4.80; N, 17.80%. 
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3.7.3.15 6-amino-1,4-dihydro-3-isopropyl-4-(2-nitrophenyl)pyrano[2,3-c]pyrazole-5- 
carbonitrile (BHD-215) Yield: 66%; mp 213-215 ºC; MS: 
m/z 325; Anal. Calcd. for C16H15N5O3: C, 59.07; H, 4.65; 
N, 21.53. Found: C, 59.07; H, 4.65; N, 21.53%. 
 
 
 
3.7.4 General procedure for the 6-amino-1,4-dihydro-3-isopropyl-4-(aryl)-1-
phenylpyrano[2,3-c]pyrazole-5-carbonitrile (BHD 216-230) 
 
A mixture of the malononitrile (0.01 mol), 3-isopropyl-1-phenyl-1H-pyrazol-5(4H)-
one (0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) in 8-10 mL of MeOH 
with catalytic amount of piperidine were stirred at rt for 6-8 h. After completion of the 
reaction, the reaction mixture was filtered to give the solid products BHD-216 to 230, 
which were recrystallized from ethanol. 
 
3.7.4.1 6-amino-1,4-dihydro-3-isopropyl-1,4-diphenylpyrano[2,3-c]pyrazole-5-carbo  
nitrile (BHD-216) Yield: 75%; mp 157-159 ºC; IR (cm-1): 
3471 (N-H stretching of free primary amine), 3321 (N-H 
stretching of pyrazolo ring), 3063 (C-H stretching of 
aromatic ring), 2196 (C≡N stretching of the nitrile group), 
1658 (C=N stretching of pyrazolo ring), 1581 (N-H 
deformation pyrazolo ring), 1338 (C-N stretching of 
pyrazolo ring), 1180 (N-N deformation of pyrazolo ring),  
1026 (C-H in plane bending of aromatic ring), 846 (C-H out of plane bending for 1,4-
disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.81-0.83 (d, 3H, Ha, J = 
6.8 Hz), 1.00-1.02 (d, 3H, Hb, J = 6.9 Hz), 2.51-2.57 (m, 1H, Hc), 4.56 (s, 1H, Hd), 
6.29 (s, 2H, He), 7.14-7.31 (m, 10H, Hff-k); MS: m/z 356; Anal. Calcd. for C22H20N4O: 
C, 74.14; H, 5.66; N, 15.72. Found: C, 74.14; H, 5.66; N, 15.72%. 
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3.7.4.2 6-amino-4-(4-fluorophenyl)-1,4-dihydro-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-217) Yield: 79%; mp 162-
164 ºC; IR (cm-1): 3458 (N-H stretching of free primary 
amine), 3325 (N-H stretching of pyrazolo ring), 3063 (C-
H stretching of aromatic ring), 2200 (C≡N stretching of 
the nitrile group), 1664 (C=N stretching of pyrazolo ring), 
1600 (N-H deformation pyrazolo ring), 1342 (C-N 
stretching of pyrazolo ring), 1155 (N-N deformation of 
pyrazolo ring),  1024 (C-H in plane bending of aromatic ring), 813 (C-H out of plane 
bending for 1,4-disubstituted aromatic ring); 1H NMR (DMSO-d6) δ ppm: 0.89-0.91 
(d, 3H, Ha, J = 6.8 Hz), 1.04-1.06 (d, 3H, Hb, J = 6.9 Hz), 2.43-2.48 (m, 1H, Hc), 4.64 
(s, 1H, Hd), 6.62 (s, 2H, He), 6.90-7.76 (m, 10H, Hff’-jj’); MS: m/z 374; Anal. Calcd. 
for C22H19FN4O: C, 70.57; H, 5.11; N, 14.96. Found: C, 70.57; H, 5.11; N, 14.96%. 
 
3.7.4.3 6-amino-4-(4-chlorophenyl)-1,4-dihydro-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-218) Yield: 83%; mp 142-
144 ºC; MS: m/z 390; Anal. Calcd. for C22H19ClN4O: C, 
67.60; H, 4.90; N, 14.33. Found: C, 67.60; H, 4.90; N, 
14.33%. 
 
 
 
 
3.7.4.4 6-amino-4-(4-bromophenyl)-1,4-dihydro-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-219) Yield: 67%; mp 200-
202 ºC; MS: m/z 434; Anal. Calcd. for C22H19BrN4O: C, 
70.57; H, 5.11; N, 14.96. Found: C, 70.57; H, 5.11; N, 
14.96%. 
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3.7.4.5 6-amino-1,4-dihydro-3-isopropyl-4-(4-nitrophenyl)-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-220) Yield: 79%; mp 187-
189 ºC; MS: m/z 401; Anal. Calcd. for C22H19N5O3: C, 
65.83; H, 4.77; N, 17.45. Found: C, 65.83; H, 4.77; N, 
17.45%. 
 
 
 
 
3.7.4.6 6-amino-1,4-dihydro-3-isopropyl-1-phenyl-4-p-tolylpyrano[2,3-c]pyrazole-5- 
carbonitrile (BHD-221) Yield: 85%; mp 135-137 ºC; MS: 
m/z 370; Anal. Calcd. for C23H22N4O: C, 74.57; H, 5.99; 
N, 15.12. Found: C, 74.57; H, 5.99; N, 15.12%. 
 
 
 
 
 
3.7.4.7 6-amino-1,4-dihydro-4-(4-hydroxyphenyl)-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-222) Yield: 71%; mp 217-
219 ºC; MS: m/z 372; Anal. Calcd. for C22H20N4O2: C, 
70.95; H, 5.41; N, 15.04. Found: C, 70.95; H, 5.41; N, 
15.04%. 
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3.7.4.8 6-amino-1,4-dihydro-3-isopropyl-4-(4-methoxyphenyl)-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-223) Yield: 77%; mp 196-
198 ºC; MS: m/z 386; Anal. Calcd. for C23H22N4O2: C, 
71.48; H, 5.74; N, 14.50. Found: C, 71.48; H, 5.74; N, 
14.50%. 
 
 
 
 
3.7.4.9 6-amino-1,4-dihydro-3-isopropyl-4-(3,4-dimethoxyphenyl)-1-phenylpyrano  
[2,3-c]pyrazole-5-carbonitrile (BHD-224) Yield: 73%; 
mp 208-210 ºC; MS: m/z 416; Anal. Calcd. for 
C24H24N4O3: C, 69.21; H, 5.81; N, 13.45. Found: C, 69.21; 
H, 5.81; N, 13.45 %. 
 
 
 
 
3.7.4.10 6-amino-4-(3-chlorophenyl)-1,4-dihydro-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-225) Yield: 69%; mp 233-
235 ºC; MS: m/z 390; Anal. Calcd. for C22H19ClN4O: C, 
67.60; H, 4.90; N, 14.33. Found: C, 67.60; H, 4.90; N, 
14.33%. 
 
  
 
3.7.4.11 6-amino-4-(3-bromophenyl)-1,4-dihydro-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-226) Yield: 70%; mp 156-
158 ºC; MS: m/z 434; Anal. Calcd. for C22H19BrN4O: C, 
70.57; H, 5.11; N, 14.96. Found: C, 70.57; H, 5.11; N, 
14.96%. 
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3.7.4.12 6-amino-1,4-dihydro-3-isopropyl-4-(3-nitrophenyl)-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-227) Yield: 80%; mp 239-
241 ºC; MS: m/z 401; Anal. Calcd. for C22H19N5O3: C, 
65.83; H, 4.77; N, 17.45. Found: C, 65.83; H, 4.77; N, 
17.45%. 
 
 
 
 
3.7.4.13 6-amino-1,4-dihydro-4-(3-hydroxyphenyl)-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-228) Yield: 75%; mp 214-
216 ºC; MS: m/z 372; Anal. Calcd. for C22H20N4O2: C, 
70.95; H, 5.41; N, 15.04. Found: C, 70.95; H, 5.41; N, 
15.04%. 
 
 
 
 
3.7.4.14 6-amino-4-(2-chlorophenyl)-1,4-dihydro-3-isopropyl-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-229) Yield: 68%; mp 174-
176 ºC; MS: m/z 390; Anal. Calcd. for C22H19ClN4O: C, 
67.60; H, 4.90; N, 14.33. Found: C, 67.60; H, 4.90; N, 
14.33%. 
 
  
 
 
3.7.4.15 6-amino-1,4-dihydro-3-isopropyl-4-(2-nitrophenyl)-1-phenylpyrano[2,3-c]  
pyrazole-5-carbonitrile (BHD-230) Yield: 63%; mp 219-
221 ºC; MS: m/z 401; Anal. Calcd. for C22H19N5O3: C, 
65.83; H, 4.77; N, 17.45. Found: C, 65.83; H, 4.77; N, 
17.45%. 
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3.8 Spectral discussion 
3.8.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
3.8.1.1 Mass fragmentation pattern for BHD-208 
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3.8.1.2 Mass fragmentation pattern for BHD-217 
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3.8.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For pyrano[2,3-c]pyrazoles (BHD-201 to 230), 
confirmatory bands for primary amine (-NH2) and nitrile (C≡N) stretching band was 
observed at 3400-3500 cm-1 and 2190-2220 cm-1 respectively. Another characteristic 
band for N-H deformation was observed at 1580-1620 cm-1, which suggested the 
formation of pyranopyrazoles ring system. 
 
3.8.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 1H 
NMR spectra confirmed the structures of pyrano[2,3-c]pyrazoles (BHD-201 to 230) 
on the basis of following signals: singlet for primary amino group proton was 
observed at 5.91-6.62 δ ppm and a singlet for the methine proton of pyran ring at 
4.52-4.64 δ ppm. The aromatic ring protons and J value were found to be in 
accordance with substitution pattern on phenyl ring. 
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Mass spectrum of BHD-203 
 
IR spectrum of BHD-203 
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1H NMR spectrum of BHD-203 
 
Expanded 1H NMR spectrum of BHD-203 
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Expanded 1H NMR spectrum of BHD-203 
 
Mass spectrum of BHD-206 
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IR spectrum of BHD-206 
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1H NMR spectrum of BHD-206 
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Expanded 1H NMR spectrum of BHD-206 
 
Expanded 1H NMR spectrum of BHD-206 
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Mass spectrum of BHD-208 
 
IR spectrum of BHD-208 
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1H NMR spectrum of BHD-208 
 
Expanded 1H NMR spectrum of BHD-208 
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Expanded 1H NMR spectrum of BHD-208 
 
Mass spectrum of BHD-216 
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IR spectrum of BHD-216 
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Expanded 1H NMR spectrum of BHD-216 
 
Expanded 1H NMR spectrum of BHD-216 
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Mass spectrum of BHD-217 
 
IR spectrum of BHD-217 
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1H NMR spectrum of BHD-217 
 
Expanded 1H NMR spectrum of BHD-217 
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3.9 Biological evaluation 
3.9.1 Antimicrobial evaluation 
All the synthesized compounds (BHD-201 to BHD-230) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [123, 124] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and greseofulvin as 
standard drugs. The standard strains were procured from the Microbial Type Culture 
Collection (MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, 
India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [123]. Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 200 μg mL-1, 100 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.25 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied. 
The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds BHD-201 to 230 
 
Code Minimal inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
BHD-201 200 100 100 100 250 1000 250 
BHD-202 500 500 250 250 250 200 200 
BHD-203 500 500 100 250 500 500 >1000 
BHD-204 500 500 250 500 500 >1000 1000 
BHD-205 250 62.5 250 500 >1000 >1000 >1000 
BHD-206 100 200 62.5 125 500 >1000 >1000 
BHD-207 250 250 250 500 1000 500 >1000 
BHD-208 200 500 62.5 500 1000 500 500 
BHD-209 100 200 500 500 250 >1000 >1000 
BHD-210 500 500 100 250 250 1000 250 
BHD-211 500 62.5 250 250 250 200 200 
BHD-212 100 250 100 250 500 500 >1000 
BHD-213 500 250 250 500 500 >1000 1000 
BHD-214 500 500 250 500 >1000 >1000 >1000 
BHD-215 500 100 100 125 500 >1000 1000 
BHD-216 200 500 250 500 1000 500 >1000 
BHD-217 250 500 62.5 500 1000 500 500 
BHD-218 250 500 500 500 250 >1000 >1000 
BHD-219 500 500 1000 1000 500 1000 1000 
BHD-220 200 100 100 500 500 1000 200 
BHD-221 250 250 250 250 500 500 1000 
BHD-222 100 500 500 1000 250 500 500 
BHD-223 500 100 62.5 100 500 500 >1000 
BHD-224 250 500 500 500 200 500 200 
BHD-225 500 250 500 500 1000 1000 1000 
BHD-226 500 100 500 250 1000 >1000 1000 
BHD-227 250 62.5 100 125 250 1000 500 
BHD-228 500 250 200 500 500 1000 >1000 
BHD-229 100 250 500 1000 1000 >1000 >1000 
BHD-230 500 62.5 62.5 100 250 1000 1000 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Greseofulvin - - - - 500 100 100 
 
3.9.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds BHD-201 to BHD-230 is currently under investigation and results are 
awaited. 
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 Chapter 4 
  
 Microwave assisted synthesis and 
 biological evaluation of 1,2,4-triazolo 
 [1,5-a]pyrimidines 
 
 
  
4.1 Introduction 
The condensation of a ring of 1,2,4-triazole and another one of pyrimidine gives rise 
to the formation of bicyclic heterocycles known as 1,2,4-triazolopyrimidines. Four 
different possibilities exist for the relative orientation of both rings, so four different 
isomeric families of compounds are defined: 1,2,4-triazolo[1,5-a]pyrimidine (1), 
1,2,4-triazolo[1,5-c]pyrimidine (2), 1,2,4-triazolo[4,3-a]pyrimidine (3) and 1,2,4-
triazolo[4,3-c]pyrimidine (4). 
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(1) 1,2,4-triazolo[1,5-a]pyrimidine (2) 1,2,4-triazolo[1,5-c]pyrimidine
(3) 1,2,4-triazolo[4,3-a]pyrimidine (4) 1,2,4-triazolo[4,3-c]pyrimidine  
 
Among these isomeric families of compounds, 1,2,4-triazolo[1,5-a]pyrimidine 
derivatives are  thermodynamically more stable and, thus, the most studied ones [1], a 
few of them being commercially available. Revisions surveying the synthesis, 
reactivity, spectroscopic characterization and crystallographic studies of 1,2,4-
triazolo[1,5-c]pyrimidines [2], 1,2,4-triazolo[4,3-a]pyrimidines [3] and 1,2,4-triazolo 
[4,3-c]pyrimidines [4] have also been published. 
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 From the standpoint of biological activity, fused heteroaromatic systems are 
often of much greater interest than the constituent monocyclic compounds. Recently, 
1,2,4-triazolo[1,5-a]pyrimidines have aroused increasing attention from the chemical 
and biological view points, due to their diverse pharmacological activities, such as 
antitumor potency [5, 6], inhibition of KDR kinase [7], antifungal effect [8] and 
macrophage activation [9]. They have proved to be promising anticancer agents with 
dual mechanisms of tubulin polymerization promotion [5, 6] as well as cyclin 
dependent kinases 2 inhibition [10]. Some examples of published derivatives of 1,2,4-
triazolo[1,5-a]pyrimidine with their biological activities are as following.  
N
N
N
N
NH2
O
(5) Activity: A2A adenosine receptor antagonists [11]
R
N
N
N
N
CH3
H3C
NH S
O
O
CH3
(6) Activity: latent leishmanicidal activity [12]
N
N
N
N
HN
Cl
CH3
F3C H
F
FOHN
CH3
(7) Activity: Anticancer acticity [13]
N
N
N
N
S
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O
NN
SCH3CH2(CH3)CH
(8) Activity: antifungal activity [14]
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(10) Activity: Acetohydroxyacid synthase 
                       inhibitor [16]
N
N
N
N
SO2NH
F
F
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(9) Activity: Hepatitis C virus polymerase inhibitor [15]
N
N
N
N
NH
O
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(11) Activity: CDK2 inhibitors [17]
N
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(12) Activity: Anti-inflammatory [18]
N
N
N
N
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O
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(13) Activity: Antiproliferative activity [19]
N
N
N
N
NEt2
(14) Trapidil: Antiischemic and cardiatonic
                       agent [20]
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4.2 Microwave-Assisted Organic Synthesis (MAOS) – A Brief History 
While fire is now rarely used in synthetic chemistry, it was not until Robert Bunsen 
invented the burner in 1855 that the energy from this heat source could be applied to a 
reaction vessel in a focused manner. The Bunsen burner was later superseded by the 
isomantle, the oil bath or the hot plate as a means of applying heat to a chemical 
reaction. In the past few years, heating and driving chemical reactions by microwave 
energy has been an increasingly popular theme in the scientific community [21, 22]. 
 Microwave energy, originally applied for heating foodstuffs by Percy Spencer 
in the 1940s, has found a variety of technical applications in the chemical and related 
industries since the 1950s, in particular in the food-processing, drying and polymer 
industries. Other applications range from analytical chemistry (microwave digestion, 
ashing and extraction) [23] to biochemistry (protein hydrolysis, sterilization) [23], 
pathology (histoprocessing, tissue fixation) [24] and medical treatments (diathermy) 
[25]. Somewhat surprisingly, microwave heating has only been implemented in 
organic synthesis since the mid-1980s. The first reports on the use of microwave 
heating to accelerate organic chemical transformations (MAOS) were published by 
the groups of Richard Gedye (Scheme 4.1) [26] and Raymond J. Giguere/George 
Majetich [27] in 1986.  
 
NH2
O
OH
O
20% H2SO4
MW or thermal
Thermal: 1h, 90% yield  (reflux)
MW: 10 min, 99% yield  (sealed vessel)
Scheme 4.1 Hydrolysis of benzamide: The first published example (1986) of 
microwave-assisted organic synthesis.
 
 
In those early days, experiments were typically carried out in sealed teflon or 
glass vessels in a domestic household microwave oven without any temperature or 
pressure measurements. The results were often violent explosions due to the rapid 
uncontrolled heating of organic solvents under closed-vessel conditions. In the 1990s, 
several groups started to experiment with solvent-free microwave chemistry (so-
called dry-media reactions), which eliminated the danger of explosions [28]. Here, the 
reagents were pre-adsorbed onto either an essentially microwave-transparent (i.e., 
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silica, alumina or clay) or strongly absorbing (i.e., graphite) inorganic support, that 
additionally may have been doped with a catalyst or reagent. Particularly in the early 
days of MAOS, the solvent-free approach was very popular since it allowed the safe 
use of domestic microwave ovens and standard open-vessel technology. While a large 
number of interesting transformations using “dry-media” reactions have been 
published in the literature [28], technical difficulties relating to non-uniform heating, 
mixing and the precise determination of the reaction temperature remained unresolved, 
in particular when scale-up issues needed to be addressed. 
 Alternatively, microwave-assisted synthesis has been carried out using 
standard organic solvents under open-vessel conditions. If solvents are heated by 
microwave irradiation at atmospheric pressure in an open vessel, the boiling point of 
the solvent typically limits the reaction temperature that can be achieved. In order to 
nonetheless achieve high reaction rates, high-boiling microwave-absorbing solvents 
have been frequently used in open-vessel microwave synthesis [29]. However, the use 
of these solvents presented serious challenges in relation to product isolation and 
recycling of the solvent. Because of the recent availability of modern microwave 
reactors with on-line monitoring of both temperature and pressure, MAOS in 
dedicated sealed vessels using standard solvents-a technique pioneered by Christopher 
R. Strauss in the mid-1990s [30] has been celebrating a comeback in recent years. 
This is clearly evident surveying the recently published (since 2001) literature in the 
area of controlled microwave-assisted organic synthesis (MAOS). It appears that the 
combination of rapid heating by microwaves with sealed-vessel (autoclave) 
technology will most likely be the method of choice for performing MAOS on a 
laboratory scale in the future. Importantly, recent innovations in microwave reactor 
technology now allow controlled parallel and automated sequential processing under 
sealed-vessel conditions, and the use of continuous- or stop-flow reactors for scale-up 
purposes. 
 Since the early days of microwave synthesis, the observed rate accelerations 
and sometimes altered product distributions compared to oil-bath experiments have 
led to speculation on the existence of so-called “specific” or “non-thermal” 
microwave effects [31]. Historically, such effects were claimed when the outcome of 
a synthesis performed under microwave conditions was different from that of the 
conventionally heated counterpart at the same apparent temperature. Reviewing the 
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present literature [32], it appears that today most scientists agree that in the majority 
of cases the reason for the observed rate enhancements is a purely thermal/kinetic 
effect, i.e., a consequence of the high reaction temperatures that can rapidly be 
attained when irradiating polar materials in a microwave field, although effects that 
are caused by the unique nature of the microwave dielectric heating mechanism 
(“specific microwave effects”) clearly also need to be considered. While for the 
medicinal chemist in industry this discussion may seem largely irrelevant, the debate 
on “microwave effects” is undoubtedly going to continue for many years in the 
academic world. Regardless of the nature of the observed rate enhancements, 
microwave synthesis has now truly matured and has moved from a laboratory 
curiosity in the late 1980s to an established technique in organic synthesis, heavily 
used in both academia and industry. 
The initially slow uptake of the technology in the late 1980s and 1990s has 
been attributed to its lack of controllability and reproducibility, coupled with a general 
lack of understanding of the basics of microwave dielectric heating. The risks 
associated with the flammability of organic solvents in a microwave field and the lack 
of available dedicated microwave reactors allowing for adequate temperature and 
pressure control were major concerns. Important instrument innovations now allow 
for careful control of time, temperature and pressure profiles, paving the way for 
reproducible protocol development, scale-up and transfer from laboratory to 
laboratory and from scientist to scientist. Today, microwave chemistry is as reliable as 
the vast arsenal of synthetic methods that preceded it. Since 2001, therefore, the 
number of publications related to MAOS has increased dramatically, to such a level 
that it might be assumed that, in a few years, most chemists will probably use 
microwave energy to heat chemical reactions on a laboratory scale [21, 22]. Not only 
is direct microwave heating able to reduce chemical reaction times significantly, but it 
is also known to reduce side reactions, increase yields and improve reproducibility. 
Therefore, many academic and industrial research groups are already using MAOS as 
a technology for rapid reaction optimization, for the efficient synthesis of new 
chemical entities or for discovering and probing new chemical reactivity. 
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4.3 Applications of microwaves in heterocyclic ring formation 
4.3.1 Five-membered heterocyclic rings 
4.3.1.1 Pyrroles 
The classical Paal-Knorr cyclization of 1,4-diketones to give pyrroles is dramatically 
speeded-up under microwave irradiation and high yields are obtained as shown in 
Scheme 4.2 [33]. 
 
O
O
RNH2
N
R
R = CH2C6H5,
4-MeOC6H4, 
2-ClC6H4
MW, 100-200 W, 0.5-2.0 min., solvent-free
Microwave: 2 min., Convential: Lewis acid activation, 12h.
Scheme 4.2  
 
4.3.1.2 Pyrazoles 
Another recent application of microwaves in cyclization is the preparation of 
pyrazoles from hydrazones using the Vilsmeier cyclization method by treatment with 
POCl3 and DMF [34].
 
As shown in Scheme 4.3, once again the reaction is speeded-up 
by factors of several 100-fold. 
 
MW, 210 W, 30-50 sec., DMF
Microwave: 35-50 sec., 45-78%
 Convential: 4-5 h, 41-76%
Scheme 4.3
R2 R1
R5
N
NH
R3
R4
POCl3
R2 R1
N N
R5
R4R3
R1 = H, OH; R2 = H, CH3; R3 = H, NO2; 
R4 = NO2; R5 = CH3, C2H5,
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4.3.1.3 Imidazoles 
An important classical preparation of imidazoles is from an α-diketone, an aldehyde 
and ammonia. Here again, excellent yields can be obtained in reaction times of a few 
minutes as shown in Scheme 4.4 [35]. 
 
Scheme 4.4
R1 H
O
+
R2
O
R3
O
Al2O3
NH4OAc
N NH
R3 R2
R1
MW, 130 W, 10 min., solvent-free
Microwave: 10 sec., 45-78%
 Convential: 4h, AcOH, reflux
R1 = C6H5; 4-ClC6H4, 2-thiophenyl etc.
R2 = R3 =  C6H5; 4-MeC6H4
 
 
4.3.1.4 Oxazolines 
The example of Scheme 4.5, the preparation of oxazolines shows that partially 
saturated five-membered rings can also be prepared advantageously using 
microwaves [36]. 
 
+
R OH
O
NH2
OH
HO
OH
-H2O NH
OH
HO
HO
O
R
-H2O
N
OR
OH
OH
80-95%
MW, 850 W, 200 ºC, 5 min., solvent-free
 Convential: 15-16 h
R = 2-Furyl, Phenyl, Heptadecenyl
Scheme 4.5
 
 
4.3.1.5 Triazoles and Tetrazoles 
Schemes 4.6 and 4.7 continue the overview of five-membered rings with illustrations 
of the advantageous preparation of 1,2,4-triazoles (Scheme 4.6) [37] and tetrazoles 
(Scheme 4.7) [38]
 
using microwaves. Notice that in Scheme 4.6 the starting aryl 
cyanides are also made by a Pd-catalyzed but microwave-enhanced replacement of 
aryl bromides using zinc cyanide. 
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Ar C N
NH2NH2-2HCl
NH2NH2-H2O
NN
N
NH2
Ar Ar
MW: 60 W, 130 ºC, 36-96%
Convential: 60 min., 130 ºC, 45-60%
Ar = C6H5; 4-OCH3C6H4,  4-NH2C6H4,  
4-OHC6H4, 4-CH3C6H4 etc.
Scheme 4.6
Br
R
Zn(CN)2
Pd(PPh3)4
CN
R
NaN3
NH4Cl R
N
N
NHN
R = OCH3, NO2, CH3 etc.
MW: 60 W, 175 ºC, 2 min., DMF, 78-93%
Convential: 2-16 h, 71-97%
MW: 20 W, 220 ºC, 10-25 min., DMF, 36-96%
Convential: 3-96 h, 35-97%
Scheme 4.7  
 
4.3.1.6 Oxadiazoles 
The dehydration of unsymmetrical diacylhydrazines (themselves prepared by a 
conventional Mitsunobu reaction) using Burgess’s reagent is shown in Scheme 4.8 to 
give 1,3,4-oxadiazoles rapidly under microwave irradiation [39]. 
 
MW: 150 ºC, 5 min., DMF
 Convential :90 min., 150 ºC
R = alkyl, aryl; R2 = Cl, OMe
Scheme 4.8
+
R1 OH
O
N
H
O
H2N
R2
DDC
N
H
OH
N
R2
R1
O
MeO N
S
NEt3
O O
O
NN
OR1
100%
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4.3.1.7 Isoxazolines and pyrazolines 
The acceleration of 1,3-dipolar cycloaddition reactions to give isoxazolines and 
pyrazolines by the addition of activated olefins to nitrile oxides or nitrile imides, 
respectively, is illustrated in Scheme 4.9; the resulting compounds are obtained in far    
high yield than under conventional conditions [40]. 
 
N
XH
ClAr
Al2O3
Ar C N X
Ar C N X
RC CY
RHC C(Y)(Z)
O N Me
N
X
YR
Ar
+
N
X
RY
Ar
25-73% 0-22%
N
X
YR
Ar
Z
MW: 110-140 ºC, 30 min., xylene, 50-85%
 Convential :22-40%
R = H, Ph, CO2Me;
Y = CO2Me, CO2Et;
Z = H, CN
Scheme 4.9
 
4.3.2 Benzo-derivatives of five-membered rings 
4.3.2.1 Benz-imidazoles, -oxazoles, and –thiazoles 
Ring closure reactions of appropriate o-substituted anilines to give benzimidazoles, 
benzoxazoles, and benzthiazoles takes place much faster and in significantly high 
yield under microwave conditions  than conventionally [41] as shown in Scheme 4.10.  
 
NH2
Z
+
EtO CF3
OEt O
Y
N
F3C
O
Z = NH2, OH, SH MW: 980 W, 9-11 min., toluene, 86-96% Convential : 3-5 h, 40-80%
Scheme 4.10
Y = NH, O, S
 
 
4.3.2.2 Indoles 
The classical Fischer-indole synthesis from an aryl hydrazine and a ketone is speeded-
up by several 100-fold as documented in Scheme 4.11 [42].  
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H
N
NH2 +
O
N
H
MW:30 Sec., AcOH
 Convential : AcOH rerflux, 2h
Scheme 4.11
 
 
4.3.2.3 γ-Carbolines 
The Graebe-Ullmann synthesis which converts 1-arylbenzotriazoles into carbazoles or 
their heterocyclic analogs is also accelerated under microwave conditions as shown in 
Scheme 4.12 where the 1-(4-pyridyl)benzotriazole is converted into a γ-carboline [43].  
 
N
H
N
NR2
R3
+
N
Cl
R1
N
N
NR2
R3
N
R1
H2P2O7
N
H
R2
R3
N
R1
MW, 160W, 10 min., solvent-free
MW, 160W, 5 min., solvent-free
MW: 15 min., 30-76%
Convential: 150 min., 28-80%
R1 = H, Me
R2 = R3 = H, Me
Scheme 4.12
 
 
4.3.3 Six-membered rings 
4.3.3.1 Dihydropyridines   
The Hantzsch dihydropyridine synthesis remains one of the most important routes to 
pyridine ring systems. Under conventional conditions long periods of heating are 
required and yields are poor to moderate. Microwaves dramatically reduce the heating 
times and also significantly increase the yields as shown in Scheme 4.13 [44].  
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Me OEt
O O
+
Ar H
O
25% aq NH4OH
N
H
CO2EtEtO2C
Me Me
Ar
(5 equiv)
MW: 140 ºC, 10-15 min., Solvent-free, 51-92%
Convential:12 h, 15-61%
Ar = C6H5, 2-NO2C6H4,
2-CH3OC6H4, 2-ClC6H4
Scheme 4.13
 
 
4.3.3.2 Dihydropyridopyrimidinones  
Dihydropyridopyrimidinones have been produced by ring annulations of 
aminopyrimidinones. Once again the reaction time is dramatically reduced and yields 
are much better with the solvent-free microwave conditions (Scheme 4.14) [45]. 
 
N
N
O
NH2X
Me
R
+ Ph
O
CN + Ar H
O
N
H
N
N
Ar
CN
Ph
R
X
Me
O
X = O, S; R = H, CH3;
Ar = C6H5, 2-CH3OC6H4, 2-ClC6H4
MW: 600 W, 20 min., Solvent-free, 70-75%
Convential: EtOH reflux, 40-48 h, 21-25 %
Scheme 4.14
 
 
4.3.3.3 Dihydropyrimidines 
The Biginelli reaction is important for the preparation of dihydropyrimidine 
derivatives and excellent results are found for reactions carried out with microwave 
enhancement (Scheme 4.15) [39].  
 
MW: 5 min., 60-90%
Convential:12-24 h, 15-60%
R1 OEt
O O
+
H2N
O
NH2 R2 H
O
+ HN
N
H
O
O
OEt
R1
R2
R1 = H, CH3 R2 =  C6H5, 2-CH3OC6H4,   2-ClC6H4
Scheme 4.15
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4.3.3.4 Tetrazines 
The Diels-Alder reaction between aza-olefins and aza-dicarboxylic ester to give 
tetrazines is speeded-up by a factor of 1000 by microwave enhancement as shown in 
Scheme 4.16 [46]. 
 
Ph
N
N
R
+ N N CO2EtEtO2C
N
N
N
N
Ph
CO2Et
CO2Et
R = Carbohydrate MW: 300 W, 15 min., 80-96%
Convential: 30 days
Scheme 4.16
R
 
 
4.3.4 Polycyclic six-membered rings 
4.3.4.1 Quinolines 
The Skraup synthesis has a bad reputation as it involves very messy conditions and 
gives only low yields of quinolines when carried out conventionally. Recently, it has 
been reported that microwave enhancement reduces the reaction time to a few minutes 
and allows high yields to be isolated (Scheme 4.17) [47]. 
 
NH2
R + R1
R2
R3
O
InCl3/SiO2
N
R3
R2
R1
R
R = H,  o-CH3, m-CH3, p-CH3, o-OMe, p-OMe, m-OH, m-Cl etc.
R1 = H, CH3, n-C3H7; R2 = H, C2H5;
R3 = CH3, p-MeOC6H4
MW: 600 W, 5-12 min., Solvent-free, 80-87%
Convential: H2SO4/150 ºC, low yileds
Scheme 4.17
 
 
4.3.4.2 Pyrimido[1,2-a]pyrimidines 
Pyrimido[1,2-a]pyrimidines are prepared from dihydroaminopyrimidines and 
chromone-3-aldehydes as is shown in Scheme 4.18 [48].
 
Although the conventional 
reaction must proceed in refluxing ethanol, reactions are much faster and better yields 
have been obtained with microwaves. 
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N
H
N
NH2
EtO2C
Ph
HAr
+
O
O
O
H N
N
EtO2C
Ph
HAr
N
H
H
OH
O
N
N
EtO2C
Ph
Ar
N
H
H
OH
O
H
4H
2H
Ar = C6H5, 4-CH3C6H4, 4-CH3OC6H4, 
4-ClC6H4, 2-thienyl
MW: 400 W, 20 min., Solvent-free, >95%
Convential: EtOH reflux, 4 h, 60-70 %
Scheme 4.18
 
 
4.3.5 Nucleophilic Substitutions 
4.3.5.1 Heterocyclic C-alkylations 
Nucleophilic substitution reactions can be speeded-up very considerably as is 
illustrated in Scheme 4.19 for a chloro-naphthyridine derivative [49]. 
 
N N
O
F
F
F
Cl
NH
N N
O
F
F
F
N
COOEt
COOEt
NH2
N N
O
F
F
F
HN
COOEtF3C
NH2
N N
O
F
F
F
HN
COOEt
CF3
NH2
N N
O
F
F
F
HN
COOEt
NH2
OMe
N N
O
F
F
F
HN
COOEt
OMe
Microwave: 175 ºC, 10 min, 100%
Convential: 100 ºC, 12-24 h, 35-60%
Scheme 4.19
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4.3.5.2 Heterocyclic N-alkylations 
 
Microwave: 750 W, 2-10 min, solvent-free, 71-92%
Convential: DMF reflux, 30 min.
Scheme 4.20
S
NH
O
O O
NaOH, RX
silica gel S
NR
O
O O
R = CH2C6H5, n-C16H33, CH2COOC2H5 etc.
 
 
Another class of nucleophilic substitution is involved in heterocyclic N-alkylation 
which we have illustrated in Scheme 4.20. This shows that nucleophilic substitution 
on the nitrogen atom of saccharin is significantly speeded-up by microwave 
irradiation [39].  
 
4.3.5.3 Selective-alkylation 
In Scheme 4.21, the results presented indicate that selectivity is achieved in the N 
alkylation of 1,2,4-triazole under microwave conditions where only the N1-alkyl 
derivative was formed in contradistinction to the conventional conditions which give 
a considerable amount of the di-1,4-substituted compound [50]. 
 
N
N
H
N + PhCH2Br
N
N
N
CH2Ph
+
N
N
N
CH2Ph
PhH2C Br
molar ratio 1:1 N1 N1,4
Microwave: 90-165 ºC, 1.5-5 min, 70%
Convential: 14%; only N1,4 isolated
Scheme 4.21
 
 
 
4.3.5.4 Transition metal cross-coupling 
An important type of nucleophilic substitution reactions which are recently much 
exploited are comprised of transition metal cross-coupling. A Suzuki coupling is 
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shown at the top of Scheme 4.22 to give significantly better yield in the presence of 
microwave irradiation [51].
 
At the bottom of Scheme 4.22 another Suzuki coupling is 
speeded-up by a factor of 100 [52]. 
 
N Br
Pd(OAC)2, (C6H5)4BNa
Na2CO3 N Ph
Microwave:160 W, 105 ºC, 12 min, H2O, 73%
Convential: 42%
N
N
H
HN
O
+
B
HO OH
Me
Cu(OAc)2, pyr-NMP
TFA
N
N
H2N
O
MeMicrowave: 30 sec., 60%
Convential: 48h
Scheme 4.22
 
 
4.3.6 Hetero-Diels-Alder reactions 
4.3.6.1 Intramolecular reactions 
 
N
N
R
Cl
O
O
(CH2)n N
N
O
R Cl
O
(CH2)n
+H2O
N
NH
O
R O
O
(CH2)n
Microwave: 300 W, 190 ºC, 8-15 min., DCE, bmimPF6 Microwave: 300 W, 130 ºC, 5 min., 57-77%Convential: PhCl reflux, 2-3 days
R = Bn, Ph; n = 2,3
Scheme 4.23
 
We have already seen one example of a hetero-Diels-Alder reaction involving acyclic 
components. Hetero-Diels-Alder reactions involving cyclic components which lead to 
polycyclic ring systems are of great importance. An intramolecular example shown in 
Scheme 4.23 indicates that the reaction was accelerated by a factor of around 1000 by 
microwave irradiation [53]. 
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4.3.6.2 Intermolecular reactions 
Scheme 4.24 shows two impressive examples of rate enhancement for intermolecular 
hetero-Diels-Alder reactions [53]. In the first example on the top of Scheme 4.24 the  
initial reaction is followed by elimination thus involving the conversion of a pyrazine 
derivative into a pyridine. Perhaps more impressive is the lower example in Scheme 
4.24 where an autoclave is required under conventional conditions but which can be 
dispensed with when microwave acceleration is utilized. 
 
CO2MeMeO2C
N
N
O
Ph Cl
MeO2C
MeO2C
CN -ClCN
N
CO2Me
O
NC CO2Me
Ph
N
CO2Me
CO2Me
Cl CN
-PhNCO
N
N
Ph
Cl
O
CN
Microwave: 300 W, 190 ºC, 5 min., DCE, bmimPF6
Convential: 30 min.
N
N
Ph
Cl
O
R
ethene
N
N
O
Ph Cl
R
Microwave: 300 W, 190 ºC, 40-190 min., DCB, 86-89%
Convential: Autoclave, 25 atm., 110 ºC, 12h
Scheme 4.24  
 
4.3.7 1,3-Dipolar cycloaddition reactions 
4.2.7.1 Synthesis of C-carbamoyl-1,2,3-triazoles 
We now turn to some of our own recent work which has involved microwave induced 
1,3-dipolar cycloaddition of organic azides to acetylenic amides. As shown in Scheme 
4.25, we were able to achieve these reactions under microwave conditions in a 
reasonable time at temperatures of around 70±15 ºC [54]. Under conventional 
conditions the times were roughly 100 times as long and the temperature had to be 
taken up to 120 ºC [55]. 
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N3 4 or 5
NN
N
R1
R2
R
N34 or 5
1 2
7-12
O N3
4 or 5
O
NH
Ph4
O
N
5 3
Microwave: 120-170 W, 55-85 ºC, 30 min., solvent-free, 62-80%
Convential: 24h to 1 week, 120 ºC
Ph
Ph
Ph(CH2)2
7
8
9
Ph(CH2)210
11
12
C(CH3)(CH2OCH2)
C(CH3)(CH2OCH2)
R R1
H
H
H
H
H
H
R2
CONHCH2Ph
COpiperidinyl
COpiperidinyl
CONHCH2Ph
CONHCH2Ph
COpiperidinyl
Scheme 4.25
 
 
4.3.8 Oxidation 
The osmium-catalyzed dihydroxylation reaction, the addition of osmium tetroxide to 
olefins to produce a vicinal diol, is one of the most selective and reliable organic 
transformations. Recent work by Sharpless, Fokin, and coworkers [56] has uncovered 
that electron-deficient olefins can be converted into the corresponding diols much 
more efficiently when the reaction medium is kept acidic (Scheme 4.26). 
 
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
K2OsO2(OH)4, NMO
citric acid/BuOH/H2O
Microwave: 120 ºC, 150 min., 81%
Scheme 4.26
OH
OH
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4.4 Reported synthetic strategies 
4.4.1 Amino-1,2,4-triazole and 1,3-bifunctional synthons 
4.4.1.1 Principle and Conditions 
By far the most triazolo[1,5-a]pyrimidine synthesis are condensations of 
dinucleophilic 5-amino-1,2,4-triazoles with 1,3-bifunctional synthons as shown in the 
formation of triazolo[1,5-a]pyrimidine (15) (Scheme 4.27) [57-60]. New synthetic 
conditions recently described involve melting under microwave irradiation, a reaction 
that is environmental friendly and gives higher yields than conventional heating in 
solvent [61]. Furthermore, certain lithium 1,3-diketonates have proven to be better 
synthons than the corresponding diketones [62].  
 
COOEt
OH3C
+
NHN
NH2N NH
N
N
N
O
H3C
(15)
Scheme 4.27
 
 
 Previous mechanistic conclusions have been confirmed by isolating stable 
intermediate 5-amino-1,2,4-triazole derivatives such as enamine (16) (Scheme 4.28) 
on reacting 5-amino-1,2,4-triazoles with 3-ketovinyl ethers [63], 3-ketoenamines [64], 
3-ketoaldehydes [65], enamine-2-carboxylic esters [66] or ethoxymethylene 
malonates [67].  
 
OEt
+
NHN
NH2N NH
HN
CO
N
N
Ar
(16)
Scheme 4.28
Ar
O
EtOOC
EtOH
EtOOC
CH3CN /KF
N
N
N
N
Ar
EtOOC
 
That means, the overall reaction starts with the interaction of the amino-1,2,4-
triazole amino group and the enolic (or analogous) functionality of the three-carbon 
synthon. In the two-step examples, just mentioned, the first step proceeds under 
milder conditions (sometimes just in ethanol at room temperature), but the final 
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cyclization (or the one-step reaction, if the intermediate is not trapped) requires 
stronger means (e.g., polyphosphoric acid or boiling acetic acid). Under extreme 
conditions, triazolylamide (17) was subject to flash vacuum pyrolysis between 300 
and 450 ºC to give about 50% triazolo[1,5-a]pyrimidine (18) (Scheme 4.29) [68]. 
Libraries of fused 3-aminopyrimidin-4-ones (19) and other compounds were just 
recently prepared by the solid-phase and by the solution-phase parallel synthesis [69]. 
The latter method turned out to be advantageous with respect to yield and purity. 
 
COOEt
COOEt
+
NHN
NH2N N
H
HN
COOEt
N
N
O N
H
N
N
N
O
O
(17) (18)
COOEt
NMe2
AcHN NHN
NH2N
+ 1. AcOH
2. HCl
N
N
N
H
N
O
H2N
HCl
(19)
Scheme 4.29
 
 
4.4.1.2 Use of Modified 5-amino-1,2,4-triazoles 
Scheme 4.30 shows two parallel paths of pyrimidine ring annulation: the conventional 
method, route A and a route B using a reactive amino-1,2,4-triazole derivative [70]. 
Amidine (22), formed from 5-amino-1,2,4-triazole and DMF dimethylacetal, can be 
regarded as the result of incorporating one carbon of the three-carbon synthon (20) 
into the 5-amino-1,2,4-triazole molecule; condensation with a reactive two-carbon 
component leads to target triazolo[1,5-a]pyrimidine (21).  
 
NC
NMe2
O
Ph
+
NHN
NH2N
A
BNC
O
Ph
+ NHN
NN
NMe2 N
N
N
NNC
Ph
(20)
(21)
(22) Scheme 4.30  
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Path B also serves in confirming the structure of product (21). Similar 
syntheses of 7-aryl and 7-heterocyclyl-triazolo[1,5-a]pyrimidines have been described 
[71-73], for example, that of an antipyrine derivative [74]. 
 
4.4.1.3 The diversity of 1,3-bifunctional synthons  
Examples of triazolo[1,5-a]pyrimidine synthesis published in the relevant period are 
listed in Table 1, arranged according to the bifunctional synthons used and to the 
substituents entering the positions 5 and 7. Triazolo[1,5-a]pyrimidines are included in 
reviews dealing with heterocyclic synthesis by the use of enamines [75], enamine-2-
carboxylic esters [76] and ketene mercaptals [77]. 
 
N
N N
N
1
2
34
5
6
7 8
 
 
Table 1. Syntheses of triazolo[1,5-a]pyrimidines from 1,3-bifunctional synthons and 5-amino-1,2,4-
triazoles 
Bifunctional  
Synthons 
R-5b R-7b Bifunctional  
Synthons 
R-5b R-7b 
1,3-Dialdehyde [78] H H Enamine-2-carboxylate [95] H OH 
2-Formylacetal [79] H H Acetylenedicarboxylate [96] CO2Me OH 
1,3-Diacetal [80] H H 3-Ketocarboxylate [97] R OH 
2-Formylvinyl ether [81] H H 3-Alkoxyacrylate [98] OH R 
2-Formylvinylchloride [82] H R Alkoxyalkylene malonate [99] R OH 
3-Iminiovinylchloride [83] H R 2-Chloroacrylate [100] OH R
2-Formylenamine [84] H R Malonic ester [101] OH OH 
3-Iminioenamine [85] H R Malonyl chloride [102] OH OH 
3-Ketoaldehyde [86] R H 2-Acylketene mercaptal [103] SR R’
3-Ketoacetal [87] R H 2-Cyanoketene mercaptal [104] SR NH2 
3-Ketovinyl ether [88] H R Alkoxyalkylene cyanoacetate [105] R NH2 
3-Ketovinyl sulfone [89]c  R H Alkoxyalkylene malonitrile [106] R NH2
3-Ketoenamine [90] H R 2-Formylnitrile [107] H NH2 
1,3-Diketone [91] R R’ 2-Cyanoenamine [108] H NH2 
3-Ketoalkyne [92] Rd H Malonitrile [109] NH2 NH2
2-Formylcarboxylate [93] R OH 2-Thiocarbamylcarboxylate [110] NHR OH 
2-Alkoxycarbonylacetal [94] OH H    
aor tautomeric form. 
bSubstituents on C-5 and C-7, respectively; R and R’ mean (possibly substituted) alkyl, aryl, 
heterocyclyl and H; OH means hydroxy or tautomeric oxo form. 
cAnd regioisomeric 7-R compound. 
dDeoxyaltrose derivative relating C-glycosides [111]. 
 
 In recent years, 3-ketoenamines have growing interest as building blocks for 
7-aryl-triazolo[1,5-a]pyrimidines (Scheme 4.30, Path A) [112, 113]. They also serve 
to synthesize 7-heterocyclyl-triazolo[1,5-a]pyrimidines [114, 115]. In addition to 
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usual N,N-dimethyl compounds also analogues having a free amino group can be used 
as in the synthesis of 7-trifluoromethyl derivatives [116]. Enaminones can be formed 
in situ, for instance, from dimedone and DMF dimethylacetal [117]. 
 In the course of the cyclization of the stable tetrafluorobenzoyl derivative (23) 
(Scheme 4.31) fluorine at the o-position is involved in the reaction and is replaced to 
give trifluorobenzo-triazolo[1,5-a]pyrimidine (24) [118]. Acetonyl is introduced as 
substituent into the 7-position by the use of triketone-heptan-2,4,6-trione [119]. 
  
F
F
F
F
COCl
+
NHN
NH2N
F
F
F
F
CO
NHN
NNH
DBU
F
F
F
N
H
N
N
N
O
(23) (24)
CNNC
NC CN
+
NHN
NH2N
N
N
N
N
CN
NC
H2N
(25)
COOEtAc
PhHN S
+
NHN
NH2N
N
H
N
N
N
O
(27)
PhHN
Scheme 4.31
(26)
 
 
The electron acceptor tetracyanoethylene on interaction with amino-1,2,4-
triazole first forms a charge transfer complex that after loss of hydrocyanic acid is 
transformed into dicyano-triazolo[1,5-a]pyrimidine (25) [120]. Fusion of 1,4-
naphthoquinone or indenone onto triazolo[1,5-a]pyrimidine can in a similar way be 
performed by the use of 2,3-dicyano-1,4-naphthoquinone or dicyanomethylene 
indane-1,3-dione, respectively. Another indeno-triazolo[1,5-a]pyrimidine is 
accessible from triketone-2-acetylindane-1,3-dione [121]. On the other hand, 
acetoacetic ester (26) with 5-amino-1,2,4-triazole suffers ester group cleavage to form 
anilino-triazolo[1,5-a]pyrimidine (27) [122]. 
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4.4.2 Other pyrimidine ring synthesis 
The annulation of pyrimidine onto the triazole ring can be accomplished by the use of 
heterocyclic precursors that can be regarded as masked 1,3-bifunctional reagents. This 
way, triacetic acid lactone (27) (Scheme 4.32) reacts as a masked 1,3-diketone and 
transforms 5-amino-1,2,4-triazole to triazolo[1,5-a]pyrimidine (28) together with ring 
isomer (29) and decarboxylation product (30) [123]. Oxazolones play a similar part 
[124-126]. Thus, enol ether (31) behaves as a masked 3-ethoxyacrylate and yields, 
through intermediate (32), benzamido-triazolo1,5-a]pyrimidine (33) that, under 
harsher conditions, directly forms from compound (31). 
 
Scheme 4.32
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N
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4.4.3 2-Hydrazinopyrimidines and one-carbon synthons 
A second common triazolo[1,5-a]pyrimidine synthesis consists in the condensation of 
a C1-synthon with a 2-hydrazinopyrimidine derivative (e.g., 34, Scheme 4.33). A 
triazolo[4,3-a]-pyrimidine (35) initially forms that often can be isolated [127]. 
Harsher conditions allow it to isomerize to the target triazolo[1,5-a]pyrimidine (36) 
by Dimroth rearrangement.  
 
 
Chapter 4                                                                       1,2,4-triazolo[1,5-a]pyrimidines 
     
   170
 
N
NH
NC
Ph
O
NH
NH2
HCOOH
N
H
N
NC
Ph
O
N
N
KOH (2%)
N
H
N
NC
Ph
O
N
N
(34) (35) (36)
Scheme 4.33
 
 
4.4.4 Other triazole ring synthesis 
Most cyclization of 2,3-diaminopyrimidones (37) [128] or corresponding 
quinazolones proceed with the participation of carboxylic acids or their derivatives 
(esters, anhydrides, chlorides, or orthoesters) as shown in Scheme 4.34. Noncyclized 
or saturated intermediates (38, 39) can frequently be found during synthesis of 
triazolo[1,5-a]pyrimidines. 
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Chapter 4                                                                       1,2,4-triazolo[1,5-a]pyrimidines 
     
   171
4.5 Current work 
The biological importance of 1,2,4-triazolo[1,5-a]pyrimidines is well documented. 
Over the years, various substituted derivatives of these heterocycles have shown 
utility against a range of biological targets. For example, they have demonstrated 
activity against malaria and bronchospasm and shown activity as coronary 
vasodilators, antihypertensive agents, leishmanicides, antibiotics, adenosine A2a 
antagonists, immunosuppressants, antitumor agents, fungicides, xanthine oxidase 
inhibitors and phosphodiesterase inhibitors.  
 Recognizing these facts, we have synthesized four new series of 1,2,4- 
triazolo[1,5-a]pyrimidines (BHD-301 to 340). It was achieved by one-pot, microwave 
-assisted condensation reaction of aromatic aldehyde, corresponding acetophenone 
and 5-amino-1,2,4-triazole using glacial acetic acid as a solvent. The structures of all 
the newly synthesized compounds were elucidated by FT-IR, mass spectra, 1H NMR 
and elemental analysis. The newly synthesized compounds were subjected to various 
biological activities viz., antimicrobial, antimycobacterial, anticancer and antiviral. 
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  4.6 Reaction Scheme 
+
a
Reagents and conditions: (a) gl. AcOH, MW, 120 ºC, 10-12 min
HO
R2
HN N
NH2N
R1
C
O CH3
N
H
N
N
N
BHD 301 to 340
R1
R2
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
BHD-301 4-F H C17H13FN4 292 175-177 70 0.45 0.67
BHD-302 4-F 4-F C17H12F2N4 310 158-160 76 0.41 0.61 
BHD-303 4-F 4-Cl C17H12ClFN4 326 231-233 62 0.50 0.60 
BHD-304 4-F 4-NO2 C17H12FN5O2 337 165-167 78 0.54 0.69 
BHD-305 4-F 4-CH3 C18H15FN4 306 185-187 65 0.51 0.74 
BHD-306 4-F 4-OCH3 C18H15FN4O 322 217-219 72 0.57 0.78 
BHD-307 4-F 3,4-OCH3 C19H17FN4O2 352 204-206 60 0.53 0.70 
BHD-308 4-F 3-NO2 C17H12FN5O2 337 191-193 62 0.42 0.63 
BHD-309 4-F 3-Cl C17H12ClFN4 326 224-226 71 0.46 0.67 
BHD-310 4-F 2-Cl C17H12ClFN4 326 199-201 79 0.40 0.60 
BHD-311 4-CH3 H C18H16N4 288 214-216 68 0.48 0.66 
BHD-312 4-CH3 4-F C18H15FN4 306 201-203 80 0.53 0.71 
BHD-313 4-CH3 4-Cl C18H15ClN4 322 179-181 73 0.43 0.69 
BHD-314 4-CH3 4-NO2 C18H15N5O2 333 197-199 70 0.49 0.73 
BHD-315 4-CH3 4-CH3 C19H18N4 302 185-187 75 0.54 0.72 
BHD-316 4-CH3 4-OCH3 C19H18N4O 318 224-226 60 0.60 0.64 
BHD-317 4-CH3 3,4-OCH3 C20H20N4O2 348 161-163 72 0.63 0.75 
BHD-318 4-CH3 3-NO2 C18H15N5O2 333 148-150 64 0.50 0.70
BHD-319 4-CH3 3-Cl C18H15ClN4 322 166-168 72 0.52 0.62 
BHD-320 4-CH3 2-Cl C18H15ClN4 322 210-212 76 0.48 0.61 
BHD-321 4-CF3 H C18H13F3N4 342 169-171 80 0.51 0.56
BHD-322 4-CF3 4-F C18H12F4N4 360 217-219 71 0.54 0.62 
BHD-323 4-CF3 4-Cl C18H12ClF3N4 376 231-233 82 0.45 0.70 
BHD-324 4-CF3 4-NO2 C18H12F3N5O2 387 188-190 78 0.50 0.72 
BHD-325 4-CF3 4-CH3 C19H15F3N4 356 152-154 85 0.58 0.68 
BHD-326 4-CF3 4-OCH3 C19H15F3N4O 372 172-174 80 0.61 0.75 
BHD-327 4-CF3 3,4-OCH3 C20H17F3N4O2 402 227-229 68 0.60 0.71 
BHD-328 4-CF3 3-NO2 C18H12F3N5O2 387 137-139 72 0.49 0.62 
BHD-329 4-CF3 3-Cl C18H12ClF3N4 376 212-214 74 0.47 0.68 
BHD-330 4-CF3 2-Cl C18H12ClF3N4 376 191-193 69 0.50 0.60 
BHD-331 3-CF3 H C18H13F3N4 342 156-158 80 0.49 0.59 
BHD-332 3-CF3 4-F C18H12F4N4 360 222-224 77 0.43 0.63 
BHD-333 3-CF3 4-Cl C18H12ClF3N4 376 244-246 82 0.50 0.60 
BHD-334 3-CF3 4-NO2 C18H12F3N5O2 387 198-200 69 0.56 0.67 
BHD-335 3-CF3 4-CH3 C19H15F3N4 356 205-207 65 0.61 0.74 
BHD-336 3-CF3 4-OCH3 C19H15F3N4O 372 143-145 75 0.56 0.75 
BHD-337 3-CF3 3,4-OCH3 C20H17F3N4O2 402 175-177 68 0.59 0.65 
BHD-338 3-CF3 3-NO2 C18H12F3N5O2 387 164-166 77 0.41 0.62 
BHD-339 3-CF3 3-Cl C18H12ClF3N4 376 217-219 65 0.45 0.68 
BHD-340 3-CF3 2-Cl C18H12ClF3N4 376 187-189 70 0.57 0.64 
TLC Solvent system Rf1: Hexane: Ethyl acetate - 6:4; TLC Solvent system Rf2: Chloroform: Methanol - 9:1 
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4.6.1 Plausible Reaction Mechanism 
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4.7 Experimental 
 
4.7.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer. Elemental analysis of the all the synthesized compounds was carried out 
on Elemental Vario EL III Carlo Erba 1108 model and the results are in agreement 
with the structures assigned. 
 
4.7.2 General procedure for the synthesis of 5-(4-fluorophenyl)-4,7-dihydro-7-
(aryl)-[1,2,4]triazolo[1,5-a]pyrimidines (BHD 301-310) 
 
A mixture of the 5-amino-1,2,4-triazole (0.01 mol), 4-fluoroacetophenone (0.01 mol) 
and an appropriate aromatic aldehyde (0.01 mol) in glacial acetic acid (10 mL) was 
irradiated under microwave conditions at 120 °C for 10-12 min. The microwave 
irradiation was operated in 30-second cycles. After cooling, methanol (10 mL) was 
added. The reaction mixture was allowed to stand overnight and then filtered to give 
the solid triazolopyrimidine products BHD 301-310, which were recrystallized from 
ethanol. 
 
4.7.2.1 5-(4-fluorophenyl)-4,7-dihydro-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-301) Yield: 70%; mp 175-177 ºC; MS: m/z 292; 
Anal. Calcd. for C17H13FN4: C, 69.85; H, 4.48; N, 
19.17. Found: C, 69.75; H, 4.43; N, 19.11%. 
 
 
 
 
N
H
N
N
N
F  
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4.7.2.2 5,7-bis(4-fluorophenyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine (BHD-
302) Yield: 76%; mp 158-160 ºC; MS: m/z 310; Anal. 
Calcd. for C17H12F2N4: C, 65.80; H, 3.90; N, 18.06. 
Found: C, 65.68; H, 3.82; N, 17.97%. 
 
 
 
 
 
4.7.2.3 5-(4-fluorophenyl)-4,7-dihydro-7-(4-chlorophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-303) Yield: 62%; mp 231-233 ºC; 
MS: m/z 326; Anal. Calcd. for C17H12ClFN4: C, 62.49; 
H, 3.70; N, 17.15. Found: C, 62.37; H, 3.64; N, 
17.05%. 
 
 
 
 
4.7.2.4 5-(4-fluorophenyl)-4,7-dihydro-7-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-304) Yield: 78%; mp 165-167 ºC; 
IR (cm-1): 3281 (N-H stretching of secondary amine), 
3109 (C-H stretching of aromatic ring), 1626 (C=N 
stretching of triazole ring), 1552 and 1498 (C=C 
stretching of aromatic ring), 1377 (NO2 stretching), 
1294 (C-N stretching), 1269 (C-H in plane 
deformation of aromatic ring), 1197 (C-F stretching), 
804 (C-H out of plane deformation of 1,4-disubstitution); 1H NMR (DMSO-d6) δ ppm: 
5.08-5.09 (d, 1H, Ha, J = 2.3 Hz), 6.37-6.38 (d, 1H, Hb, J = 3.6 Hz), 7.13-7.18 (t, 2H, 
Hcc’, J = 8.6 Hz), 7.53-7.55 (d, 2H, Hdd’, J = 8.6 Hz), 7.60-7.65 (m, 3H, Hee’-f), 8.21-
8.23 (d, 2H, Hgg’, J = 8.6 Hz), 10.15 (s, 1H, Hh); MS: m/z 337; Anal. Calcd. for 
C17H12FN5O2: C, 60.53; H, 3.59; N, 20.76. Found: C, 60.40; H, 3.53; N, 20.68%. 
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4.7.2.5 5-(4-fluorophenyl)-4,7-dihydro-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-305) Yield: 65%; mp 185-187 ºC; IR (cm-1): 
3282 (N-H stretching of secondary amine), 3107 (C-H 
stretching of aromatic ring), 2956 (C-H symmetrical 
stretching of CH3 group), 2839 (C-H asymmetrical 
stretching of CH3 group), 1626 (C=N stretching of 
triazole ring), 1552 and 1498 (C=C stretching of 
aromatic ring), 1292 (C-N stretching), 1269 (C-H in 
plane deformation of aromatic ring), 1197 (C-F stretching), 804 (C-H out of plane 
deformation of 1,4-disubstitution); 1H NMR (DMSO-d6) δ ppm: 2.35 (s, 3H, Ha), 
5.03-5.04 (d, 1H, Hb, J = 3.6 Hz), 6.10-6.11 (d, 1H, Hc, J = 3.6 Hz), 7.13-7.21 (m, 6H, 
Hd-f’), 7.47-7.49 (d, 2H, Hgg’, J = 8.2 Hz), 7.54 (s, 1H, Hh), 9.90 (s, 1H, Hi); MS: m/z 
306; Anal. Calcd. for C18H15FN4: C, 70.57; H, 4.94; N, 18.29. Found: C, 70.41; H, 
4.90; N, 18.21%. 
 
4.7.2.6 5-(4-fluorophenyl)-4,7-dihydro-7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-306) Yield: 72%; mp 217-219 ºC; 
IR (cm-1): 3281 (N-H stretching of secondary amine), 
3111 (C-H stretching of aromatic ring), 1624 (C=N 
stretching of triazole ring), 1552 and 1498 (C=C 
stretching of aromatic ring), 1427 (C-H asymmetrical 
deformation of CH3 group), 1294 (C-N stretching), 
1269 (C-H in plane deformation of aromatic ring), 
1197 (C-F stretching), 1058 (C-O-C symmetrical stretching of ether linkage), 804 (C-
H out of plane deformation of 1,4-disubstitution); 1H NMR (DMSO-d6) δ ppm: 3.76 
(s, 3H, Ha), 5.02 (d, 1H, Hb, J = 2.4 Hz), 6.10 (d, 1H, Hc, J = 3.4 Hz), 6.86-6.88 (d, 
2H, Hdd’, J = 8.5 Hz), 7.10-7.14 (t, 2H, Hee’, J = 8.6 Hz), 7.25-7.27 (d, 2H, Hff’, J = 8.5 
Hz), 7.50 (s, 1H, Hg), 7.61-7.64 (t, 2H, Hhh’), 10.04 (s, 1H, Hi); MS: m/z 322; Anal. 
Calcd. for C18H15FN4O: C, 67.07; H, 4.69; N, 17.38. Found: C, 66.90; H, 4.63; N, 
17.30%. 
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4.7.2.7 5-(4-fluorophenyl)-4,7-dihydro-7-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-307) Yield: 60%; mp 204-206 ºC; 
MS: m/z 352; Anal. Calcd. for C19H17FN4O2: C, 64.76; 
H, 4.86; N, 15.90. Found: C, 64.61; H, 4.81; N, 
15.79%. 
 
 
 
 
4.7.2.8 5-(4-fluorophenyl)-4,7-dihydro-7-(3-nitrophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-308) Yield: 62%; mp 191-193 ºC; 
MS: m/z 337; Anal. Calcd. for C17H12FN5O2: C, 60.53; 
H, 3.59; N, 20.76. Found: C, 60.38; H, 3.51; N, 
20.65%. 
 
 
 
4.7.2.9 5-(4-fluorophenyl)-4,7-dihydro-7-(3-chlorophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-309) Yield: 71%; mp 224-226 ºC; 
MS: m/z 326; Anal. Calcd. for C17H12ClFN4: C, 62.49; 
H, 3.70; N, 17.15. Found: C, 62.34; H, 3.65; N, 
17.08%. 
 
 
 
 
4.7.2.10 5-(4-fluorophenyl)-4,7-dihydro-7-(2-chlorophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-310) Yield: 79%; mp 199-201 ºC; 
MS: m/z 326; Anal. Calcd. for C17H12ClFN4: C, 62.49; 
H, 3.70; N, 17.15. Found: C, 62.36; H, 3.66; N, 
17.10%. 
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4.7.3 General procedure for the synthesis of 4,7-dihydro-7-(aryl)-5-p-tolyl-
[1,2,4]triazolo[1,5-a]pyrimidines (BHD 311-320) 
 
A mixture of the 5-amino-1,2,4-triazole (0.01 mol), 4-methylacetophenone (0.01 mol) 
and an appropriate aromatic aldehyde (0.01 mol) in glacial acetic acid (10 mL) was 
irradiated under microwave conditions at 120 °C for 10-12 min. The microwave 
irradiation was operated in 30-second cycles. After cooling, methanol (10 mL) was 
added. The reaction mixture was allowed to stand overnight and then filtered to give 
the solid triazolopyrimidine products BHD 311-320, which were recrystallized from 
ethanol. 
 
4.7.3.1 4,7-dihydro-7-phenyl-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine (BHD-311) 
Yield: 68%; mp 214-216 ºC; MS: m/z 288; Anal. 
Calcd. for C18H16N4: C, 74.98; H, 5.59; N, 19.43. 
Found: C, 74.83; H, 5.52; N, 19.31%. 
 
 
 
 
4.7.3.2 4,7-dihydro-7-(4-fluorophenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-312) Yield: 80%; mp 201-203 ºC; IR (cm-1): 
3194 (N-H stretching of secondary amine), 3090 (C-H 
stretching of aromatic ring), 2972 (C-H symmetrical 
stretching of CH3 group), 2860 (C-H asymmetrical 
stretching of CH3 group), 1658 (N-H deformation of 
pyrimidine ring), 1597 (C=N stretching of triazole 
ring), 1550 and 1475 (C=C stretching of aromatic 
ring), 1330 (C-N stretching), 1070 (C-F stretching), 941 (C-H in plane deformation of 
aromatic ring), 825 (C-H out of plane deformation of 1,4-disubstitution); 1H NMR 
(DMSO-d6) δ ppm: 2.35 (s, 3H, Ha), 5.04-5.05 (d, 1H, Hb, J = 3.6 Hz), 6.18 (d, 1H, Hc, 
J = 3.6 Hz), 7.07-7.11 (t, 2H, Hdd’, J = 8.7 Hz), 7.19-7.21 (d, 2H, Hee’, J = 8.0 Hz), 
7.32-7.36 (t, 2H, Hff’), 7.48-7.50 (d, 2H, Hgg’, J = 8.2 Hz), 7.55 (s, 1H, Hh), 9.96 (s, 
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1H, Hi); MS: m/z 306; Anal. Calcd. for C18H15FN4: C, 70.57; H, 4.94; N, 18.29. 
Found: C, 70.64; H, 4.90; N, 18.20%. 
 
4.7.3.3 4,7-dihydro-7-(4-chlorophenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-313) Yield: 73%; mp 179-181 ºC; MS: m/z 322; 
Anal. Calcd. for C18H15ClN4: C, 66.98; H, 4.68; N, 
17.36. Found: C, 66.87; H, 4.65; N, 17.29%. 
 
 
 
 
4.7.3.4 4,7-dihydro-7-(4-nitrophenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-314) Yield: 70%; mp 197-199 ºC; IR (cm-1): 
3192 (N-H stretching of secondary amine), 3093 (C-H 
stretching of aromatic ring), 2976 (C-H symmetrical 
stretching of CH3 group), 2862 (C-H asymmetrical 
stretching of CH3 group), 1658 (N-H deformation of 
pyrimidine ring), 1593 (C=N stretching of triazole 
ring), 1548 (NO2 stretching), 1523 and 1473 (C=C 
stretching of aromatic ring), 1352 (C-N stretching), 943 (C-H in plane deformation of 
aromatic ring), 823 (C-H out of plane deformation of 1,4-disubstitution); 1H NMR 
(DMSO-d6) δ ppm: 2.37 (s, 3H, Ha), 5.02-5.03 (d, 1H, Hb, J = 3.0 Hz), 6.33-6.34 (d, 
1H, Hc, J = 3.2 Hz), 7.20-7.22 (d, 2H, Hdd’, J = 7.8 Hz), 7.47-7.49 (d, 2H, Hee’, J = 7.6 
Hz), 7.52-7.55 (d, 2H, Hff’, J = 8.1 Hz), 7.58 (s, 1H, Hg), 8.20-8.22 (d, 2H, Hhh’, J = 
8.0 Hz), 9.96 (s, 1H, Hi); MS: m/z 333; Anal. Calcd. for C18H15N5O2: C, 64.86; H, 
4.54; N, 21.01. Found: C, 64.69; H, 4.49; N, 20.91%. 
 
4.7.3.5 4,7-dihydro-5,7-di-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine (BHD-315) 
Yield: 75%; mp 185-187 ºC; MS: m/z 302; Anal. 
Calcd. for C19H18N4: C, 75.47; H, 6.00; N, 18.53. 
Found: C, 75.31; H, 5.95; N, 18.43%. 
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4.7.3.6 4,7-dihydro-7-(4-methoxyphenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-316) Yield: 60%; mp 224-226 ºC; IR (cm-1): 
3196 (N-H stretching of secondary amine), 3086 (C-H 
stretching of aromatic ring), 3020 (C-H symmetrical 
stretching of CH3 group), 2858 (C-H asymmetrical 
stretching of CH3 group), 1662 (N-H deformation of 
pyrimidine ring), 1595 (C=N stretching of triazole 
ring), 1550 and 1467 (C=C stretching of aromatic 
ring), 1429 (C-H asymmetrical deformation of CH3 group), 1330 (C-N stretching), 
1176 (C-O-C asymmetrical stretching of ether linkage), 941 (C-H in plane 
deformation of aromatic ring), 829 (C-H out of plane deformation of 1,4-
disubstitution); 1H NMR (DMSO-d6) δ ppm: 2.36 (s, 3H, Ha), 3.76 (s, 3H, Hb), 5.04-
5.05 (d, 1H, Hc, J = 3.4 Hz), 6.10-6.11 (d, 1H, Hd, J = 3.5 Hz), 6.86-6.88 (d, 2H, Hee’, 
J = 8.6 Hz), 7.19-7.21 (d, 2H, Hff’, J = 8.1 Hz), 7.24-7.26 (d, 2H, Hgg’, J = 8.6 Hz), 
7.48-7.50 (d, 2H, Hhh’, J = 8.1 Hz), 7.56 (s, 1H, Hi), 9.92 (s, 1H, Hj); MS: m/z 318; 
Anal. Calcd. for C19H18N4O: C, 71.68; H, 5.70; N, 17.60. Found: C, 71.68; H, 5.70; N, 
17.60%. 
 
4.7.3.7 4,7-dihydro-7-(3,4-dimethoxyphenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-317) Yield: 72%; mp 161-163 ºC; MS: m/z 348; 
Anal. Calcd. for C20H20N4O2: C, 68.95; H, 5.79; N, 
16.08. Found: C, 68.81; H, 5.76; N, 16.00%. 
 
 
 
 
 
4.7.3.8 4,7-dihydro-7-(3-nitrophenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-318) Yield: 64%; mp 148-150 ºC; MS: m/z 333; 
Anal. Calcd. for C18H15N5O2: C, 64.86; H, 4.54; N, 
21.01. Found: C, 64.71; H, 4.49; N, 20.91%. 
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4.7.3.9 4,7-dihydro-7-(3-chlorophenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-319) Yield: 72%; mp 166-168 ºC; MS: m/z 322; 
Anal. Calcd. for C18H15ClN4: C, 66.98; H, 4.68; N, 
17.36. Found: C, 66.84; H, 4.63; N, 17.25%. 
 
 
 
 
4.7.3.10 4,7-dihydro-7-(2-chlorophenyl)-5-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine 
(BHD-320) Yield: 76%; mp 210-212 ºC; MS: m/z 322; 
Anal. Calcd. for C18H15ClN4: C, 66.98; H, 4.68; N, 
17.36. Found: C, 66.86; H, 4.67; N, 17.27%. 
 
 
 
 
4.7.4 General procedure for the synthesis of 5-(4-(trifluoromethyl)phenyl)-4,7-
dihydro-7-(aryl)-[1,2,4]triazolo[1,5-a]pyrimidines (BHD 321-330) 
 
A mixture of the aminoazole (0.01 mol), 4-trifluoromethylacetophenone (0.01 mol) 
and an appropriate aromatic aldehyde (0.01 mol) in glacial acetic acid (10 mL) was 
irradiated under microwave conditions at 120 °C for 10-12 min. The microwave 
irradiation was operated in 30-second cycles. After cooling, methanol (10 mL) was 
added. The reaction mixture was allowed to stand overnight and then filtered to give 
the solid triazolopyrimidine products BHD 321-330, which were recrystallized from 
ethanol. 
 
4.7.4.1 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-phenyl-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-321) Yield: 80%; mp 169-171 ºC; 
MS: m/z 342; Anal. Calcd. for C18H13F3N4: C, 63.16; 
H, 3.83; N, 16.37. Found: C, 63.02; H, 3.77; N, 
16.29%. 
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4.7.4.2 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-fluorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-322) Yield: 71%; mp 217-
219 ºC; MS: m/z 360; Anal. Calcd. for C18H12F4N4: C, 
60.00; H, 3.36; N, 15.55. Found: C, 59.87; H, 3.29; N, 
15.47%. 
 
 
 
 
4.7.4.3 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-chlorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-323) Yield: 82%; mp 231-
233 ºC; IR (cm-1): 3196 (N-H stretching of secondary 
amine), 3088 (C-H stretching of aromatic ring), 1656 
(N-H deformation of pyrimidine ring), 1597 (C=N 
stretching of triazole ring), 1548 and 1491 (C=C 
stretching of aromatic ring), 1330 (C-N stretching), 
1132 (C-F stretching), 941 (C-H in plane deformation 
of aromatic ring), 804 (C-H out of plane deformation of 1,4-disubstitution), 723 (C-Cl 
stretching); 1H NMR (DMSO-d6) δ ppm: 5.24-5.25 (d, 1H, Ha, J = 3.6 Hz), 6.23-6.24 
(d, 1H, Hb, J = 3.6 Hz), 7.30-7.33 (d, 2H, Hcc’, J = 8.6 Hz), 7.35-7.39 (d, 2H, Hdd’, J = 
8.4 Hz), 7.59 (s, 1H, He), 7.69-7.72 (d, 2H, Hff’, J = 8.3 Hz), 8.80-8.83 (d, 2H, Hgg’, J 
= 8.2 Hz), 10.23 (s, 1H, Hh); MS: m/z 376; Anal. Calcd. for C18H12ClF3N4: C, 57.38; 
H, 3.21; N, 14.87. Found: C, 57.21; H, 3.16; N, 14.80%. 
 
4.7.4.4 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-nitrophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-324) Yield: 78%; mp 188-
190 ºC; IR (cm-1): MS: m/z 387; Anal. Calcd. for 
C18H12F3N5O2: C, 55.82; H, 3.12; N, 18.08. Found: C, 
55.69; H, 3.05; N, 17.99%. 
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4.7.4.5 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-p-tolyl-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-325) Yield: 85%; mp 152-154 ºC; 
IR (cm-1): 3196 (N-H stretching of secondary amine), 
3093 (C-H stretching of aromatic ring), 3032 (C-H 
symmetrical stretching of CH3 group), 2904 (C-H 
asymmetrical stretching of CH3 group), 1656 (N-H 
deformation of pyrimidine ring), 1595 (C=N 
stretching of triazole ring), 1548 and 1514 (C=C 
stretching of aromatic ring), 1323 (C-N stretching), 1116 (C-F stretching), 941 (C-H 
in plane deformation of aromatic ring), 804 (C-H out of plane deformation of 1,4-
disubstitution); 1H NMR (DMSO-d6) δ ppm: 2.31 (s, 3H, Ha), 5.21-5.22 (d, 1H, Hb, J 
= 3.5 Hz), 6.15 (d, 1H, Hc, J = 3.6 Hz), 7.14-7.16 (d, 2H, Hdd’, J = 8.0 Hz), 7.19-7.21 
(d, 2H, Hee’, J = 8.1 Hz), 7.54 (s, 1H, Hf), 7.67-7.69 (d, 2H, Hgg’, J = 8.4 Hz), 7.79-
7.81 (d, 2H, Hhh’, J = 8.2 Hz), 10.12 (s, 1H, Hi); MS: m/z 356; Anal. Calcd. for 
C19H15F3N4: C, 64.04; H, 4.24; N, 15.72. Found: C, 63.91; H, 4.17; N, 15.63%. 
 
4.7.4.6 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-methoxyphenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-326) Yield: 80%; mp 172-
174 ºC; IR (cm-1): 3194 (N-H stretching of secondary 
amine), 3090 (C-H stretching of aromatic ring), 1656 
(N-H deformation of pyrimidine ring), 1595 (C=N 
stretching of triazole ring), 1550 and 1512 (C=C 
stretching of aromatic ring), 1329 (C-N stretching), 
1192 (C-O-C asymmetrical stretching of ether 
linkage), 1130 (C-F stretching), 939 (C-H in plane deformation of aromatic ring), 808 
(C-H out of plane deformation of 1,4-disubstitution); 1H NMR (DMSO-d6) δ ppm: 
3.77 (s, 3H, Ha), 5.21-5.22 (d, 1H, Hb, J = 2.8 Hz), 6.14-6.15 (d, 1H, Hc, J = 3.6 Hz), 
6.87-6.89 (d, 2H, Hdd’, J = 8.6 Hz), 7.25-7.27 (d, 2H, Hee’, J = 8.6 Hz), 7.56 (s, 1H, 
Hf), 7.68-7.70 (d, 2H, Hgg’, J = 8.3 Hz), 7.80-7.82 (d, 2H, Hhh’, J = 8.2 Hz), 10.11 (s, 
1H, Hi); MS: m/z 372; Anal. Calcd. for C19H15F3N4O: C, 61.29; H, 4.06; N, 15.05. 
Found: C, 61.19; H, 4.01; N, 14.98%. 
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4.7.4.7 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(3,4-dimethoxyphenyl)-[1,2,4] 
triazolo[1,5-a]pyrimidine (BHD-327) Yield: 68%; mp 
227-229 ºC; MS: m/z 402; Anal. Calcd. for 
C20H17F3N4O2: C, 59.70; H, 4.26; N, 13.92. Found: C, 
59.70; H, 4.26; N, 13.92%. 
 
 
 
 
4.7.4.8 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(3-nitrophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-328) Yield: 72%; mp 137-
139 ºC; MS: m/z 387; Anal. Calcd. for C18H12F3N5O2: 
C, 55.82; H, 3.12; N, 18.08. Found: C, 55.71; H, 3.07; 
N, 17.95%. 
 
 
 
4.7.4.9 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(3-chlorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-329) Yield: 74%; mp 212-
214 ºC; MS: m/z 376; Anal. Calcd. for C18H12ClF3N4: 
C, 57.38; H, 3.21; N, 14.87. Found: C, 57.25; H, 3.18; 
N, 14.78%. 
 
 
 
4.7.4.10 5-(4-(trifluoromethyl)phenyl)-4,7-dihydro-7-(2-chlorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-330) Yield: 69%; mp 191-
193 ºC; MS: m/z 376; Anal. Calcd. for C18H12ClF3N4: 
C, 57.38; H, 3.21; N, 14.87. Found: C, 57.22; H, 3.15; 
N, 14.79%. 
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4.7.5 General procedure for the synthesis of 5-(3-(trifluoromethyl)phenyl)-4,7-
dihydro-7-(aryl)-[1,2,4]triazolo[1,5-a]pyrimidines (BHD 331-340) 
 
A mixture of the aminoazole (0.01 mol), 3-trifluoromethylacetophenone (0.01 mol) 
and an appropriate aromatic aldehyde (0.01 mol) in glacial acetic acid (10 mL) was 
irradiated under microwave conditions at 120 °C for 10-12 min. The microwave 
irradiation was operated in 30-second cycles. After cooling, methanol (10 mL) was 
added. The reaction mixture was allowed to stand overnight and then filtered to give 
the solid triazolopyrimidine products BHD 331-340, which were recrystallized from 
ethanol. 
 
4.7.5.1 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-phenyl-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-331) Yield: 80%; mp 156-158 ºC; 
MS: m/z 342; Anal. Calcd. for C18H13F3N4: C, 63.16; 
H, 3.83; N, 16.37. Found: C, 63.02; H, 3.77; N, 
16.29%. 
 
 
4.7.5.2 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-fluorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-332) Yield: 77%; mp 222-
224 ºC; MS: m/z 360; Anal. Calcd. for C18H12F4N4: C, 
60.00; H, 3.36; N, 15.55. Found: C, 59.87; H, 3.29; N, 
15.47%. 
 
 
 
4.7.5.3 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-chlorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-333) Yield: 82%; mp 244-
246 ºC; MS: m/z 376; Anal. Calcd. for C18H12ClF3N4: 
C, 57.38; H, 3.21; N, 14.87. Found: C, 57.21; H, 3.16; 
N, 14.80%. 
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4.7.5.4 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-nitrophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-334) Yield: 69%; mp 198-
200 ºC; IR (cm-1): 3200 (N-H stretching of secondary 
amine), 3090 (C-H stretching of aromatic ring), 1660 
(N-H deformation of pyrimidine ring), 1600 (C=N 
stretching of triazole ring), 1548 and 1519 (C=C 
stretching of aromatic ring), 1350 (C-N stretching), 
1126 (C-F stretching), 950 (C-H in plane deformation 
of aromatic ring), 806 (C-H out of plane deformation of 1,4-disubstitution); 1H NMR 
(DMSO-d6) δ ppm: 5.23-5.24 (d, 1H, Ha, J = 3.0 Hz), 6.40-6.41 (d, 1H, Hb, J = 3.4 
Hz), 7.54-7.61 (m, 4H, Hc-e), 7.67-7.69 (d, 1H, Hf, J = 7.6 Hz), 7.85-7.87 (d, 1H, Hg, J 
= 7.6 Hz), 7.91 (s, 1H, Hh), 8.21-8.23 (d, 2H, Hii’, J = 8.5 Hz), 10.36 (s, 1H, Hj); MS: 
m/z 387; Anal. Calcd. for C18H12F3N5O2: C, 55.82; H, 3.12; N, 18.08. Found: C, 55.69; 
H, 3.05; N, 17.99%. 
 
4.7.5.5 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-p-tolyl-[1,2,4]triazolo[1,5-a] 
pyrimidine (BHD-335) Yield: 65%; mp 205-207 ºC; 
IR (cm-1): 3254 (N-H stretching of secondary amine), 
3036 (C-H stretching of aromatic ring), 2978 (C-H 
symmetrical stretching of CH3 group), 2870 (C-H 
asymmetrical stretching of CH3 group), 1658 (N-H 
deformation of pyrimidine ring), 1599 (C=N 
stretching of triazole ring), 1552 and 1514 (C=C 
stretching of aromatic ring), 1433 (C-H asymmetrical deformation of CH3 
group),1348 (C-N stretching), 1134 (C-F stretching), 952 (C-H in plane deformation 
of aromatic ring), 800 (C-H out of plane deformation of 1,4-disubstitution); 1H NMR 
(DMSO-d6) δ ppm: 2.31 (s, 3H, Ha), 5.21-5.22 (d, 1H, Hb, J = 3.2 Hz), 6.14-6.15 (d, 
1H, Hc, J = 3.6 Hz), 7.14-7.16 (d, 2H, Hdd’, J = 8.1 Hz), 7.19-7.21 (d, 2H, Hee’, J = 8.2 
Hz), 7.54 (s, 1H, Hf), 7.57-7.61 (t, 1H, Hg, J = 7.8 Hz), 7.65-7.67 (d, 1H, Hh, J = 7.8 
Hz), 7.85-7.87 (d, 1H, Hi, J = 7.8 Hz), 7.91 (s, 1H, Hj), 10.17 (s, 1H, Hk); MS: m/z 
356; Anal. Calcd. for C19H15F3N4: C, 64.04; H, 4.24; N, 15.72. Found: C, 63.91; H, 
4.17; N, 15.63%. 
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4.7.5.6 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(4-methoxyphenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-336) Yield: 75%; mp 143-
145 ºC; IR (cm-1): 3257 (N-H stretching of secondary 
amine), 3041 (C-H stretching of aromatic ring), 1662 
(N-H deformation of pyrimidine ring), 1599 (C=N 
stretching of triazole ring), 1550 and 1510 (C=C 
stretching of aromatic ring), 1431 (C-H asymmetrical 
deformation of CH3 group), 1346 (C-N stretching), 
1120 (C-F stretching), 1159 (C-O-C asymmetrical stretching of ether linkage), 952 
(C-H in plane deformation of aromatic ring), 804 (C-H out of plane deformation of 
1,4-disubstitution); 1H NMR (DMSO-d6) δ ppm: 3.76 (s, 3H, Ha), 5.17 (s, 1H, Hb), 
6.13-6.14 (d, 1H, Hc), 6.87-6.89 (d, 2H, Hdd’, J = 8.2 Hz), 7.26-7.28 (d, 2H, Hee’, J = 
8.2 Hz), 7.51 (s, 1H, Hf), 7.57-7.61 (t, 1H, Hg, J = 7.7 Hz), 7.65-7.67 (d, 1H, Hh, J = 
7.5 Hz), 7.85-7.87 (d, 1H, Hi, J = 7.6 Hz), 7.91 (s, 1H, Hj), 10.22 (s, 1H, Hk); MS: m/z 
372; Anal. Calcd. for C19H15F3N4O: C, 61.29; H, 4.06; N, 15.05. Found: C, 61.19; H, 
4.01; N, 14.98%. 
 
4.7.5.7 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(3,4-dimethoxyphenyl)-[1,2,4] 
triazolo[1,5-a]pyrimidine (BHD-337) Yield: 68%; mp 
175-177 ºC; MS: m/z 402; Anal. Calcd. for 
C20H17F3N4O2: C, 59.70; H, 4.26; N, 13.92. Found: C, 
59.70; H, 4.26; N, 13.92%. 
 
 
 
 
4.7.5.8 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(3-nitrophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-338) Yield: 77%; mp 164-
166 ºC; MS: m/z 387; Anal. Calcd. for C18H12F3N5O2: 
C, 55.82; H, 3.12; N, 18.08. Found: C, 55.71; H, 3.07; 
N, 17.95%. 
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4.7.5.9 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(3-chlorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-339) Yield: 65%; mp 217-
219 ºC; MS: m/z 376; Anal. Calcd. for C18H12ClF3N4: 
C, 57.38; H, 3.21; N, 14.87. Found: C, 57.25; H, 3.18; 
N, 14.78%. 
 
 
 
4.7.5.10 5-(3-(trifluoromethyl)phenyl)-4,7-dihydro-7-(2-chlorophenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine (BHD-340) Yield: 70%; mp 187-
189 ºC; MS: m/z 376; Anal. Calcd. for C18H12ClF3N4: 
C, 57.38; H, 3.21; N, 14.87. Found: C, 57.22; H, 3.15; 
N, 14.79%. 
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4.8 Spectral discussion 
4.8.1 Mass spectral study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. Systematic fragmentation pattern was observed in mass 
spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
 
4.8.1.1 Mass fragmentation pattern for BHD-306 
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4.8.1.2 Mass fragmentation pattern for BHD-312 
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4.8.1.3 Mass fragmentation pattern for BHD-325 
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4.8.1.4 Mass fragmentation pattern for BHD-336 
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4.8.2 IR spectral study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet method. 
Various functional groups present in molecule were identified by characteristic 
frequency obtained for them. For 1,2,4-triazolo[1,5-a]pyrimidines (BHD-301 to 340), 
confirmatory bands for secondary amine (NH) and nitrile (C=N) stretching band were 
observed at 3190-3500 cm-1 and 1590-1650 cm-1 respectively. Another characteristic 
band for N-H deformation and C-N stretching were observed at 1600-1680 cm-1 and 
1290-1350 cm-1 respectively, which suggested the formation of pyrimidine ring. 
 
4.8.3 1H NMR spectral study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 MHz 
spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
1H NMR spectra confirmed the structures of triazolopyrimidines BHD-301 to 
340 on the basis of following signals: two characteristic peaks for the methine proton 
of pyrimidine ring and for the methine proton of triazole ring were observed at 5.02-
5.25 δ ppm and 7.50-7.65 δ ppm respectively. And another singlet for amino group 
proton was observed at 9.90-10.36 δ ppm. The aromatic ring protons and J value were 
found to be in accordance with substitution pattern on phenyl ring. 
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Mass spectrum of BHD-304 
 
IR spectrum of BHD-304 
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1H NMR spectrum of BHD-304 
 
Expanded 1H NMR spectrum of BHD-304 
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Mass spectrum of BHD-305 
 
IR spectrum of BHD-305 
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1H NMR spectrum of BHD-305 
 
Expanded 1H NMR spectrum of BHD-305 
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Mass spectrum of BHD-306 
 
IR spectrum of BHD-306 
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1H NMR spectrum of BHD-306 
 
Expanded 1H NMR spectrum of BHD-306 
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Expanded 1H NMR spectrum of BHD-306 
 
Mass spectrum of BHD-312 
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IR spectrum of BHD-312 
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Expanded 1H NMR spectrum of BHD-312 
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Mass spectrum of BHD-314 
 
IR spectrum of BHD-314 
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1H NMR spectrum of BHD-314 
 
Expanded 1H NMR spectrum of BHD-314 
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Expanded 1H NMR spectrum of BHD-314 
 
Mass spectrum of BHD-316 
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IR spectrum of BHD-316 
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Expanded 1H NMR spectrum of BHD-316 
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Mass spectrum of BHD-323 
 
IR spectrum of BHD-323 
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1H NMR spectrum of BHD-323 
 
Expanded 1H NMR spectrum of BHD-323 
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Expanded 1H NMR spectrum of BHD-323 
 
Mass spectrum of BHD-325 
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IR spectrum of BHD-325 
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Expanded 1H NMR spectrum of BHD-325 
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Mass spectrum of BHD-326 
 
IR spectrum of BHD-326 
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1H NMR spectrum of BHD-326 
 
Expanded 1H NMR spectrum of BHD-326 
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Expanded 1H NMR spectrum of BHD-326 
 
Mass spectrum of BHD-334 
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IR spectrum of BHD-334 
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Expanded 1H NMR spectrum of BHD-334 
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Mass spectrum of BHD-335 
 
IR spectrum of BHD-335 
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1H NMR spectrum of BHD-335 
 
Expanded 1H NMR spectrum of BHD-335 
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Expanded 1H NMR spectrum of BHD-335 
 
Mass spectrum of BHD-336 
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IR spectrum of BHD-336 
40060080010001200140016001800200024002800320036004000
1/cm
-15
0
15
30
45
60
75
90
105
%T
32
57
.8
8
32
00
.0
1
31
55
.6
5
30
41
.8
4
29
78
.1
9
29
20
.3
2
28
18
.0
9
16
62
.6
9
15
99
.0
4
15
50
.8
2
15
10
.3
1
14
67
.8
8
14
31
.2
3
14
06
.1
5
13
46
.3
6
13
27
.0
7
12
46
.0
6
11
59
.2
6
11
20
.6
8 1
07
2.
46
10
35
.8
1
98
3.
73
95
2.
87
90
2.
72
83
3.
28 8
04
.3
4 7
31
.0
5
69
8.
25
67
3.
18
55
9.
38
336  
1H NMR spectrum of BHD-336 
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Expanded 1H NMR spectrum of BHD-336 
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4.9 Biological evaluation 
4.9.1 Antimicrobial evaluation 
All the synthesized compounds (BHD-301 to 340) were tested for their antibacterial 
and antifungal activity (MIC) in vitro by broth dilution method [129, 130] with two 
Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus pyogenes 
MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, Pseudomonas 
aeruginosa MTCC 441 and three fungal strains Candida albicans MTCC 227, 
Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin, and greseofulvin as standard 
drugs. The standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using microdilution broth method 
according to NCCLS standards [129]. Serial dilutions of the test compounds and 
reference drugs were prepared in Muellere-Hinton agar. Drugs (10 mg) were 
dissolved in dimethylsulfoxide (DMSO, 1 mL). Further progressive dilutions with 
melted Muellere-Hinton agar were performed to obtain the required concentrations. In 
primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the 
synthesized drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 200 μg mL-1, 100 μg mL-1, 
50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.25 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest concentration of 
the tested compound that yields no visible growth (turbidity) on the plate. To ensure 
that the solvent had no effect on the bacterial growth, a control was performed with 
the test medium supplemented with DMSO at the same dilutions as used in the 
experiments and it was observed that DMSO had no effect on the microorganisms in 
the concentrations studied.  
The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds BHD-301 to 340 
 
Code Minimal inhibition concentration (µg mL-1 ) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
BHD-301 200 100 100 100 250 1000 250 
BHD-302 500 500 250 250 250 200 200 
BHD-303 500 200 100 250 500 500 >1000 
BHD-304 500 500 250 500 500 >1000 1000 
BHD-305 250 62.5 250 500 1000 500 500 
BHD-306 100 200 62.5 200 500 200 >1000 
BHD-307 250 250 250 500 1000 500 >1000 
BHD-308 500 500 200 500 >1000 >1000 >1000 
BHD-309 100 200 500 500 250 >1000 >1000 
BHD-310 500 500 100 250 250 1000 250 
BHD-311 500 62.5 250 250 250 200 200 
BHD-312 100 250 100 250 500 500 >1000 
BHD-313 500 250 250 500 500 >1000 1000 
BHD-314 500 500 250 500 >1000 >1000 >1000 
BHD-315 500 250 100 100 500 >1000 250 
BHD-316 200 500 250 500 1000 500 >1000 
BHD-317 250 500 500 500 1000 500 500 
BHD-318 250 500 500 500 250 >1000 >1000 
BHD-319 500 500 1000 1000 500 1000 1000 
BHD-320 200 100 100 500 500 1000 200 
BHD-321 250 250 250 250 500 500 1000 
BHD-322 100 500 500 1000 250 500 500 
BHD-323 500 100 62.5 100 500 500 >1000 
BHD-324 250 500 500 500 200 500 200 
BHD-325 500 250 500 500 1000 1000 1000 
BHD-326 500 100 500 250 1000 >1000 1000 
BHD-327 100 62.5 62.5 100 250 100 500 
BHD-328 500 250 200 500 500 1000 >1000 
BHD-329 100 250 500 1000 1000 >1000 >1000 
BHD-330 250 62.5 100 100 250 1000 1000 
BHD-331 500 500 250 200 >1000 >1000 >1000 
BHD-332 200 500 250 200 500 >1000 >1000 
BHD-333 250 250 500 500 500 250 500 
BHD-334 500 500 250 500 >100 >1000 >1000 
BHD-335 500 500 250 500 250 >1000 >1000 
BHD-336 250 200 200 100 250 500 250 
BHD-337 200 500 250 1000 250 500 >1000 
BHD-338 100 62.5 200 500 1000 >1000 500 
BHD-339 500 250 500 250 >1000 >1000 1000 
BHD-340 250 250 500 250 >1000 >1000 >1000 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Ciprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Greseofulvin - - - - 500 100 100 
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4.9.2 Antimycobacterial, anticancer and antiviral evaluation 
Antimycobacterial, anticancer and antiviral screening of all the newly synthesized 
compounds BHD-301 to BHD-340 is currently under investigation and results are 
awaited. 
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Summary 
 
The work presented in the Thesis entitled “Synthesis of Heterocyclic Compounds of 
Therapeutic Interest” can be summarized as below. 
 
Chapter 1 briefly introduces importance of bicyclic and tricyclic aromatic 
heterocycles in drug discovery as well as concept of “privileged structures”. Chapter 1 
further describes aims and objectives of the proposed research work. 
In Chapter 2, synthesis of forty novel 3-cyano-2-pyridone derivatives are 
reported, which  draw a special attention for their wide spectrum biological activities 
along with their importance and utility as intermediates in preparing variety of 
heterocyclic compounds. The synthesis was achieved by the reaction of an aromatic 
aldehydes, 2-cyano-N-(substituted)acetamides and malononitrile by using methanol as 
a solvent and piperidine as a catalyst. 
Chapter 3 describes the applications of multicomponent one-pot synthesis and 
brief review of the reported synthetic strategies for the synthesis of pyranopyrazole 
derivatives. Pyranopyrazoles have been the subject of intense research due to the 
interesting pharmacological activities found for several of their derivatives. Chapter 3 
includes synthesis of thirty novel pyrano[2,3-c]pyrazoles, which has been synthesized 
by one-pot three-component cyclocondensation reaction of aromatic aldehydes, 
malononitrile and substituted pyrazolin-5-ones in the presence of piperidine as 
catalyst.  
Chapter 4 describes applications of microwaves in heterocyclic ring formation. 
Recently, 1,2,4-triazolo[1,5-a]pyrimidines have aroused increasing from the 
standpoint of biological activity, due to their diverse pharmacological activities. It 
includes synthesis of forty novel 1,2,4-triazolo[1,5-a]pyrimidines and brief review of 
the reported synthetic strategies. Forty 1,2,4-triazolo[1,5-a]pyrimidines were 
synthesized by one-pot, microwave-assisted condensation reaction of aromatic 
aldehyde, corresponding acetophenone and 5-amino-1,2,4-triazole using glacial acetic 
acid as a solvent. Thus, a new green chemistry approach was developed leading to the 
improvement in the reaction time, yield and simplicity of work up procedure. 
All the synthesized compounds were characterized by IR, Mass, 1H NMR 
spectroscopy and elemental analyses. 
Thus, 110 compounds are synthesized and characterized in entire thesis work. 
The synthesized compounds are screened for antimicrobial activity, results of which 
are incorporated in the thesis. Looking at the antimicrobial activity results (i.e. 
antibacterial and antifungal), remarkable number of compounds have demonstrated 
excellent antimicrobial activity as compared to the standard drugs.  
All the newly synthesized compounds are also under antimycobacterial, 
anticancer and antiviral evaluation and their results are awaited.  
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